Vascular Endothelial Growth Factor Inhibitors for Ocular Indications

Number: 0701

Table Of Contents

Policy
Applicable CPT / HCPCS / ICD-10 Codes
Background
References

---

Brand Selection for Medically Necessary Indications for Commercial Medical Plans

Byooviz and Cimerli

As defined in Aetna commercial policies, health care services are not medically necessary when they are more costly than alternative services that are at least as likely to produce equivalent therapeutic or diagnostic results. Byooviz (ranibizumab-nuna) and Cimerli (ranibizumab-eqrn) are more costly to Aetna than other vascular endothelial growth factor (VEGF) inhibitors for certain indications. There is a lack of reliable evidence that Byooviz and Cimerli are superior to the lower cost VEGF inhibitor: Avastin (bevacizumab) for the medically necessary indications listed below. Therefore, Aetna considers Byooviz and Cimerli to be medically necessary only for members who have a contraindication, intolerance or ineffective response to the available equivalent alternative VEGF inhibitor: Avastin for the following medically necessary indications:

• Diabetic macular edema
• Diabetic retinopathy
• Macular edema following retinal vein occlusion 
• Myopic choroidal neovascularization
• Neovascular (wet) age-related macular degeneration (AMD).

Alymsys, Eylea, Eylea HD, Lucentis, Mvasi, Susvimo, Vabysmo, Vegzelma, Zirabev

As defined in Aetna commercial policies, health care services are not medically necessary when they are more costly than alternative services that are at least as likely to produce equivalent therapeutic or diagnostic results. Alymsys (bevacizumab-maly), Eylea (aflibercept), Eylea HD (aflibercept), Lucentis (ranibizumab), Mvasi (bevacizumab-awwb), Susvimo (ranibizumab), Vabysmo (faricimab-svoa), Vegzelma (bevacizumab-adcd), and Zirabev (bevacizumab-bvzr) are more costly to Aetna than other vascular endothelial growth factor (VEGF) inhibitors for certain indications. There is a lack of reliable evidence that Alymsys, Eylea, Eylea HD, Lucentis, Mvasi, Susvimo, Vabysmo, Vegzelma, and Zirabev are superior to the lower cost VEGF inhibitors: Avastin (bevacizumab), Byooviz (ranibizumab-nuna), Cimerli (ranibizumab-eqrn) for the medically necessary indications listed below. Therefore, Aetna considers Alymsys, Eylea, Eylea HD, Lucentis, Mvasi, Susvimo, Vabysmo, Vegzelma, and Zirabev to be medically necessary only for members who have a contraindication, intolerance or ineffective response to the available equivalent alternative VEGF inhibitors: Avastin and Byooviz or Cimerli for the following medically necessary indications:

• Diabetic macular edema
• Diabetic retinopathy
• Macular edema following retinal vein occlusion
• Myopic choroidal neovascularization
• Neovascular (wet) age-related macular degeneration (AMD).

---

Policy

Scope of Policy

This Clinical Policy Bulletin addresses vascular endothelial growth factor inhibitors for ocular indications for commercial medical plans. For Medicare criteria, see Medicare Part B Criteria.

Note: Requires Precertification:

Precertification of aflibercept [(Eylea), (Eylea HD)], brolucizumab-dbll (Beovu), faricimab-svoa (Vabysmo), pegaptanib sodium injection (Macugen), ranibizumab (Lucentis), ranibizumab (Susvimo), ranibizumab-eqrn (Cimerli), and ranibizumab-nuna (Byooviz) is required of all Aetna participating providers and members in applicable plan designs. For precertification of aflibercept [(Eylea), (Eylea HD)], brolucizumab-dbll (Beovu), faricimab-svoa (Vabysmo), pegaptanib sodium injection (Macugen), ranibizumab (Lucentis), ranibizumab (Susvimo), ranibizumab-eqrn (Cimerli), and ranibizumab-nuna (Byooviz), call (866) 752-7021 or fax (888) 267-3277. For Statement of Medical Necessity (SMN) precertification forms, see Specialty Pharmacy Precertification.

Intravitreal aflibercept [(Eylea), (Eylea HD)]

1. Criteria for Initial Approval

   Aetna considers intravitreal aflibercept [(Eylea), or (Eylea HD)] injection medically necessary for the treatment of the following indications:

   1. Diabetic macular edema;
   2. Diabetic retinopathy;
   3. Macular edema following retinal vein occlusion;
   4. Neovascular (wet) age-related macular degeneration (AMD);
   5. Retinopathy of prematurity.

   Aetna considers all other indications as experimental and investigational (for additional information, see Experimental and Investigational and Background sections). 

2. Continuation of Therapy

   Aetna considers continuation of aflibercept [(Eylea) or (Eylea HD)] therapy medically necessary for an indication listed in Section I for members who have demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss).

Intravitreal bevacizumab (Avastin), bevacizumab-adcd (Vegzelma), bevacizumab-awwb (Mvasi), bevacizumab-bvzr (Zirabev), and bevacizumab-maly (Alymsys)

1. Criteria for Initial Approval

   Aetna considers intravitreal bevacizumab (Avastin), bevacizumab-adcd (Vegzelma), bevacizumab-awwb (Mvasi), bevacizumab-bvzr (Zirabev), or bevacizumab-maly (Alymsys) injections medically necessary for treatment of the following retinal disorders:

   1. Diabetic macular edema;
   2. Neovascular (wet) age-related macular degeneration (AMD);
   3. Macular edema following retinal vein occlusion;
   4. Proliferative diabetic retinopathy;
   5. Choroidal neovascularization (CNV) (including myopic choroidal neovascularization (mCNV), angioid streaks, choroiditis [including choroiditis secondary to ocular histoplasmosis], idiopathic degenerative myopia, retinal dystrophies, rubeosis iridis, pseudoxanthoma elasticum, and trauma);
   6. Neovascular glaucoma;
   7. Retinopathy of prematurity;
   8. Polypoidal choroidal vasculopathy.

   Aetna considers all other indications as experimental and investigational (for additional information, see Experimental and Investigational and Background sections).  

2. Continuation of Therapy

   Aetna considers continuation of Avastin, Vegzelma, Mvasi, Zirabev, or Alymsys therapy medically necessary for an indication outlined in Section I for members who have demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss).

Intravitreal brolucizumab-dbll (Beovu)

1. Criteria for Initial Approval

   1. Neovascular (Wet) Age-Related Macular Degeneration

      Aetna considers brolucizumab-dbll intravitreal injection (Beovu) medically necessary for treatment of neovascular (wet) age-related macular degeneration.

   2. Diabetic Macular Edema

      Aetna considers brolucizumab-dbll intravitreal injection (Beovu) medically necessary for treatment of diabetic macular edema.

   Aetna considers all other indications as experimental and investigational.

2. Continuation of Therapy

   Aetna considers continuation of brolucizumab-dbll (Beovu) therapy medically necessary for an indication listed in Section I for members who have demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss).

Intravitreal faricimab-svoa (Vabysmo)

1. Criteria for Initial Approval

   1. Diabetic Macular Edema

      Aetna considers faricimab-svoa injection (Vabysmo) medically necessary for treatment of diabetic macular edema.

   2. Neovascular (Wet) Age-Related Macular Degeneration

      Aetna considers faricimab-svoa injection (Vabysmo) medically necessary for treatment of neovascular (wet) age-related macular degeneration.

   Aetna considers all other indications as experimental and investigational.

2. Continuation of Therapy

   Aetna considers continuation of faricimab-svoa injection (Vabysmo) therapy medically necessary for an indication listed in Section I for members who have demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss).
   

Pegaptanib Sodium Injection (Macugen)

1. Criteria for Initial Approval

   Aetna considers pegaptanib sodium injection (Macugen) medically necessary for the treatment of neovascular (wet) age-related macular degeneration (AMD).

   Aetna considers all other indications as experimental and investigational (for additional information, see Experimental and Investigational and Background sections). 

2. Continuation of Therapy

   Aetna considers continuation of pegaptanib sodium injection (Macugen) therapy, for a maximum of 2 years of treatment for each eye, medically necessary in members requesting reauthorization for neovascular (wet) age-related macular degeneration who have demonstrated a positive clinical response to Macugen therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA], or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss).

Ranibizumab (Lucentis), ranibizumab-eqrn (Cimerli), and Ranibizumab-nuna (Byooviz)

1. Criteria for Initial Approval

   Aetna considers intravitreal ranibizumab (Lucentis), ranibizumab-eqrn (Cimerli), or ranibizumab-nuna (Byooviz) medically necessary for the treatment of the following indications:

   1. Diabetic macular edema;
   2. Diabetic retinopathy;
   3. Macular edema following retinal vein occlusion;
   4. Myopic choroidal neovascularization;
   5. Neovascular (wet) age-related macular degeneration (AMD).

   Aetna considers all other indications as experimental and investigational (for additional information, see Experimental and Investigational and Background sections).

2. Continuation of Therapy

   Aetna considers continuation of intravitreal ranibizumab (Lucentis), ranibizumab-eqrn (Cimerli), or ranibizumab-nuna (Byooviz) therapy medically necessary for an indicaton listed in Section I for members who have demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss).

Ranibizumab Injection (Susvimo)

1. Criteria for Initial Approval

   Neovascular (Wet) Age-Related Macular Degeneration

   Aetna considers intravitreal ranibizumab injection (Susvimo) medically necessary for treatment of neovascular (wet) age-related macular degeneration when all of the following criteria are met:

   1. Member has a diagnosis of neovascular (wet) age-related macular degeneration; and
   2. Member has previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor (e.g., Avastin, Eylea) within the past 6 months; and
   3. Must be used in conjunction with the Susvimo ocular implant.

   Aetna considers all other indications as experimental and investigational (for additional information, see Experimental and Investigational and Background sections).

2. Continuation of Therapy

   Aetna considers continuation of intravitreal ranibizumab injection (Susvimo) therapy medically necessary for an indication listed in Section I for members who have demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss).

Ranibizumab (Susvimo) Ocular Implant

Aetna considers the ranibizumab (Susvimo) ocular implant medically necessary when used with intravitreal ranibizumab injection (Susvimo) for treatment of neovascular (wet) age-related macular degeneration and when criteria are met for intravitreal ranibizumab injection (Susvimo).

Note: Vascular endothelial growth factor (VEGF) inhibitors for ocular indications are contraindicated and considered not medically necessary for persons with endophthalmitis or with ocular or periocular infections.

Note: Concurrent use of more than one VEGF inhibitor in the same eye is considered experimental and investigational because the safety and effectiveness of combinational use of VEGF inhibitors for ocular indications has not been established.

Related Policies

• CPB 0594 - Verteporfin (Visudyne) Photodynamic Therapy
• CPB 0685 - Bevacizumab for Non-Ocular Indications
• CPB 0706 - Anecortave Acetate (Retaane)
• CPB 0765 - Age-Related Macular Degeneration
• CPB 0842 - Ziv-Aflibercept (Zaltrap)

Dosage and Administration

Below includes dosing recommendations as per the FDA-approved prescribing information. Please consult the Full Prescribing Information for complete details for recommended dose adjustments.

Aflibercept (Eylea)

Aflibercept injection is available as Eylea which is supplied as 2 mg/0.05 mL solution in a single-dose pre-filled syringe and solution in a single-dose vial for intravitreal injection. 

• Neovascular (Wet) Age-Related Macular Degeneration (AMD): The recommended dose for Eylea is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 3 months, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months). Although Eylea may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most individuals when Eylea was dosed every 4 weeks compared to every 8 weeks. Some individuals may need every 4 week (monthly) dosing after the first 12 weeks (3 months). Although not as effective as the recommended every 8 week dosing regimen, individuals may also be treated with one dose every 12 weeks after one year of effective therapy. Treated individuals should be assessed regularly.
• Macular Edema Following Retinal Vein Occlusion (RVO): The recommended dose for Eylea is 2 mg (0.05 mL) administered by intravitreal injection once every 4 weeks (approximately every 25 days, monthly).
• Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR): The recommended dose for Eylea is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 5 injections followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months). Although Eylea may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most individuals when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some individuals may need every 4 week (monthly) dosing after the first 20 weeks (5 months).
• Retinopathy of Prematurity: The recommended dose for Eylea is 0.4 mg (0.01 mL or 10 microliters) administered by intravitreal injection. Treatment may be given bilaterally on the same day. Injections may be repeated in each eye. The treatment interval between doses injected into the same eye should be at least 10 days.

Source: Regeneron, 2023b

Aflibercept (Eylea HD)

Aflibercept is also supplied as Eylea HD 8 mg (0.07 mL of 114.3 mg/mL solution) in a single-dose vial for intravitreal injection.

• Neovascular (Wet) Age-Related Macular Degeneration (nAMD): The receommended dose for Eylea HD is 8 mg (0.07 mL of 114.3 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followd by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week.
• Diabetic Macular Edema (DME): The recommended dose for Eylea HD is 8 mg (0.07 mL of 114.3 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week.
• Diabetic Retinopathy (DR): The recommended dose for Eylea HD is 8 mg (0.07 mL of 114.3 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 12 weeks, +/- 1 week.

Source: Regeneron Pharmaceuticals, 2023a

Brolucizumab-dbll (Beovu)

Brolucizumab is available as Beovu 6 mg/0.05 mL solution for intravitreal injection in a single-dose pre-filled syringe and a single-dose vial. 

Neovascular (wet) age-related macular degeneration (nAMD):

The recommended dose for Beovu is 6 mg (0.05 mL of 120 mg/mL solution) via intravitreal injection monthly (approximately every 25-31 days) for the first three doses, followed by 6 mg (0.05 mL) via intravitreal injection every 8-12 weeks.

Diabetic macular edima (DME):

The recommended dose for Beovu is 6 mg (0.05 mL of 120 mg/mL solution) via intravitreal injection every six weeks (approximately every 39-45 days) for the first five doses, followed by 6 mg (0.05 mL) via intravitreal injection once every 8-12 weeks.

Source: Novartis Pharmaceuticals, 2022a

Faricimab-svoa (Vabysmo)

Faricimab-svoa is available as Vabysmo 120 mg/mL solution i a single-dose vial for intravitreal injection.

Neovascular (wet) age-related macular degeneration (nAMD):

The recommended dose is Vabysmo 6 mg(0.05 mL of 120 mg/mL solution) via intravitreal injection every 4 weeks (approximately) every 28 ± 7 days, monthly) for the first 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks later to determine whether to give a 6 mg dose via intravitreal injection on one of the following three regimens:

1. Weeks 28 and 44;
2. Weeks 24, 36 and 48; or
3. Weeks 20, 28, 36 and 44. 

Some individuals may require every 4 week (monthly) dosing after the first 4 doses. individuals should be assessed regularly.

Diabetic macular edima (DME):

The recommended dose for Vabysmo is by following one of these two dose regimens: 1) 6 mg (0.05 mL of 120 mg/mL solution) via intravitreal injection every 4 weeks (approximately every 28 days ± 7 days, monthly) for at least 4 doses. If after at least 4 doses, resolution of edema based on the central subfield thickness (CST) of the macula as measured by optical coherence tomography is achieved, then the interval of dosing may be modified by extensions of up to 4 week interval increments or reductions of up to 8 week interval increments based on CST and visual acuity evaluations through week 52; or 2) 6 mg given every 4 weeks for the first 6 doses, followed by 6 mg dose via intravitreal injection at intervals of every 8 weeks (2 months) over the next 28 weeks.

Some individuals may require every 4 week (monthly) dosing after the first 4 doses. Individuals should be assessed regularly.

Source: Genentech, 2023

Pegaptanib Sodium (Macugen)

Pegaptanib sodium is available as Macugen 0.3 mg/90 µL solution in a single-use syringe for intravitreal injection.

Macugen 0.3 mg should be administered once every six weeks by intravitreous injection into the eye to be treated.

Note: Macugen has been withdrawn from the U.S. market.

Source: Bausch + Lomb, 2016

Ranibizumab (Lucentis)

Ranibizumab is available as Lucentis 0.05 mL for ophthalmic intravitreal Injections in: 10 mg/mL solution (Lucentis 0.5 mg) and 6 mg/mL solution (Lucentis 0.3 mg) in single-use prefilled syringe; 10 mg/mL solution (Lucentis 0.5 mg) and 6 mg/mL solution (Lucentis 0.3 mg) in single-use glass vials.

• Neovascular (Wet) Age-Related Macular Degeneration (AMD): Lucentis 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days). Although not as effective, individuals may be treated with 3 monthly doses followed by less frequent dosing with regular assessment. Although not as effective, individuals may also be treated with one dose every 3 months after 4 monthly doses. Treated individuals should be assessed regularly.
• Macular Edema Following Retinal Vein Occlusion (RVO): Lucentis 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
• Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR): Lucentis 0.3 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
• Myopic Choroidal Neovascularization (mCNV): Lucentis 0.5 mg (0.05 mL) is recommended to be initially administered by intravitreal injection once a month (approximately 28 days) for up to three months. Individuals may be retreated if needed.

Source: Genentech, 2018

Ranibizumab-eqrn (Cimerli)

Ranibizumab-eqrn is available as Cimerli 10 mg/mL solution (Cimerli 0.5 mg) and 6 mg/mL solution (Cimerli 0.3 mg) in a single-dose glass vial designed to provide 0.05 mL for intravitreal injection.

The recommended dosing is 0.5 mg (0.05 mL) administered by intravitreal injetion once a month (approximately 28 days) for the following indications:

• Macular edema following retinal vein occlusion (RVO)
• Myopic choroidal neovascularization (mCNV)

  • Treatment for up to 3 months and individuals may be retreated if needed

• Neovascular (wet) age-related macular degeneration (AMD)

  • Although not as effective, individuals may be treated with 3 monthly doses followed by less frequent dosing with regular assessment
  • Although not as effective, individuals may also be treated with one dose every 3 months after 4 monthly doses. Individuals should be reassessed regularly.

The recommended dosing is 0.3 mg (0.05 mL) administered by intravitreal injection once a month (approximately 28 days) for:

• Diabetic macular edema (DME) and diabetic retinopathy (DR)

Source: Coherus BioSciences, 2022a

Ranibizumab-nuna (Byooviz)

Ranibizumab-nuna is available as Byooviz 10 mg/mL solution in a single-dose glass vial designed to provide 0.05 mL for intravitreal injection.

The recommended dosing is 0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection once a month (approximately 28 days) for the following indications:

• Macular edema following retinal vein occlusion (RVO)
• Myopic choroidal neovascularization (mCNV)
• Neovascular (Wet) age-related macular dengeration (AMD)

Source: Biogen, 2021

Ranibizumab Injection (Susvimo)

Ranibizumab injection is available as Susvimo 100 mg/mL solution in a single-dose vial for intravitreal use via ranibizumab (Susvimo) ocular implant.

Neovascular (wet) age-related macular degeneration (AMD):

The recommended dose is ranibizumab injection (Susvimo) 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the Susvimo implant with refills every 24 weeks (approximately 6 months).

Supplemental treatment with 0.5 mg intravitreal ranibizumab injection may be administered in the affected eye if clinically necessary.

Initial implantation, refill-exchange, and implant removal (if necessary) require strict aseptic conditions.

Source: Genentech,2022

Experimental and Investigational

1. Aetna considers aflibercept [(Eylea) and (Eylea HD)] experimental and investigational for the treatment of the following because its effectiveness for these indications has not been established (not an all-inclusive list):

   1. Central serous chorioretinopathy
   2. Choroidal neovascularization due to ocular histoplasmosis
   3. Colorectal cancer
   4. Cystoid macular edema
   5. Myopic choroidal neovascularization
   6. Neovascular glaucoma
   7. Ovarian cancer
   8. Polypoidal choroidal vasculopathy
   9. Prostate cancers
   10. Radiation retinopathy
   11. Retinitis pigmentosa
   12. Uterine leiomyosarcomas.

2. Aetna considers intravitreal bevacizumab (Avastin) and respective biosimilar injections experimental and investigational for the treatment of amelanotic melanoma / "leakage" from an amelanotic choroid malignancy.

3. Aetna considers intravitreal bevacizumab (Avastin) and respective biosimilar injections experimental and investigational for the treatment of radiation maculopathy.

4. Aetna considers subconjunctival injection of bevacizumab (Avastin) and respective biosimilars experimental and investigational for the management of bleb encapsulation/needling following trabeculectomy.

5. Aetna considers intravitreal ranibizumab (Lucentis), ranibizumab (Susvimo), ranibizumab-eqrn (Cimerli), ranibizumab-nuna (Byooviz), bevacizumab (Avastin) and its respective biosimilar injections experimental and investigational for treatment of the following indications (not an all-inclusive list) because their effectiveness for these indications has not been established:

   1. Amblyopia
   2. Central serous retinopathy
   3. Choroidal hemorrhage not related to a medically necessary indication
   4. Choroidal melanoma
   5. Coat's disease (Coates' disease, also known as exudative retinitis or retinal telangiectasis)
   6. Cystoid macular edema
   7. Glaucoma surgery, control of wound healing
   8. Hypertensive retinopathy
   9. Primary pterygium (including as adjunctive therapy for primary pterygium surgery)
   10. Radiation retinopathy
   11. Retinal angioma
   12. Sickle cell retinopathy
   13. Vitreous hemorrhage not related to a medically necessary indication.

6. Aetna considers topical administration, subconjunctival or intrastromal injections of ranibizumab, ranibizumab-eqrn, ranibizumab-nuna, bevacizumab, bevacizumab-adcd, bevacizumab-awwb, bevacizumab-bvzr, or bevacizumab-maly for the treatment of corneal neovascularization experimental and investigational because their effectiveness for this indication has not been established.

7. Aetna considers pegaptanib sodium injection (Macugen) experimental and investigational for the treatment of the following indications (not an all-inclusive list) because its effectiveness for these indications has not been established:

   1. Central retinal vein occlusion
   2. Cystoid macular degeneration
   3. Diabetic macular edema
   4. Ocular von Hippel Lindau disease lesions.

Note: Vascular endothelial growth factor (VEGF) inhibitors for ocular indications are contraindicated and considered not medically necessary for persons with endophthalmitis or with ocular or periocular infections.

Note: Concurrent use of more than one VEGF inhibitor in the same eye is considered experimental and investigational because the safety and effectiveness of combinational use of VEGF inhibitors for ocular indications has not been established.

---

Table:

CPT Codes / HCPCS Codes / ICD-10 Codes

Code	Code Description
CPT codes covered if selection criteria are met:
67028	Intravitreal injection of a pharmacologic agent (separate procedure)
Other CPT codes related to the CPB:
92081	Visual field examination, unilateral or bilateral, with interpretation and report; limited examination (eg, tangent screen, Autoplot, arc perimeter, or single stimulus level automated test, such as Octopus 3 or 7 equivalent)
92082	Visual field examination, unilateral or bilateral, with interpretation and report; intermediate examination (eg, at least 2 isopters on Goldmann perimeter, or semiquantitative, automated suprathreshold screening program, Humphrey suprathreshold automatic diagnostic test, Octopus program 33)
92083	Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30 deg, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2)
99172	Visual function screening, automated or semi-automated bilateral quantitative determination of visual acuity, ocular alignment, color vision by pseudoisochromatic plates, and field of vision (may include all or some screening of the determination[s] for contrast sensitivity, vision under glare)
99173	Screening test of visual acuity, quantitative, bilateral
Pegaptanib sodium injection (Macugen):
HCPCS codes covered if selection criteria are met:
J2503	Injection, pegaptanib sodium, 0.3 mg
ICD-10 codes covered if selection criteria are met:
E11.3111 - E11.3119, E11.3211 - E11.3219, E11.3311 - E11.3219, E11.3411 - E11.3419, E11.3511 - E11.3519	Type II diabetes with retinopathy with macular edema
H35.3210 - H35.3293	Exudative age-related macular degeneration
ICD-10 codes not covered for indications listed in the CPB (not all-inclusive):
A18.50 - A18.59	Tuberculosis of eye
A51.43	Secondary syphilitic oculopathy [chorioretinitis]
A71.0 - A71.9	Trachoma
B02.30 - B02.39	Zoster ocular disease
B25.9	Cytomegalovirus disease (retinitis)
B30.0	Keratoconjunctivitis due to adenovirus
B30.1	Conjunctivitis due to adenovirus
B30.3	Acute epidemic hemorrhagic conjunctivitis (enteroviral)
B30.4	Histoplasmosis capsulati, unspecified [retinitis]
B30.8	Other viral conjunctivitis
B39.5	Histoplasmosis duboisii [retinitis]
B39.9	Histoplasmosis, unspecified [retinitis]
B58.01	Toxoplasma chorioretinitis
C69.20 - C69.32	Malignant neoplasm of retina and choroid
E10.311 - E10.37x9	Type I diabetes mellitus with ophthalmic complications
E13.311 - E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy
E88.49	Other mitochondrial metabolism disorders [NARP syndrome]
H00.011 - H00.029	Hordeolum externum
H01.001 - H01.029	Blepharitis
H01.00A - H01.00B	Unspecified blepharitis
H01.01A - H01.01B	Ulcerative blepharitis
H01.02A - H01.02B	Squamous blepharitis
H04.001 - H04.039	Dacryoadenitis
H04.301 - H04.439	Acute and chronic inflammation of lacrimal passages
H05.001 - H05.019	Cellulitis of orbit
H10.011 - H10.9	Conjunctivitis
H15.001 - H15.9	Scleritis and episcleritis
H16.001 - H16.9	Keratitis
H30.001 - H30.93	Chorioretinal inflammation
H31.001 - H31.099	Chorioretinal scars
H31.101 - H31.9	Choroidal degeneration, dystrophy, hemorrhage and rupture, detachment and other disorders
H32	Chorioretinal disorders in diseases classified elsewhere
H33.001 - H33.8	Retinal detachments and breaks
H34.00 - H34.9	Retinal vascular occlusions
H35.30	Degeneration of macula and posterior pole [other than exudative age-related macular degeneration]
H35.3110 - H35.3194	Nonexudative age-related macular degeneration
H35.40 - H35.54	Peripheral retinal degeneration
H35.70 - H35.739	Separation of retinal layers
H35.81 - H35.9	Other retinal disorders
H44.00 - H44.39	Disorders of globe
H44.601 - H44.699	Retained (old) intraocular foreign body, magnetic
Q85.81, Q85.82, Q85.83, Q85.89	Other phakomatoses, NEC [von Hippel-Lindau]
Brolucizumab-dbll (Beovu):
HCPCS codes covered if selection criteria are met:
J0179	Injection, brolucizumab-dbll, 1 mg
ICD-10 codes covered if selection criteria are met:
E08.311, E08.3211 – E08.3219, E08.3311 – E08.3319, E08.3411 – E08.3419, E08.3511 - E08.3519, E08.37X1 – E08.3X79, E09.311, E09.3211 – E09.3219, E09.3311 – E09.3319, E09.3411 – E09.3419, E09.3511 – E09.3519, E09.37X1 - E09.37X9, E10.311, E10.3211 – E10.3219, E10.3311 – E10.3319, E10.3411 – E10.3419, E10.3511 – E10.3519, E10.37X1 – E10.37X9, E11.311, E11.3211 – E11.3219, E11.3311 – E11.3319, E11.3411 – E11.3419, E11.3511 – E11.3519, E11.37X1 – E11.37X9, E13.311, E13.3211 – E13.3219, E13.3311 – E13.3319, E13.3411 – E13.3419, E13.3511 – E13.3519, E13.37X1 – E13.37X9	Diabetes mellitus with retinopathy with macular edema
H35.3210 - H35.3293	Exudative age-related macular degeneration
Ranibizumab (Lucentis) or Bevacizumab (Avastin):
CPT codes not covered for indications listed in the CPB:
66030	Injection, anterior chamber of eye (separate procedure); medication
68200	Subconjunctival injection
Other CPT codes related to the CPB:
67027	Implantation of intravitreal drug delivery system (eg, ganciclovir implant), includes concomitant removal of vitreous
67028	Intravitreal injection of a pharmacologic agent (separate procedure)
HCPCS codes covered if selection criteria are met:
C9257	Injection, bevacizumab, 0.25mg [Avastin] [intraocular dose]
J2778	Injection, ranibizumab, 0.1 mg
J2779	Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg
J9035	Injection, bevacizumab, 10 mg [Avastin] [chemotherapy dose]
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
Q5118	Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg
Q5124	Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg
Q5129	Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
ICD-10 codes covered if selection criteria are met:
B39.4	Histoplasmosis capsulati, unspecified [retinitis]
B39.5	Histoplasmosis duboisii [retinitis - see H32]
B39.9	Histoplasmosis, unspecified [retinitis - see H32]
E08.311 - E08.3599, E09.311 - E09.3599, E10.311 - E10.3599, E11.311 - E11.3599, E13.311 - E13.3599	Diabetes mellitus with retinopathy
E08.311, E08.3211 - E08.3219, E08.3311 - E08.3319, E08.41, E08.51, E09.311 E09.3211 - E09.3219, E09.3311 - E09.3312, E09.3411 - E09.3419, E09.3511 - E09.3599, E10.311, E10.3211 - E10.3219, E10.3311 - E10.3319, E10.3411 - E10.3419, E10.3511 - E10.3599, E11.311, E11.3211 - E11.3219, E11.3311 - E11.3319, E11.3411 - E11.3419, E11.3511 - E11.3599, E13.11, E13.3211 - E13.3219, E13.3311 - E13.3319, E13.3411 - E13.3419, E13.3511 - E13.3599	Diabetes mellitus with retinopathy with macular edema
H21.1X1 - H21.1X9	Other vascular disorders of iris and ciliary body [rubeosis iridis]
H30.001 - H30.049	Focal chorioretinitis and focal retinochoroiditis
H30.101 - H30.149	Disseminated chorioretinitis and disseminated retinochoroiditis
H30.90 - H30.93	Unspecified chorioretinal inflamation
H31.20 - H31.29	Hereditary choroidal dystrophies
H34.8110 - H34.8192	Central retinal vein occlusion
H34.8310 - H34.8392	Tributary (branch) retinal vein occlusion
H35.011 - H35.019	Retinal vascular changes; changes in vascular appearance
H35.041 - H35.049	Retinal microaneurysms NOS
H35.051 - H35.059	Retinal neovascularization, unspecified [polypoidal choroidal vasculopathy]
H35.061 - H35.069	Retinal vasculitis
H35.09	Other intraretinal microvascular abnormalities
H35.101 - H35.179	Retinopathy of prematurity
H35.3210 - H35.3293	Exudative age-related macular degeneration
H35.33	Angioid streaks of macula
H35.50 - H35.54	Hereditary retinal dystrophies
H40.89	Other specified glaucoma [associated with vascular disorders]
H44.2A1 - H44.2A9	Degenerative myopia with choroidal neovascularization
H44.20 - H44.23	Degenerative myopia
M31.8	Other specified necrotizing vasculopathies [polypoidal choroidal vasculopathy]
Q82.8	Other specified congenital malformations of skin [pseudoxanthoma elasticum]
ICD-10 codes not covered for indications listed in the CPB (not all-inclusive):
A18.50 - A18.59	Tuberculosis of eye
A51.43	Secondary syphilitic oculopathy [chorioretinitis])
A71.0 - A71.9	Trachoma
B02.30 - B02.39	Zoster ocular disease
B25.9	Cytomegalovirus disease (retinitis)
B30.0	Keratoconjunctivitis due to adenovirus
B30.1	Conjunctivitis due to adenovirus
B30.3	Acute epidemic hemorrhagic conjunctivitis (enteroviral)
B30.8	Other viral conjunctivitis
B58.01	Toxoplasma chorioretinitis
C69.20 - C69.32	Malignant neoplasm of retina and choroid
D18.09	Hemangioma of other sites [retina]
D57.1	Sickle-cell disease without crisis [Sickle cell retinopathy]
E88.49	Other mitochondrial metabolism disorders [NARP syndrome]
H00.011 - H00.029	Hordeolum externum
H01.001 - H01.29	Blepharitis
H01.00A - H01.00B	Unspecified blepharitis
H01.01A - H01.01B	Ulcerative blepharitis
H01.02A - H01.02B	Squamous blepharitis
H04.001 - H04.039	Dacryoadenitis
H04.301 - H04.429	Acute and chronic inflammation of lacrimal passages
H05.001 - H05.019	Cellulitis of orbit
H10.011 - H10.9	Conjunctivitis
H11.001 - H11.069	Pterygium
H15.001 - H15.9	Scleritis and episcleritis
H16.001 - H16.9	Keratitis
H30.20 - H30.819, H31.00 - H31.12	Pars planitis, Harada's disease, chorioretinal scars and degenerations except angioid streaks
H31.101 - H31.9	Choroidal degeneration, dystropy, hemorrhage and rupture, detachment and other disorders
H33.001 - H33.8	Retinal detachments and breaks
H34.00 - H34.239	Retinal vascular occlusion, central retinal artery occlusion, arterial branch occlusion, partial arterial occlusion, and transient arterial occlusion
H34.821 - H34.829	Venous engorgement
H35.021 - H35.029	Exudative retinopathy [Coates' disease]
H35.031 - H35.039	Hypertensive retinopathy
H35.071 - H35.079	Retinal telangiectasia
H35.30	Degeneration of macula and posterior pole [other than exudative age-related macular degeneration]
H35.3110 - H35.3194	Nonexudative age-related macular degeneration
H35.381 – H35.389	Toxic maculopathy [radiation maculopathy]
H35.40 - H35.54	Peripheral retinal degeneration
H35.70 - H35.739	Separation of retinal layers
H35.81 - H35.9	Other retinal disorders
H36	Retinal disorders in diseases classified elsewhere [Sickle cell retinopathy]
H40.001 - H40.9	Glaucoma [except when associated with vascular disorders]
H44.00 - H44.19, H44.30 - H44.9	Disorders of globe
H53.001 - H53.039	Amblyopia ex anopsia
Q85.81, Q85.82, Q85.83, Q85.89	Other phakomatoses, NEC [von Hippel-Lindau]
Z98.83	Filtering (vitreous) bleb after glaucoma surgery status [Bleb encapsulation]
Intravitrial aflibercept (Eylea), Eylea HD:
HCPCS codes covered if selection criteria are met:
C9161	Injection, aflibercept hd, 1 mg
J0178	Injection, aflibercept, 1 mg
ICD-10 codes covered if selection criteria are met:
E08.311 - E08.3599, E09.311 - E09.3599, E10.311 - E10.3599, E11.311 - E11.3599, E13.311 - E13.3599	Diabetes mellitus with retinopathy
H34.8110 - H34.8192	Central retinal vein occlusion
H34.8310 - H34.8392	Tributary (branch) retinal vein occlusion
H35.101 - H35.169	Retinopathy of prematurity
H35.3210 - H35.3293	Exudative age-related macular degeneration
H35.81	Retinal edema
H44.20 - H44.23	Degenerative myopia
ICD-10 codes not covered for indications listed in the CPB (not all-inclusive):
A71.0 - A71.9	Trachoma
B02.30 - B02.39	Zoster ocular disease
B30.0	Keratoconjunctivitis due to adenovirus
B30.1	Conjunctivitis due to adenovirus
B30.3	Acute epidemic hemorrhagic conjunctivitis (enteroviral)
B30.8	Other viral conjunctivitis
B39.0-B39.9	Histoplasmosis [including ocular histoplasmosis]
C19	Malignant neoplasm of rectosigmoid junction
C53.0 - C55	Malignant neoplasm of cervix uteri [uterine leiomyosarcoma]
C56.1 - C56.9	Malignant neoplasm of ovary
C61	Malignant neoplasm of prostate
H00.011 - H00.029	Hordeolum externum
H01.001 - H01.029	Blepharitis
H01.00A - H01.00B	Unspecified blepharitis
H01.01A - H01.01B	Ulcerative blepharitis
H01.02A - H01.02B	Squamous blepharitis
H04.001 - H04.039	Dacryoadenitis
H04.301 - H04.429	Acute and chronic inflammation of lacrimal passages
H05.001 - H05.019	Cellulitis of orbit
H15.001 - H15.9	Scleritis and episcleritis
H16.001 - H16.9	Keratitis
H31.9	Other specified disorders of choroid [myopic choroid neovascularization]
H35.00 - H35.019	Background retinopathy and retinal vascular changes [radiation retinopathy]
H35.051 - H35.059	Retinal neovascularization, unspecified [myopic]
H35.351 - H35.359	Cystoid macular degeneration
H35.52	Pigmentary retinal dystrophy [retinitis pigmentosa]
H35.711 - H35.719	Central serous chorioretinopathy
H40.89	Other glaucoma [neovascular glaucoma]
H44.001 - H44.19	Endophthalmitis
H44.2A1 - H44.2A9	Degenerative myopia with choroidal neovascularization
H59.031 - H59.039	Cystoid macular edema following cataract surgery
M31.0 - M31.9	Other necrotizing vasculopathies [polypoidal choroidal vasculopathy]
T66.xxxA - T66.xxxS	Radiation sickness, unspecified [radiation retinopathy]
Faricimab-svoa (Vabysmo):
HCPCS codes covered if selection criteria are met:
J2777	Injection, faricimab-svoa, 0.1 mg
ICD-10 codes covered if selection criteria are met:
E08.311, E08.3211-E08.3219, E08.3311 - E08.3319, E08.3411 - E08.3419, E08.3511 - E08.3519, E09.311, E09.3211 - E09.3219, E09.3311 - E09.3319, E09.3411 - E09.3419, E09.3511 - E09.3519, E10.311, E10.3211 - E10.3219, E10.3311 - E10.3319, E10.3411 - E10.3419, E10.3511 - E10.3519, E11.311, E11.3211 - E11.3219, E11.3311 - E11.3319, E11.3411 - E11.3419, E11.3511 - E11.3519, E13.311, E13.3211 - E13.3219, E13.3311 - E13.3319, E13.3411 - E13.3419, E13.3511 - E13.3519	Diabetic Macular Edema
H35.3210 - H35.3293	Exudative age-related macular degeneration

---

Background

Age-Related Macular Degeneration

Vascular endothelial growth factor (VEGF) is a naturally occurring substance in the body responsible for the growth of new blood vessels (neovascularization). In the retina however, VEGF may stimulate growth of abnormally fragile vessels prone to leakage. This leakage causes scarring in the macula and eventually leads to loss of central vision.

Age-related macular degeneration (AMD), characterized as a progressive degenerative disease of the macula, is the leading cause of blindness in developed countries afflicting approximately 15 million people in the United States. Age‐related macular degeneration (AMD) is a major cause of painless central vision loss and is a leading cause of blindness in people over 60.

The neovascular (wet) form of the disease is responsible for the majority of cases of severe vision loss and is due to proliferation of abnormal blood vessels behind the retina. These new blood vessels tend to be very fragile and often leak blood and fluid into the retina, that causes visual abnormalities, and cause scar tissue that destroys the central retina. The blood and fluid raise the macula from its normal place at the back of the eye. Damage to the macula occurs rapidly and results in a deterioration of sight over a period of months to years. The development of these abnormal blood vessels is due in part to the activity of vascular endothelial growth factor (VEGF), which induces angiogenesis, and increases vascular permeability and inflammation, all of which are thought to contribute to the progression of the neovascular (wet) form of AMD. Between 80% to 90% of AMD is dry, yet more than 80% of the visual loss attributable to AMD is caused by the wet form.

The natural history of AMD is variable, with clinical manifestations dependent on disease type, extent, and whether one or both eyes are affected. Principle risk factors include age, smoking, family history, Caucasian ethnicity, contralateral eye disease, diabetes, and cataract surgery. Genetics play a particularly strong role, with a single polymorphism estimated responsible for as much as 43% of disease occurrence. Treatment options for AMD include laser phototherapy and VEGF inhibitors.

Central Retinal Vein Occlusion

Central retinal vein occlusion (CRVO) is a common retinal vascular disorder. The exact etiology is un known, however may be caused by arteriosclerotic changes in the central retinal artery or from a thrombotic occlusion of the central retinal vein.

Occlusion of the central retinal vein leads to backup of the blood in the retinal venous system and increases resistance to the venous blood flow. This increased resistance causes stagnation of the blood and ischemia to the retina. Ischemic damage to the retina stimulates increase production of vascular endothelial growth factor (VEGF), and increased levels of VEGF stimulate neovascularization of the posterior and anterior segment of the eye. Retinal Vein Occlusion can lead to Macular Edema or growth of fragile new blood vessels.

Treatment of CRVO includes aspirin, anti-inflammatory agents, isovolemic hemodilution, plasmapheresis, systemic anticoagulation, fibrinolytic agents, systemic corticosteroids, local anticoagulation with intravitreal injections of alteplase, intravitreal injections of triamcinolone, intravitreal injections of bevacizumab.

There are 2 types of CRVO; ischemic and nonischemic:

• Nonischemic CRVO is the milder form of the disease and presents with good vision, few retinal hemorrhages and cotton‐wool spots, and good perfusion to the retina. This type may resolve fully with good visual outcome or may progress to the ischemic type.
• Ischemic CRVO is the more severe form and presents with severe visual loss, extensive retinal hemorrhages, and cotton‐wool spots. Poor perfusion of the retinal and patients may end up with neovascular glaucoma and painful blind eye.

In branch retinal vein occlusion (BRVO) the blockage occurs in a smaller branch of the vessels that connect to the central retinal vein.

Both types of Retinal Vein Occlusion can lead to Macular Edema or growth of fragile new blood vessels.

Diabetic Macular Edema

Diabetic Macular Edema (DME) is the consequence of retinal microvascular changes from poorly controlled diabetes and diabetic retinopathy. DME is associated with thickening of the basement membrane and reduction of pericytes which are believed to increase permeability of the retinal vasculature. This compromises the blood‐retinal barrier causing a leakage of plasma constituents and subsequent retinal edema and hypoxia, all of which stimulates the production of vascular endothelial growth factor (VEGF). DME damages the central retina, which impairs color and pinpoint vision, leading to blurry, washed‐out vision. DME can be classified as either focal or diffuse types. In both cases, the predominant labeled treatment for DME is macular focal/grid laser photocoagulation (cauterization of ocular blood vessels). Intravitreal steroids and anti‐VEGF agents are also used off‐label. (Non‐diabetic causes of macular edema include: AMD, uveitis, RVO, and certain genetic disorders.)

Polypoidal Choroidal Vasculopathy

In a meta-analysis, Yong et al (2015) evaluated the effectiveness and tolerability of photodynamic therapy (PDT) compared to intra-vitreal VEGF inhibitors in the treatment of polypoidal choroidal vasculopathy (PCV).  Relevant studies were selected through an extensive search of the PubMed, Embase, Web of Science, and Cochrane Library databases.  Outcomes of interest included visual outcomes, anatomic variables, and adverse events.  A total of 6 studies enrolling a total of 346 patients were included.  The weighted mean differences (WMDs) of the mean changes in LogMAR VA when comparing PDT with anti-VEGF were -0.02 (95 % confidence interval [CI]: -0.12 to 0.08) at 3 months, 0.02 (95 % CI: -0.12 to 0.16) at 6 months, 0.02 (95 % CI: -0.15 to 0.18) at 12 months, and -0.17 (95 % CI: -0.90 to 0.55) at 24 months.  There were no significant differences between the 2 groups at any of the time-points.  Photodynamic therapy was found to be associated with greater reduction of central retinal thickness (CRT) at 6 months (WMD: 44.94; 95 % CI: 16.44 to 73.44; p = 0.002), and it was superior to anti-VEGF therapy in achieving complete polyp regression (odd ratio, OR: 6.85; 95 % CI: 2.15 to 21.79; p = 0.001).  Rates of adverse events did not differ significantly between the 2 treatments.  The authors concluded that PDT appeared to result in greater CRT reduction at 6 months and higher polyp regression rate.  However, the 2 treatments appeared to be comparable in terms of best corrected visual acuity(BCVA) change and adverse events.

In a retrospective, observational study, Kim et al (2015) evaluated treatment outcomes of intra-vitreal VEGF in eyes with PCV that exhibited poor baseline VA.  This study included 47 eyes with treatment-naïve PCV with baseline VA of 20/200 or worse treated with intra-vitreal anti-VEGF.  Eyes were divided into 2 groups according to the presence of sub-macular hemorrhage (hemorrhage and no-hemorrhage groups).  The BCVA at baseline was compared with that measured at 3 and 6 months after treatment.  A mean of 3.3 ± 0.9 intra-vitreal anti-VEGF injections were performed during the 6-month follow-up period.  In the hemorrhage group (n = 23), 6 patients additionally underwent pneumatic displacement with or without intra-vitreal tissue plasminogen activator.  The logarithm of minimal angle of resolution BCVA at diagnosis, 3, and 6 months was 1.47 ± 0.49, 0.91 ± 0.79, and 0.81 ± 0.83, respectively.  Compared with baseline, BCVA was significantly better at 3 and 6 months (p = 0.007 and p = 0.001, respectively).  In the no-hemorrhage group (n = 24), the BCVA at defined time-points was 1.23 ± 0.32, 1.06 ± 0.33, and 1.02 ± 0.35, respectively; BCVA was significantly better at 3 and 6 months compared with baseline (p = 0.006 and p = 0.025, respectively).  The authors concluded that intra-vitreal anti-VEGF was found to be beneficial in PCV eyes with poor baseline VA, regardless of the presence of sub-macular hemorrhage.  The magnitude of visual improvement was relatively greater in eyes with sub-macular hemorrhage.

Oishi et al (2015) stated that the optimal treatment of PCV is still undetermined.  Photodynamic therapy is effective for PCV but the treatment effect declines after 1 year.  While some reports showed the efficacy of anti- VEGF therapy for PCV, other reports showed treatment-refractory cases.  These researchers reviewed the results of their multi-center randomized trial, conducted to compare the effectiveness of PDT and ranibizumab in PCV patients.  The results showed that ranibizumab is more effective in visual gain in 2-year follow-up.  Central retinal thickness improved with both treatments and there was no difference between them.  The authors concluded that their results provided evidence that ranibizumab is superior to PDT monotherapy for treatment of PCV in terms of VA.

In a retrospective study, Chang et al (2016) examined the clinical outcome after more than 4 years for PCV treated with anti- VEGF therapy and investigated the factors predictive of long-term visual outcomes.  This study included 31 eyes, with PCV treated with anti-VEGF therapy (either ranibizumab or bevacizumab, or both), and were followed-up for 4 years or longer.  The BCVA at baseline was compared with that measured at 3 months and at the final follow-up.  Factors associated with final VA were also analyzed.  The mean follow-up period was 53.0 ± 4.3 months.  During the follow-up period, the patients were treated with an average of 8.8 ± 3.0 intra-vitreal anti-VEGF injections; BCVA at diagnosis at 12, 24, and 36 months, and at final follow-up was 0.52 ± 0.35, 0.46 ± 0.36, 0.57 ± 0.45, 0.76 ± 0.56, and 0.83 ± 0.60, respectively.  When compared to the baseline value, the BCVA was significantly improved at 3 months (p = 0.006), whereas the BCVA at final follow-up was significantly decreased compared to the baseline value (p = 0.018).  Among the included eyes, 48.4 % experienced deterioration of VA and 51.6 % showed stable vision; BCVA at 12 months was most strongly associated with VA at final follow-up.  The authors concluded that although the long-term treatment outcome of PCV is generally unfavorable, stable vision can be achieved in approximately 50 % of the patients; VA at 12 months after the initial treatment was predictive of long-term visual outcomes.

Aflibercept [(Eylea), (Eylea HD)]

U.S. Food and Drug Administration (FDA)-Approved Indications

Eylea is indicated for the treatment of:

• Diabetic macular edema
• Diabetic retinopathy
• Neovascular (wet) age-related macular degeneration
• Macular edema following retinal vein occlusion
• Retinopathy of prematurity.

Eylea HD is indicated for the treatment of:

• Diabetic macular edema
• Diabetic retinopathy
• Neovascular (wet) age-related macular degeneration

Aflibercept is available as Eylea and Eylea HD (Regeneron Pharmaceuticals).  Aflibercept injection is a vascular endothelial growth factor (VEGF) inhibitor administered as an intravitreal injection. 

Aflibercept is a fully human recombinant fusion protein that binds all isoforms of VEGFA, and prevents their binding to VEGFR‐1 and VEGFR‐2. Aflibercept also binds to Placental Growth Factor (PlGF) inhibiting the binding to VEGFR‐1. Inhibiting the binding to these receptors decreases inflammation and vascular permeability, prevents the progression of neovascular AMD, and prevents further loss of vision.

Eylea and Eylea HD are contraindicated in ocular or periocular infection, active intraocular inflammation, and hypersensitivity. Per the label, Eylea and Eylea HD include warnings and precautions for risk of endophthalmitis and retinal detachments, which may occur following intravitreal injections, increases in intraocular pressure, which have been seen within 60 minutes of an intravitreal injection, and there is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors. Eylea and Eylea HD have not been studied in pregnant women, so the treatment should be used only in pregnant women if the potential benefits of the treatment outweigh any potential risks. Age-related macular degeneration does not occur in children and aflibercept has not been studied in children. In the clinical studies, approximately 76% (2049/2701) of patients randomized to treatment with Eylea were 65 years of age or older and approximately 46% (1250/2701) were 75 years of age or older. No significant differences in efficacy or safety were seen with increasing age in these studies. The most common adverse reactions (5% or more) reported in patients receiving Eylea or Eylea HD were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased (Regeneron, 2019; 2023a).

In a multi-center, randomized, double-masked study, Heier et al (2011) evaluated anatomic outcomes and vision, injection frequency, and safety during the as-needed (PRN) treatment phase of a study evaluating a 12-week fixed dosing period followed by PRN dosing to week 52 with VEGF Trap-Eye for neovascular (wet) AMD.  A total of 159 patients with subfoveal choroidal neovascularization (CNV) secondary to wet AMD were included in this study.  Patients were randomly assigned to 1 of 5 intra-vitreal VEGF Trap-Eye treatment groups: 0.5 mg or 2 mg every 4 weeks or 0.5, 2, or 4 mg every 12 weeks during the fixed-dosing period (weeks 1 to 12).  From weeks 16 to 52, patients were evaluated monthly and were retreated PRN with their assigned dose (0.5, 2, or 4 mg).  Main outcome measures included change in central retinal/lesion thickness (CR/LT), change in total lesion and CNV size, mean change in BCVA, proportion of patients with 15-letter loss or gain, time to first PRN injection, re-injection frequency, and safety at week 52.  The decrease in CR/LT at week 12 versus baseline remained significant at weeks 12 to 52 (-130 μm from baseline at week 52) and CNV size regressed from baseline by 2.21 mm(2) at 48 weeks.  After achieving a significant improvement in BCVA during the 12-week, fixed-dosing phase for all groups combined, PRN dosing for 40 weeks maintained improvements in BCVA to 52 weeks (5.3-letter gain; p < 0.0001).  The most robust improvements and consistent maintenance of VA generally occurred in patients initially dosed with 2 mg every 4 weeks for 12 weeks, demonstrating a gain of 9 letters at 52 weeks.  Overall, a mean of 2 injections was administered after the 12-week fixed-dosing phase, and the mean time to first re-injection was 129 days; 19 % of patients received no injections and 45 % received 1 or 2 injections.  Treatment with VEGF Trap-Eye was generally safe and well-tolerated, with few ocular or systemic AEs.  The authors concluded that PRN dosing with VEGF Trap-Eye at weeks 16 to 52 maintained the significant anatomic and vision improvements established during the 12-week fixed-dosing phase with a low frequency of re-injections.  Repeated dosing with VEGF Trap-Eye was well-tolerated over 52 weeks of treatment.

On November 18, 2011, the FDA approved aflibercept ophthalmic solution (Eylea, Regeneron Pharmaceuticals Inc.) for the treatment of neovascular (wet) AMD.  The FDA's approval of Eylea was based on positive results from the 2 phase III VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) trials.  Both found the drug non-inferior to ranibizumab, which is currently the most potent FDA-approved treatment option for wet AMD.  In VIEW 1 (n = 1,217), conducted in the United States, and VIEW 2 (n = 1,240), conducted in Europe, all regimens of the drug, including 2 mg dosed every 2 months (after 3 loading doses), successfully met the primary endpoint of statistical non-inferiority compared with ranibizumab.  The proportions of patients who maintained or improved vision over the course of 52 weeks in VIEW 1 were 96 %, 95 %, and 95 % of patients receiving aflibercept 0.5 mg monthly, 2.0 mg monthly, and 2.0 mg every 2 months, respectively.  This compared with 94 % of patients receiving the standard 0.5-mg monthly dose of ranibizumab.  For the secondary endpoint, visual acuity, the new drug was better.  Patients receiving 2 mg monthly had a greater mean improvement in visual acuity at week 52, with a gain of 10.9 letters compared with 8.1 letters with ranibizumab (p < 0.01).  All other dose groups were not significantly different from ranibizumab with respect to this secondary endpoint.  In VIEW 2, vision was maintained in 96 % of all aflibercept dose groups and in 94 % of the ranibizumab group.  All doses were statistically non-inferior to ranibizumab, and no differences were noted between the drugs in visual acuity gain.

In September of 2012 the FDA approved aflibercept injection (Eylea) for use in macular edema following central retinal vein occlusion (CRVO).  Boyer et al (2012) conducted a multi-center, randomized, prospective, controlled trial to assess the efficacy and safety of intravitreal VEGF Trap-Eye in eyes with macular edema secondary to CRV. A total of 189 eyes with macular edema secondary to CRVO were included in this study.  Eyes were randomized 3:2 to receive VEGF Trap-Eye 2 mg or sham injection monthly for 6 months.  At week 24, 56.1 % of VEGF Trap-Eye treated eyes gained 15 letters or more from baseline versus 12.3 % of sham-treated eyes (p < 0.001).  The VEGF Trap-Eye treated eyes gained a mean of 17.3 letters versus sham-treated eyes, which lost 4.0 letters (p < 0.001).  Central retinal thickness decreased by 457.2 µm in eyes treated with VEGF Trap-Eye versus 144.8 µm in sham-treated eyes (p < 0.001), and progression to any neovascularization occurred in 0 and 5 (6.8 %) of eyes treated with VEGF Trap-Eye and sham-treated eyes, respectively (p = 0.006).  Serious ocular AEs were reported by 3.5 % of VEGF Trap-Eye patients and 13.5 % of sham patients while incidences of non-ocular serious AEs generally were well-balanced between both groups.  Conjunctival hemorrhage, reduced VA, and eye pain were the most common AEs.  The investigators concluded that at 24 weeks, monthly intra-vitreal injection of VEGF Trap-Eye 2 mg in eyes with macular edema resulting from CRVO improved VA and CRT, eliminated progression resulting from neovascularization, and was associated with a low rate of ocular AEs related to treatment.

In October 2014, the FDA approved aflibercept injection for the treatment of macular edema following retinal vein occlusion (RVO), which includes macular edema following branch retinal vein occlusion (BRVO) in addition to the previously-approved indication of macular edema following central retinal vein occlusion (CRVO) (Regeneron, 2014).  The recommended dosage of aflibercept in patients with macular edema following RVO is 2 milligrams (mg) (0.05 mL) every month (4 weeks) via intravitreal injection. 

The expanded indication was based on the previously-approved indication for macular edema following CRVO and the positive results from the double-masked, randomized, controlled Phase 3 VIBRANT study of 181 patients with macular edema following BRVO (Regeneron, 2014).  The VIBRANT study compared aflibercept 2 mg once every 4 weeks with macular laser photocoagulation (control). The study continued for 52 weeks. At 24 weeks, significantly more patients treated with aflibercept gained at least 15 letters in vision (three lines on an eye chart) from baseline as measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, the primary endpoint of the study, compared with patients who received control (53 percent vs. 27 percent; P less than 0.01).  Patients treated with aflibercept achieved a 17.0 letter mean improvement over baseline in best-corrected visual acuity (BCVA) compared to a 6.9 letter mean improvement in patients who received control (P less than 0.01), a key secondary endpoint. 

The incidence of non-ocular serious adverse events (SAE) was 8.8 percent in the aflibercept group and 9.8 percent in the control group (Regeneron, 2014). One death and one Anti-Platelet Trialists' Collaboration (APTC)-defined arterial thromboembolic event (non-fatal stroke) occurred during the trial, both in patients in the control group.  The most common ocular adverse events in patients treated with aflibercept included conjunctival hemorrhage and cataract.  There were no cases of intraocular inflammation in either group.  There was one ocular SAE in a patient in the aflibercept group, which was traumatic cataract.

In June 2014, the U.S. Food and Drug Administration (FDA) approved aflibercept (Eylea) injection for the treatment of diabetic macular edema (DME) (Regeneron, 2014).  The FDA approval of aflibercept in DME was based on the one-year data from the Phase 3 VISTA-DME and VIVID-DME studies of 862 patients, which compared aflibercept 2 mg given monthly, aflibercept 2 mg given every two months (after five initial monthly injections), or macular laser photocoagulation (at baseline and then as needed).  In the DME studies, after one year, the mean changes in best corrected visual acuity (BCVA), as measured by the ETDRS chart for the monthly and every two month aflibercept groups, were statistically significantly improved compared to the control group and were similar to each other.  Across both trials, patients in both aflibercept dosing groups gained, on average, the ability to read approximately two additional lines on an eye chart compared with almost no change in the control group. The VISTA-DME and VIVID-DME studies will continue as planned for a total of three years.  

In the Phase 3 VISTA-DME and VIVID-DME trials, aflibercept injection 2 mg dosed monthly and aflibercept 2 mg dosed every two months after 5 initial monthly doses achieved statistically significant improvements in the primary endpoint of mean change in BCVA at one year and the secondary endpoint of proportion of patients who gained at least 15 letters in BCVA versus baseline compared to control (Regeneron, 2014). 

In the VISTA-DME trial, patients receiving aflibercept 2 mg monthly had a mean change from baseline in BCVA of 12.5 letters (p less than 0.01 compared to control), patients receiving aflibercept 2 mg every two months (after 5 initial monthly injections) had a mean change from baseline in BCVA of 10.7 letters (p less than 0.01 compared to control), and patients receiving control treatment had a mean change from baseline in BCVA of 0.2 letters (Regeneron, 2014).  In the VISTA-DME trial, the percentage of patients who gained at least 15 letters in BCVA from baseline, or three lines of vision, was 41.6 percent in the aflibercept 2 mg every month group (p less than 0.01 compared to control), 31.1 percent in the aflibercept 2 mg every 2 months group (after 5 initial monthly injections) (p less than 0.01 compared to control), and 7.8 percent in the control group. 

In the VIVID-DME trial, patients receiving aflibercept 2 mg monthly had a mean change from baseline in BCVA of 10.5 letters (p less than 0.01 compared to control), patients receiving aflibercept 2 mg every two months (after 5 initial monthly injections) had a mean change from baseline in BCVA of 10.7 letters (p less than 0.01 compared to control), and patients receiving control had a mean change from baseline in BCVA of 1.2 letters (Regeneron, 2014).  In the VIVID-DME trial, the percentage of patients who gained at least 15 letters in BCVA from baseline, or three lines of vision, was 32.4 percent in the aflibercept 2 mg every month group (p less than 0.01 compared to control), 33.3 percent in the aflibercept 2 mg every 2 months group (after 5 initial monthly injections) (P less than 0.01 compared to control), and 9.1 percent in the control group. 

In these trials, aflibercept had a similar overall incidence of adverse events (AEs), ocular serious AEs, and non-ocular serious AEs across treatment groups and the control group (Regeneron, 2014).  Arterial thromboembolic events as defined by the Anti-Platelet Trialists' Collaboration (non-fatal stroke, non-fatal myocardial infarction, and vascular death) also occurred at similar rates across treatment groups and the control group.  The most frequent ocular treatment emergent AEs (TEAEs) observed in the VISTA-DME and VIVID-DME trials included conjunctival hemorrhage, eye pain, cataract, and vitreous floaters.  The most common non-ocular TEAEs included hypertension and nasopharyngitis, which occurred with similar frequency in the treatment groups and the control group. 

The FDA approved aflibercept (Eylea) injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME) (FDA, 2015). 

The approval of aflibercept for the treatment of diabetic retinopathy in DME was based on two year data from the Phase 3 VISTA-DME and VIVID-DME studies of 862 patients, which compared aflibercept 2 mg monthly, aflibercept 2 mg every two months (after five initial monthly injections), or macular laser photocoagulation (at baseline and then as needed) (Regeneron, 2015). In these studies, on the primary endpoint of mean change in Best Corrected Visual Acuity (BCVA) at one year, patients treated with aflibercept monthly or every two months showed statistically significant improvements compared to the control group. Patients in both aflibercept groups gained, on average, the ability to read approximately two additional lines on an eye chart compared with almost no change in the control group. 

A pre-specified secondary endpoint in the studies at year 2 evaluated diabetic retinopathy severity based on an established grading scale measuring retinal damage (Regeneron, 2015). In the VISTA-DME trial, 38 percent of patients receiving aflibercept monthly or every two months (after 5 initial monthly injections) achieved a 2-step or better improvement on the diabetic retinopathy severity scale (DRSS), compared to 16 percent of patients receiving control. In the VIVID-DME trial, approximately 30 percent of patients receiving aflibercept monthly or every two months (after 5 initial monthly injections) achieved a 2-step or better improvement on the DRSS, compared to 8 percent of patients receiving control. 

In these trials at year 2, aflibercept had a similar overall incidence of adverse events (AEs), ocular serious AEs, and non-ocular serious AEs across treatment groups and the control group (Regeneron, 2015). Arterial thromboembolic events as defined by the Anti-Platelet Trialists' Collaboration (non-fatal stroke, non-fatal myocardial infarction, and vascular death) also occurred at similar rates across treatment groups and the control group. The most frequent ocular treatment emergent AEs (TEAEs) observed in the VISTA-DME and VIVID-DME trials included conjunctival hemorrhage, eye pain, cataract, and vitreous floaters. The most common non-ocular TEAEs included hypertension and nasopharyngitis, which occurred with similar frequency in the treatment groups and the control group. 

In a multi-center, randomized, double-masked, phase II clinical trial, Do and colleagues (2011) compared different doses and dosing regimens of vascular endothelial growth factor (VEGF) Trap-Eye with laser photocoagulation in eyes with diabetic macular edema (DME).  Diabetic patients (n = 221) with center-involved DME were included in this study.  Participants were assigned randomly to 1 of 5 treatment regimens: VEGF Trap-Eye 0.5 mg every 4 weeks (0.5q4); 2 mg every 4 weeks (2q4); 2 mg every 8 weeks after 3 initial monthly doses (2q8); or 2 mg dosing as needed after 3 initial monthly doses (2PRN), or macular laser photocoagulation.  Main outcome measures included the change in best-corrected visual acuity (BCVA) at 24 weeks (the primary end point) and at 52 weeks, proportion of eyes that gained 15 letters or more in ETDRS BCVA, and mean changes in central retinal thickness (CRT) from baseline.  As previously reported, mean improvements in BCVA in the VEGF Trap-Eye groups at week 24 were 8.6, 11.4, 8.5, and 10.3 letters for 0.5q4, 2q4, 2q8, and 2PRN regimens, respectively, versus 2.5 letters for the laser group (p ≤ 0.0085 versus laser).  Mean improvements in BCVA in the VEGF Trap-Eye groups at week 52 were 11.0, 13.1, 9.7, and 12.0 letters for 0.5q4, 2q4, 2q8, and 2PRN regimens, respectively, versus -1.3 letters for the laser group (p ≤ 0.0001 versus laser).  Proportions of eyes with gains in BCVA of 15 or more ETDRS letters at week 52 in the VEGF Trap-Eye groups were 40.9 %, 45.5 %, 23.8 %, and 42.2 % versus 11.4 % for laser (p = 0.0031, p = 0.0007, p = 0.1608, and p = 0.0016, respectively, versus laser).  Mean reductions in CRT in the VEGF Trap-Eye groups at week 52 were -165.4 μm, -227.4 μm, -187.8 μm, and -180.3 μm versus -58.4 μm for laser (p < 0.0001 versus laser).  Vascular endothelial growth factor Trap-Eye generally was well-tolerated.  The most frequent ocular adverse events with VEGF Trap-Eye were conjunctival hemorrhage, eye pain, ocular hyperemia, and increased intraocular pressure, whereas common systemic adverse events included hypertension, nausea, and congestive heart failure.  The authors concluded that significant gains in BCVA from baseline achieved at week 24 were maintained or improved at week 52 in all VEGF Trap-Eye groups.  Moreover, they stated that VEGF Trap-Eye warrants further investigation for the treatment of DME.

On February 8, 2023, the U.S. Food and Drug Administration (FDA) approved Eylea (aflibercept) injection for the treatment of preterm infants with retinopathy of prematurity (ROP). With this first new pediatric approval, Eylea is currently indicated to treat five retinal conditions caused by ocular angiogenesis. The FDA approval was based on supporting data from two randomized global phase 3 trials, BUTTERFLEYE (n=113) and FIREFLEYE (n=120). Both studies investigated Eylea 0.4 mg versus laser photocoagulation (laser) in infants with ROP. The results from both studies, showed that approximately 80% of Eylea-treated infants achieved an absence of both active ROP and unfavorable structural outcomes at 52 weeks of age, which is better than would have been anticipated without treatment. No new safety concerns were observed in either trial (Regeneron, 2023a).

On August 18, 2023, the U.S. Food and Drug Administration approved Eylea HD (aflibercept) injection 8 mg for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The FDA approval for this dose was based on supporting data from the PULSAR and PHOTON studies for the treatment of patients with nAMD and DME, respectively (Regeneron Pharmaceuticals, 2023b).

In the PULSAR trial, a randomized, multi-center, double-masked, active-controlled study, investigators evaluated the safety and efficacy of aflibercept (Eylea HD) in treatment-naive patients with nAMD. In total, 1009 patients were treated and assessed for efficacy (673 with Eylea HD). Patient treatment randomization occurred in a 1:1:1 ratio to 1 of 3 treatment groups: 1) Eylea HD given every 12 weeks following 3 initial monthly doses (HDq12), 2) Eylea HD given every 16 weeks following 3 initial monthly doses (HDq16), and 3) Eylea 2 mg administered every 8 weeks (2q8) following 3 initial monthly doses. Patients in the Eylea HD groups could be treated as frequently as every 8 weeks per protocol-defined visual and anatomic criteria, starting at week 16. The main efficacy endpoint was the change from baseline in best corrected visual acuity at week 48 as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score. Both HDq12 and HDq16 treatments showed as being non-inferior and clinically equivalent to 2q8 treatment with regard to the change in BCVA score at week 48 using the pre-specified non-inferiority margin of 4 letters. At 48 weeks completion, the mean number of injections given were 5.2 in the HDq16 group (n=312), 6.1 in the HDq12 group (n=316) and 6.9 in the Eylea q8 group (n=309). The efficacy results in all subgroups (e.g., age, gender, geographic region, ethnicity, race, baseline BCVA and lesion type) were consistent with those in the overall population (Regeneron Pharmaceuticals, 2023a).

In the PHOTON trial, a randomized, multi-center, double-masked, active-controlled study, investigators evaluated the safety and efficacy of aflibercept (Eylea HD) in patients with DME involving the center of the macula. In total, 658 patients were treated and assessed for efficacy (491 with Eylea HD). Patient treatment randomization occurred in a 2:1:1 ration to 1 of 3 treatment groups: 1) Eylea HD given every 12 weeks following 3 initial monthly doses (HDq12), 2) Eylea HD given every 16 weeks following 3 initial monthly doses (HDq16), and 3) Eylea 2 mg given every 8 weeks (2q8) following 5 initial monthly doses. Patients in the Eylea HD groups could be treated as frequently as every 8 weeks per protocol-defined visual and anatomic criteria, starting at week 16. The main efficacy endpoint was the change from baseline BCVA at week 48 as measured by ETDRS letter score. Both HDq12 and HDq16 treatments showed as being non-inferior and clinically equivalent to 2q8 treatment with regard to the change in BCVA score at week 48 using the pre-specified non-inferiority margin of 4 letters. At 48 weeks completion, the mean number of injections administered were 5.0 in the HDq16 group (n=155), 6.0 in the HDq12 group (n=298) and 7.9 in the Eylea q8 group (n=156). The efficacy results in all subgroups (e.g., age, gender, geographic region, race, baseline, BCVA, baseline CRT and prior DME treatment) were consistent with those in the overall population (Regeneron Pharmaceuticals, 2023a).

The efficacy and safety data of Eylea HD in DR were taken from the PHOTON study. A key efficacy outcome was the change in the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (ETDRS-DRSS). The ETDRS-DRSS score was assessed at baseline and approximately every 3 months thereafter for the duration of the study. Baseline ETDRS-DRSS scores, in general, were balanced across treatment groups. The Eylea HDq16 group did not meet the non-inferiority criteria for the proportion of patients with a ≥2-step improvement on ETDRS-DRSS and was not considered clinical equivalent to Eylea given every 8 weeks. The results of the subgroups (e.g., age, gender, race, ethnicity, baseline BCVA and prior DME treatment) on the proportion of patients who achieved a ≥2-step improvement on the ETDRS-DRSS from baseline to week 48 generally were consistent with those in the overall population (Regeneron Pharmaceuticals, 2023a).

Aflibercept (Intravitreal) for Degenerative Myopia/Myopic Choroid Neovascularization

Zhang et al (2015) stated that choroidal neovascularization (CNV) secondary to pathologic myopia has a very high incidence in global, especially in Asian, populations.  It is a common cause of irreversible central vision loss, and severely affects the quality of life (QOL) in the patients with pathologic myopia.  The traditional therapeutic modalities for CNV secondary to pathologic myopia include thermal laser photocoagulation, surgical management, trans-pupillary thermotherapy, and photodynamic therapy (PDT) with verteporfin.  However, the long-term outcomes of these modalities are disappointing.  Recently, intravitreal administration of anti-VEGF biological agents, including bevacizumab, ranibizumab, pegaptanib, aflibercept, and conbercept, has demonstrated promising outcomes for this ocular disease.  The anti-VEGF regimens are more effective on improving visual acuity (VA), reducing central fundus thickness and central retina thickness (CRT) than the traditional modalities.  These anti-VEGF agents thus hold the potential to become the 1st-line medicine for treatment of CNV secondary to pathologic myopia.  This review followed the trend of "from bench to bedside", initially discussing the pathogenesis of myopic CNV, delineating the molecular structures and mechanisms of action of the currently available anti-VEGF drugs, and then systematically comparing the up-to-date clinical applications as well as the safety and effectiveness of the anti-VEGF drugs to the CNV secondary to pathologic myopia.  The authors stated that aflibercept and conbercept are the chimeric proteins containing the fragments of murine Fab and human Fc, and belong to the new generation of anti-VEGF agents.  They were originally approved for treatment of wet age-related macular degeneration (wARMD), their safety and effectiveness in the treatment of myopic CNV need to be confirmed/proven by large-scale rigorous clinical trials.

In an international, phase-III, multi-center, randomized, double-masked, sham-controlled study, Ikuno et al (2015) evaluated intravitreal aflibercept 2 mg in patients with myopic CNV.  Patients aged greater than or equal to 18 years with high myopia (less than or equal to -6.0 diopters (D) or axial length of greater than or equal to 26.5 mm), active myopic CNV, and best-corrected visual acuity (BCVA) of 73 to 35 Early Treatment Diabetic Retinopathy Study letters in the study eye were included.  Patients were randomized 3:1 to intravitreal aflibercept or sham.  In the intravitreal aflibercept arm, patients received 1 injection at baseline.  Additional injections were performed in case of CNV persistence or recurrence at monthly visits through week 44.  In the sham arm, patients received sham injections through week 20.  At week 24, after assessment of the primary efficacy end-point, sham patients received a mandatory intravitreal aflibercept injection followed by intravitreal aflibercept (if disease persisted/recurred) or sham injection every 4 weeks.  Main outcome measures were mean change in BCVA from baseline to week 24.  A total of 122 patients were randomized to intravitreal aflibercept (n = 91) or sham (n = 31).  Baseline demographics were similar across groups.  At week 24, patients in the intravitreal aflibercept and sham groups gained 12.1 and lost 2 letters, respectively (p < 0.0001).  By week 48, patients in the intravitreal aflibercept and sham/intravitreal aflibercept groups gained 13.5 and 3.9 letters.  Patients in the intravitreal aflibercept group received 2 injections (median) in the 1st study quarter (week 0 to 8).  Median number of injections in quarters 2 to 4 was 0.  Patients in the "sham/intravitreal aflibercept" group received 2 and 1 (median) intravitreal aflibercept injections in quarters 3 and 4.  Central retinal thickness improved in parallel with visual gains.  Incidence of ocular adverse events (AEs) was similar in both groups through week 48 (37.4 % versus 38.7); most were assessed by investigators as mild.  No deaths occurred.  The authors concluded that intravitreal aflibercept 2 mg was effective for treatment of myopic CNV with clinically important visual and anatomic benefits achieved with a limited number of injections given in the first 8 weeks of treatment.  No new safety concerns occurred with treatment.  They stated that intravitreal aflibercept should be considered as a therapeutic option for myopic CNV.

In a retrospective study, Brue et al (2016) evaluated long-term effectiveness of intravitreal injections of aflibercept as primary treatment for subfoveal/juxtafoveal myopic CNV.  A total of 38 treatment-naive eyes of 38 patients with subfoveal/juxtafoveal myopic CNV received initial intravitreal aflibercept injections and were followed for at least 18 months.  Aflibercept was applied again for persistent or recurrent CNV, as required.  Statistical analysis was carried out using SPSS.  Mean patient age was 45.8 years, and mean eye refractive error was -7.79 D.  For the total patient group (n = 38 eyes), mean logMAR BCVA significantly improved from 0.69 at baseline to 0.15 at 18 months (p < 0.01).  Over 50 % of the treated eyes obtained resolution with 1 aflibercept injection.  Patients were also grouped according to age, as less than 50 years (n = 20 eyes) and greater than or equal to 50 years (n = 18 eyes).  Mean BCVA improvement was significantly greater in eyes of the younger myopic CNV group, compared with those of greater than or equal to 50 years (0.21 versus 0.35; p < 0.05).  The mean number of aflibercept injections was 1.8 for the less than 50 years myopic CNV group, and 3.6 for the  greater than or equal to 50 years myopic CNV group (p < 0.001).  Correlation between spherical equivalent refraction and final VA reached statistical significance only for the less than 50 years myopic CNV group (p < 0.001; Levene's correlation).  The authors concluded that intravitreal aflibercept provided long-term VA improvement in myopic CNV.  The less than 50 years old myopic CNV group had significantly fewer injections, with greater VA improvement.  They stated that intravitreal aflibercept in myopic CNV did not require the 3-injection loading phase used for aflibercept treatment of neovascular ARMD.

Pece and Milani (2016) evaluated the use of aflibercept for the treatment of subfoveal myopic CNV.  A total of 32 patients (33 eyes) with myopic subfoveal CNV were consecutively enrolled in this prospective open-label case-series study.  All patients were treated with an off-label 2-mg intravitreal injection of aflibercept.  After the 1st injection, administration of aflibercept followed an "on demand" pro re nata (PRN) regimen.  The primary outcome was change in BCVA score after 12 months.  Mean follow-up was 12 months, and the median number of aflibercept injections was 2.0 (range of 1 to 4).  Overall, mean BCVA improved from 0.59 ± 0.37 logMAR at baseline to 0.38 ± 0.33 logMAR at 12 months, a change of -0.21 ± 0.23 logMAR (p < 0.0001), and from 70.5 ± 18.5 to 81.1 ± 16.4 letters, a change of 10.6 ± 11.4 (p < 0.0001).  Improvements were similar among patients irrespective of previous PDT.  The Increase in BCVA was greater in younger patients (aged less than 50 years) and those with baseline BCVA of greater than or equal to 75 letters.  The authors concluded that intravitreal aflibercept in a PRN regimen is effective for the treatment of myopic CNV, with no apparent short-term safety effects.  Treated eyes had BCVA gains after 12 months, with a median of 2 injections.

Korol et al (2016) determined the effectiveness of intravitreal aflibercept injections for the treatment of patients with CNV associated with pathologic myopia.  In this uncontrolled, prospective cohort study, 31 eyes of 30 consecutive patients affected by CNV associated with pathologic myopia were treated with intravitreal aflibercept (2 mg) as needed following 2 initial monthly doses and observed over a 12-month follow-up period.  The primary end-point was change in BCVA at month 12, while CRT on optical coherence tomography (OCT), neovascularization activity on fluorescein angiography, the number of aflibercept injections administered, and safety were examined as secondary end-points.  Patients received a mean of 2.6 intravitreal aflibercept injections over the 12-month study period.  Compared with baseline, BCVA improved significantly at all time-points (p < 0.05).  Mean (standard deviation [SD]) decimal BCVA was 0.2 (0.1) at baseline and 0.35 (0.16) at month 12.  The greatest improvement in BCVA was seen within the first 2 months (p = 0.01).  Mean (SD) CRT on OCT decreased from 285 (62) µm at baseline to 227 (42) µm (p = 0.01) at month 12.  There was a continuous decrease in mean CRT on OCT over time.  No cases of endophthalmitis, uveitis, stroke, or retinal detachment were noted.  No patient demonstrated an intra-ocular pressure (IOP) of greater than 20 mmHg during any study visit.  The authors concluded that the 12-month results of intravitreal aflibercept for myopic CNV using an as-needed regimen were positive, showing benefits in visual and anatomic outcomes and an acceptable tolerability profile.

In a retrospective study Wang and colleagues (2018) compared the efficacy of intra-vitreal aflibercept and bevacizumab for patients with mCNV.  Patients with treatment-naïve mCNV received 1 + PRN intravitreal bevacizumab from March 2008 to February 2013, while from March 2013 to July 2016 patients were treated by 1 + PRN intravitreal aflibercept, all with monthly follow-up for 12 months.  Primary outcome measures included change in CFT in 1 mm by SD-OCT, and BCVA at month 12.  Complications after injections were recorded.  The intra-group changes in CFT and BCVA were compared with Wilcoxon signed rank test, the between-group difference compared with Wilcoxon rank sum test.  Fisher's exact test was used for categorical comparison between groups.  A total of 78 eyes of 78 patients were collected.  There were 42 eyes (27 women) in bevacizumab group, with mean age of 53.2 ± 5.4 years.  The mean BCVA significantly improved from baseline 0.56 ± 0.35 logMAR to 0.35 ± 0.35 logMAR at month 12 after bevacizumab treatment (p < 0.001).  The mean CFT significantly decreased from baseline 315.3 ± 25.6 μm to 253.7 ± 24.4 μm at month 12 following intra-vitreal bevacizumab (p < 0.001).  There were 36 eyes (24 women) in aflibercept group, with mean age of 52.8 ± 6.8 years.  The mean BCVA significantly improved from baseline 0.61 ± 0.47 logMAR to 0.38 ± 0.41 logMAR at month 12 after aflibercept treatment (p < 0.001).  The mean CFT significantly decreased from baseline 328.2 ± 19.8 μm to 241.8 ± 27.2 μm at month 12 following intra-vitreal aflibercept (p < 0.001).  The baseline demographics, lens status, axial length, refractive errors, duration of symptoms, BCVA, and CFT did not differ significantly between groups (p > 0.05).  There was no significant difference between bevacizumab and aflibercept groups in BCVA and CFT from month 1 to month 12 (p > 0.05).  Injection number of aflibercept was 2.11 ± 0.41, less than that of bevacizumab (3.23 ± 0.38) during 12-month period (p = 0.01).  There were no systemic thrombo-embolic event, elevated IOP, retinal detachment, or infectious endophthalmitis following injections in both groups.  The authors concluded that both aflibercept and bevacizumab could effectively treat choroidal neovascularization in high myopes; intra-vitreal aflibercept had similar efficacy but less treatment number than bevacizumab for mCNV during 12-month period.  Moreover, these investigators stated that a prospective, randomized, multi-centered trial is needed to prove the efficacy between 2 anti-VEGF agents. The authors stated that this study had several drawbacks.  This was a retrospective, non-randomized, and comparative study performed in 1 institution.  This trial had low sample size (n = 36 eyes in aflibercept group) and possibly homogenous patient population.  Some bias may have occurred in this study. 

Aflibercept (Intravitreal) for the Treatment of Central Serous Chorioretinopathy

In a prospective, longitudinal study, Tekin and colleagues (2018) evaluated the short-term efficacy and tolerability results of intra-vitreal aflibercept injection as a therapeutic option for eyes with chronic CSC.  A total of 10 eyes (10 patients) with chronic CSC who had been followed for more than 6months after the first intra-vitreal injection of aflibercept were recruited for the study.  The BCVA and CMT values obtained by spectral-domain OCT were recorded at baseline and the 1st, 3rd, and 6th months after the injection.  The mean logMAR BCVA was 0.70 ± 0.25 at baseline.  At the 1st, 3rd, and 6th months after the injection, the mean logMAR BCVA were 0.39 ± 0.36, 0.32 ± 0.39, and 0.29 ± 0.34, respectively.  The mean and median BCVA over the entire follow-up period was significantly improved compared with baseline BCVA (p < 0.05 for each one).  The mean CMT was 449.30 ± 142.53 μm at baseline.  It was measured as 302.60 ± 72.28 μm on the 1st month, 294.30 ± 72.85 μm on the 3rd month, and 294.60 ± 83.84 μm on the 6th month after the injection.  The mean and median CMT during the entire follow-up period was significantly decreased compared with baseline CMT (p < 0.05 for each one). None of the patients had any serious ocular or systemic AEs over the course of the study.  The authors concluded that short-term results of this study demonstrated that intra-vitreal aflibercept may be used as a therapeutic option to improve the BCVA and reduce the CMT in chronic CSC.  These preliminary, short-term findings from a small (n = 10) study need to be validated by well-designed studies with larger sample size and long-term follow-up.

In a prospective, pilot study, Pitcher and colleagues (2015) examined the role of intra-vitreal aflibercept injection as a treatment for eyes with CSC.  This trial included 12 patients with chronic CSCR who received a 6-month treatment regimen of intra-vitreal aflibercept.  Patients were followed with monthly ETDRS BCVA and spectral domain optical coherence tomography (SD-OCT) with enhanced depth imaging.  All patients were men between 29 and 64 years (median of 55).  Sub-foveal fluid was present on OCT for a median duration of 6 months (range of 4 to 29 months) prior to treatment.  Baseline BCVA ranged from 20/25 to 20/160 (median of 20/50) with a mean of 62 (SD = 13) ETDRS letters.  No patients experienced serious ocular or systemic AEs over the course of the study.  Post-treatment BCVA ranged from 20/20 to 20/200 (median of 20/40), with a mean of 64 (SD = 16) ETDRS letters (p = 0.56).  At baseline, 3 patients (25 %) had BCVA of greater than or equal to 20/40 versus 7 patients (58 %) at the conclusion of the study; 2 patients gained at least 15 ETDRS letters and no patients lost more than 15 ETDRS letters; 6 of 12 patients (50 %) had complete resolution of sub-foveal fluid.  Mean central macular thickness decreased from 400 µm (SD = 104 µm) to 306 µm (SD = 94 µm) (p = 0.03), and mean sub-foveal fluid decreased from 159 µm (SD = 93 µm) to 49 µm (SD = 68 µm) (p = 0.02).  Mean choroidal thickness decreased from 307 µm (SD = 72 µm) to 263 µm (SD = 63 µm) (p = 0.0003).  The authors concluded that intra-vitreal aflibercept was well-tolerated over a 6-month treatment course for chronic CSC; no change was observed in VA metrics.  These researchers stated that anatomic trends may suggest some morphological activity, but larger controlled trials are needed.

Salehi and associates (2015) noted that central CSC is characterized by serous detachment of the neural retina with dysfunction of the choroid and RPE.  The effects on the retina are usually self-limited, although some people are left with irreversible vision loss due to progressive and permanent photoreceptor damage or RPE atrophy.  There have been a variety of interventions used in CSC, including, but not limited to, laser treatment, PDT, and intra-vitreal injection of anti-VEGF agents.  However, it is not known whether these or other treatments offer significant advantages over observation or other interventions.  Currently, there is no evidence-based consensus on the management of CSC.  Due in large part to the propensity for CSC to resolve spontaneously or to follow a waxing and waning course, the most common initial approach to treatment is observation.  It remains unclear whether this is the best approach with regard to safety and efficacy.  In a Cochrane review, these investigators compared the relative effectiveness of interventions for CSC.  They searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2015, Issue 9), Ovid Medline, Ovid Medline In-Process and Other Non-Indexed Citations, Ovid MedlineDaily, Ovid OLDMedline (January 1946 to February 2014), Embase (January 1980 to October 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en).  No date or language restrictions in the electronic searches were used for trials.  The authors last searched the electronic databases on October 5, 2015; RCTs that compared any intervention for CSC with any other intervention for CSC or control were included.  Two review authors independently selected studies and extracted data.  Data were pooled from all studies using a fixed-effect model.  For interventions applied to the eye (i.e., not systemic interventions), direct and indirect evidence was synthesized in a network meta-analysis model.  The authors included 25 studies with 1,098 subjects (1,098 eyes) and follow-up from 16 weeks to 12 years.  Studies were conducted in Europe, North and South America, Middle East, and Asia.  The trials were small (most trials enrolled fewer than 50 subjects) and poorly reported; often it was unclear whether key aspects of the trial, such as allocation concealment, had been done.  A substantial proportion of the trials were not masked.  The studies considered a variety of treatments: anti-VEGF (ranibizumab, bevacizumab), PDT (full-dose, half-dose, 30 %, low-fluence), laser treatment (argon, krypton and micro-pulse laser), beta-blockers, carbonic anhydrase inhibitors, Helicobacter pylori treatment, and nutritional supplements (Icaps, lutein); there were only 1 or 2 trials contributing data for each comparison.  The authors down-graded for risk of bias and imprecision for most analyses, reflecting study limitations and imprecise estimates.  Network meta-analysis (as planned in the protocol) did not help to resolve this uncertainty due to a lack of trials, and problems with intransitivity, particularly with respect to acute or chronic CSC.  Low quality evidence from 2 trials suggested little difference in the effect of anti-VEGF (ranibizumab or bevacizumab) or observation on change in VA at 6 months in acute CSC (MD 0.01 LogMAR (logarithm of the minimal angle of resolution), 95 % CI: -0.02 to 0.03; 64 subjects); CSC had resolved in all subjects by 6 months.  There were no significant adverse effects noted.  Low quality evidence from 1 study (58 subjects) suggested that half-dose PDT treatment of acute CSC probably resulted in a small improvement in vision (MD -0.10 logMAR, 95 % CI: -0.18 to -0.02), less recurrence (RR 0.10, 95 % CI: 0.01 to 0.81) and less persistent CSC (RR 0.12, 95 % CI: 0.01 to 1.02) at 12 months compared to sham treatment.  There were no significant AEs noted  .Low quality evidence from 2 trials (56 subjects) comparing anti-VEGF to low-fluence PDT in chronic CSC found little evidence for any difference in VA at 12 months (MD 0.03 logMAR, 95 % CI: -0.08 to 0.15).  There was some evidence that more people in the anti-VEGF group had recurrent CSC compared to people treated with PDT but, due to inconsistency between trials, it was difficult to estimate an effect.  More people in the anti-VEGF group had persistent CSC at 12 months (RR 6.19, 95 % CI: 1.61 to 23.81; 34 subjects).  Two small trials of micro-pulse laser, one in people with acute CSC and one in people with chronic CSC, provided low quality evidence that laser treatment may lead to better VA (MD -0.20 logMAR, 95 % CI: -0.30 to -0.11; 45 subjects).  There were no significant adverse effects noted.  Other comparisons were largely inconclusive.  The authors identified 12 ongoing trials covering the following interventions: aflibercept and eplerenone in acute CSC; spironolactone, eplerenone, lutein, PDT, and micro-pulse laser in chronic CSC; and micro-pulse laser and oral mifepristone in 2 trials where type of CSC not clearly specified.  The authors concluded that CSC remains an enigmatic condition in large part due to a natural history of spontaneous improvement in a high proportion of people and also because no single treatment has provided overwhelming evidence of efficacy in published RCTs.  While a number of interventions have been proposed as potentially efficacious, the quality of study design, execution of the study and the relatively small number of subjects enrolled and followed to revealing end-points limited the utility of existing data.  It is not clear whether there is a clinically important benefit to treating acute CSC that often resolves spontaneously as part of its natural history.  The authors concluded that RCTs comparing individual treatments to the natural history would be valuable in identifying potential treatment groups for head-to-head comparison.  Of the interventions studied to date, PDT or micro-pulse laser treatment appeared the most promising for study in future trials.

In a single-case study, Astroz et al (2017) reported the pathogenic factors that account for cystoid macular edema and cystoid macular degeneration in chronic CSC.  The clinical course and multi-modal imaging findings, including fundus color photography, fundus autofluorescence, SD-OCT, and FA, of 1 eye with cystoid macular edema due to chronic CSC was documented.  This case described a 44-year old woman with a history of chronic CSC presented with progressive visual decline in the right eye; BCVA was 20/40.  Funduscopic examination revealed diffuse RPE changes and macular edema; FA demonstrated perifoveal microaneurysms and leakage in a petaloid configuration; SD-OCT demonstrated cysts at the level of the inner nuclear layer, an epiretinal membrane, vitreomacular traction, and an attenuated RPE band.  Central subfield thickness was 486 μm; 3 intra-vitreal injections of aflibercept were administered over 16 weeks following which there was resolution of leakage, release of vitreomacular traction, and resolution of microaneurysms.  Central sub-field thickness reduced to 379 μm, but persistent intra-retinal cysts were observed.  There was subjective improvement in visual symptoms, but Snellen acuity remained at 20/40.  The authors concluded that intra-retinal cystic changes in chronic CSC may be the result of multi-factorial pathogenic factors and may represent the co-existence of cystoid macular edema and cystoid macular degeneration.  These investigators stated that anti-VEGF may play an important role in the treatment of cystoid macular edema caused by CSC.

Aflibercept (Intravitreal) for the Treatment of Choroidal Neovascularization Due To Ocular Histoplasmosis

In a prospective, masked, open-label study, Walia and colleagues (2016) examined the safety and efficacy of intravitreal aflibercept injection (IAJ) in the treatment of CNV secondary to presumed ocular histoplasmosis syndrome (POHS).  A total of 5 subjects will receive 2.0-mg IAJ every 8 weeks with 3 initial monthly doses over a 12-month period.  No adverse systemic or ocular AEs were reported.  At month 6, the mean VA improved by 7.8 ETDRS letters, mean central sub-foveal thickness decreased by 38.8 microns and mean OCT volume decreased by 0.076 mm3.  At month 12, the mean VA improved by 12.4 ETDRS letters, mean central sub-foveal thickness decreased by 34.6 microns and mean OCT volume decreased by 0.576 mm³.  The authors concluded that the use of IAJ 2.0-mg for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome yielded no systemic or ocular AEs and produced improvement in VA and reduction of OCT thickness and volume. 

In a randomized, open-label phase I/II study, Toussaint and associates (2018) examined the effect of IAI in patients with presumed ocular histoplasmosis syndrome and CNV.  A total of 39 eyes from 39 patients were randomized in a 1:1 ratio to 2 groups.  The Sustained Group eyes (n = 19) underwent monthly IAI for 3 months, then mandatory IAI every 2 months for 12 months (with an option for monthly PRN dosing, if needed).  The PRN Group eyes (n = 20) received 1 IAI at randomization, then monthly PRN IAI for 12 months.  Average age of subjects was 50 years (19 to 75), with 16 men and 23 women; 10, 12, and 17 eyes demonstrated extra-foveal, juxta-foveal, and sub-foveal CNV, respectively.  All eyes in both groups received IAI at baseline, with the Sustained and PRN groups receiving on an average 7.5 (5 to 11) and 4.6 (1 to 10) injections, respectively, over the 12 months.  At baseline, overall average VA was 68 letters (13 to 87 letters) with Snellen equivalent of 20/42 (20/20 to 20/160).  At 12-month follow-up, Sustained Group's average VA was 84.9 letters (74 to 94) and Snellen equivalent was 20/21 (20/13 to 20/32), indicating an average improvement of 12 letters (6 letters loss to 36 letters gain) (p < 0.01).  The PRN Group's 12-month average VA was 80.9 letters (60 to 94) and Snellen equivalent was 20/26 (20/13 to 20/63), indicating an average gain of 19 letters (4 to 75) (p < 0.01).  Mean baseline central subfield thickness (CST) was 374 μm and mean 1-year CST was 260 μm (p < 0.01) among all study participants.  The Sustained Group's mean baseline CST was 383 μm and mean 12-month CST was 268 μm (p < 0.01).  Mean baseline CST of the PRN Group was 360.8 μm, with the final mean CST of 260.5 μm (p < 0.01).  No reported endophthalmitis, retinal tears, detachments, vitreous hemorrhage, nor adverse thrombotic events were reported.  The authors concluded that intravitreal aflibercept resulted in improved visual and anatomical outcomes with a favorable safety profile; PRN IAI dosing required less injections with similar visual and anatomical outcomes compared with sustained dosing. 

Furthermore, an UpToDate review on “Diagnosis and treatment of disseminated histoplasmosis in HIV-uninfected patients” (Kauffman, 2020) does not mention aflibercept as a therapeutic option.

Aflibercept (Intravitreal) for the Treatment of Cystoid Macular Edema

Moustafa and Moschos (2015) stated that cystoid macular edema (CME) in retinitis pigmentosa (RP) has been managed in several ways as documented in the literature, with little success, though.  These investigators reported for the first time in literature the use of aflibercept in a patient with RP and CME.  A 52-year old man presented for blurred vision in his right eye.  Best-corrected visual acuity (BCVA) was 3/10 in his right eye and 7/10 in his left eye.  Physical examination and appropriate laboratory tests lead to the diagnosis of bilateral RP with CME in the right eye.  Retinal thickness in the foveal area of the right eye was 631 μm.  The patient was treated with a single intravitreal injection of 0.05 ml/0.5 mg aflibercept.  One month later, BCVA of the right eye increased to 4/10, while BCVA of the left eye was unchanged.  RT in the right eye decreased to 129 μm.  Multi-focal electroretinographic response did not improve, yet peaks were better-shaped and no areas of eccentral vision were present; these improvements were maintained 3 and 6 months after injection.  The authors concluded that this first-reported case indicated that intravitreal aflibercept injection for addressing CME in RP appeared to be an effective treatment.  Moreover, they stated that additional studies are needed to confirm the afore-mentioned result.

Swituła (2015) presented a case report of a 20-year old man with quiescent, idiopathic intermediate uveitis in his right eye treated with systemic corticosteroids and persistent CME, admitted for further treatment due to chronic reduction in VA.  A therapy involving intravitreal injections of ranibizumab (Lucentis), followed by bevacizumab (Avastin) was started, leading to transient improvement of VA and edema reduction confirmed in OCT.  A decision of switching to intravitreal aflibercept was made.  After a single intravitreal injection of aflibercept, a complete and sustained resolution of macular edema was achieved. 

Strong et al (2016) presented an interesting case of bilateral RP-associated CME that responded on 2 separate occasions to intravitreal injections of aflibercept, despite previously demonstrating only minimal response to intravitreal ranibizumab.  This unique case would support a trial of intravitreal aflibercept for the treatment of RP-associated CME.  This case entailed a 38-year old man who presented to the UK with a 3-year history of bilateral RP-associated CME.  Previous treatment with topical dorzolamide, oral acetazolamide, and intravitreal ranibizumab had demonstrated only minimal reduction of CME.  Following re-confirmation of the diagnosis by clinical examination and OCT imaging, bilateral loading doses of intravitreal aflibercept were given.  Central macular thickness reduced and the patient returned to Dubai.  After 6 months, the patient was treated with intravitreal ranibizumab due to re-accumulation of fluid and the unavailability of aflibercept in Dubai.  Only minimal reduction of central macular thickness was observed.  Once available in Dubai, intravitreal aflibercept was administered bilaterally with further reduction of central macular thickness observed; VA remained stable throughout.  The authors noted that this was the 1st case report to demonstrate a reduction of RP-associated CME following intravitreal aflibercept, despite inadequate response to ranibizumab on 2 separate occasions.  Aflibercept may provide superior action to other anti-VEGF medications due to its intermediate size (115 kDa) and higher binding affinity.  They stated that this is worthy of further investigation in a large prospective cohort over an extended time to determine the safety and effectiveness of intravitreal aflibercept for use in this condition.

In a retrospective, observation, case-series study, Spooner et al (2020) examined the 12-month outcomes of eyes switched from intravitreal ranibizumab or bevacizumab to aflibercept for CME due to retinal vein occlusion (RVO).  These investigators examined eyes with RVO switched to aflibercept for at least 12 months.  To be included in the study, eyes had to have macular edema despite treatment for at least 6 months with bevacizumab and/or ranibizumab before the switch, CFT of greater than or equal to 300 μm at time of switch, and VA of less than or equal to 60 ETDRS letters (20/40 Snellen equivalent).  Outcome measures included change in VA (in ETDRS letters), CFT, and interval between intravitreal injections.  A total of 27 eyes of 27 patients were included in the analysis: 13 with branch RVO, and 14 with central RVO.  Mean VA before switch was 54.2 ± 23.7 letters (20/80 Snellen equivalent) and mean CFT was 460.4 ± 178.2 μm.  Mean number of previous anti- VEGF injections was 29.5 ± 19.2.  At 12 months, mean VA improved by 8.7 ± 13.2 letters (p < 0.01) and mean CFT decreased by 180.9 ± 207.7 μm compared with baseline (p < 0.01).  Mean injection interval increased by 1.6 ± 2.0 weeks to 6.9 ± 1.2 weeks, however, this was not statistically significant (p = 0.18).  The authors concluded that in this small retrospective study, eyes switched to intravitreal aflibercept for persistent CME due to RVO improved vision and macular thickness; however, larger, longer, prospective studies are needed to validate these findings.  The main drawbacks of this study were its retrospective nature, absence of control group, small sample size (n = 27), and limited follow-up period (12 months).

Aflibercept (Intravitreal) for the Treatment of Polypoidal Choroidal Vasculopathy

In a randomized, double-masked, sham-controlled, multi-center, phase-IV, investigator-driven clinical trial, Marques and co-workers (2017) compared the safety and efficacy of intra-vitreal aflibercept (IVA) with sham PDT (sPDT) versus IVA with verteporfin PDT (vPDT) in a Caucasian population with treatment-naive polypoidal choroidal vasculopathy (PCV) who enrolled into a treat-and-extend (T&E) regimen.  The primary outcomes are: change in BCVA from baseline, and polyp regression at week 52, assessed by ICGA.  A total of 50 patients with treatment-naive PCV will be recruited from Portuguese and Spanish clinical sites.  Eligible patients will receive monthly IVA for 3 months (week 0, week 4 and week 8).  At week 16, all patients will repeat ICGA and undergo central randomization (1:1 ratio) into one of the following groups: Group 1-IVA T&E + vPDT; Group 2-IVA T&E + sPDT.  PDT will be performed at week 16, week 28 and week 40 in the presence of active polyps.  After week 16, the presence of macular fluid on OCT will determine the schedule of observations.  When present, the interval between visits/injections will decrease 2 weeks (minimum 6 weeks).  When not, the interval between visits/injections will increase 2 weeks (maximum 12 weeks).  Efficacy will be evaluated based on BCVA, CRT and polyp regression.  Safety parameters will include assessment of IOP, AEs and SAEs.  The authors stated that this is the first randomized clinical trial in a Caucasian population conducted to evaluate the safety and efficacy of aflibercept in PCV, either alone or in combination with PDT.  Moreover, they stated that since it is mainly a proof-of-concept study with a relatively small study population (n = 50), further validation of its main results will be needed.

In a double-masked, sham-controlled, phase-IIIb/IV randomized clinical trial, Lee and colleagues (2018) evaluated IVA in patients with PCV and compared IVA monotherapy with IVA plus rescue PDT.  This 96-week trial was conducted at multiple centers in Australia, Germany, Hong Kong, Hungary, Japan, Singapore, South Korea, and Taiwan from May 2014 to August 2016, and included adults 50 years or older with symptomatic macular PCV and a BCVA of 73 to 24 Early Treatment Diabetic Retinopathy Study letters (20/40 to 20/320 Snellen equivalent).  Subjects received 2 mg of IVA at weeks 0, 4, and 8.  At week 12, subjects with a sub-optimal response were randomized 1:1 to receive IVA plus sham PDT (IVA monotherapy) or a "rescue" of IVA plus rescue PDT (IVA/PDT).  Subjects who did not qualify for rescue received IVA every 8 weeks; those qualifying for rescue received IVA every 4 weeks plus sham/active PDT.  When the rescue criteria were no longer met, injection intervals were gradually extended to 8 weeks.  Main outcome measures included non-inferiority of IVA monotherapy to IVA/PDT for mean change in BCVA from baseline to week 52 (95 % CI of the difference entirely above -5 letters).  Of the 318 participants, the mean (SD) age was 70.6 (8.2) years, 96 (30.2 %) were women, and 152 (47.8 %) were Japanese.  Monotherapy with IVA was non-inferior to IVA/PDT for the primary end-point (+10.7 versus +10.8 letters, respectively; 95 % CI: -2.9 to 1.6; p = 0.55), with few subjects requiring rescue therapy (19 [12.1 %] versus 23 [14.3 %], respectively). Participants in both treatment groups had similar reductions in central subfield thickness from baseline to week 52 (-137.7 [IVA monotherapy] versus -143.5 μm [IVA/PDT]).  At week 52, 49 (38.9 %) and 60 participants (44.8 %) had no polypoidal lesions observed on ICGA in the IVA monotherapy and IVA/PDT groups, respectively.  Furthermore, 116 (81.7 %) and 136 (88.9 %), respectively, had no polypoidal lesions with leakage.  The most frequent ocular AEs were conjunctival hemorrhage (IVA monotherapy, 8 [5.1 %]) and dry eye (IVA/PDT, 9 [5.6 %]).  The authors concluded that improvement in visual and/or functional outcomes was achieved in more than 85 % of participants who were treated with IVA monotherapy, with no signs of leakage from polypoidal lesions in more than 80 %.  As fewer than 15 % met the criteria of a sub-optimal response to receive PDT, the potential benefit of adding PDT could not be determined.

Wolff and associates (2018) stated that PCV is a choroidal pathology characterized by frequent occurrences of sub-retinal hemorrhages and resistance to monotherapies such as ranibizumab or bevacizumab IVT injections.  In a prospective, multi-center study, these researchers evaluated both the anatomical and functional efficacy of IVT aflibercept as a monotherapy in PCV in a Caucasian population.  This trial was conducted in either treatment-naïve patients with PCV or PVC patients who had not been treated with anti-VEGF within the previous 3 months or with PDT within the previous 6 months.  All patients had been treated with 3 initial monthly loading doses of aflibercept followed by a Q8 regimen for 28 weeks in total.  All patients underwent a complete ophthalmic examination including the measurement of BCVA before each IVT  aflibercept injection and after 28 weeks as well as an OCT of the macula.  At baseline and 28 weeks, the polypoidal dilations were analyzed with ICGA.  A total of 34 eyes of 34 patients were included in this study.  All patients were followed for 28 weeks and received 5 IVT aflibercept injections.  The mean baseline BCVA was 55 letters.  After 28 weeks, significant +13 letters in BCVA and a regression of exudative signs on OCT in all patients were observed.  In 62 % of the cases, polyp disappearance was observed on ICGA.  The authors concluded that aflibercept as a monotherapy provided both a significant visual gain and the regression of polypoidal dilations.  They stated that aflibercept use in monotherapy may reduce the hemorrhagic risk and atrophy linked to PDT.

Medina-Baena and colleagues (2018) noted that PCV is a subtype of neovascular ARMD characterized by an abnormal branching vascular network with aneurysmal polypoidal choroidal vascular lesions.  PCV is more prevalent in Asian populations than in Caucasians, which may explain its under-diagnosis in Western countries.  Evidence regarding the efficacy of different anti-VEGF agents on PCV is scarce, with most of these studies being conducted in Asian treatment-naïve patients.  Ranibizumab was the first anti-VEGF agent to demonstrate the superiority of a combination of PDT and anti-VEGF over PDT or anti-VEGF monotherapy for inducing polyp regression in Asian patients with PCV.  The efficacy of other anti-VEGF agents has been less studied.  Resistance to ranibizumab has been described.  Aflibercept offers another mechanism of targeting choroidal neovascular lesions.  In this case-study, a 75-year old Caucasian woman presenting to the authors’ office was diagnosed with PCV using ICGA.  Combination therapy with a loading dose of 0.5 mg IVT ranibizumab followed by PDT at standard fluence at month 4 and a 4th dose of ranibizumab at month 5 yielded no visual or anatomic outcomes.  Treatment was switched to IVT aflibercept at month 6 (3 monthly loading doses of 2.0 mg) followed by half-fluence PDT (month 9); OCT revealed remission of the anatomic lesions.  Right-eye VA increased to 0.6; IVT aflibercept injections were administered bi-monthly afterwards.  Follow-up during 1 year has shown functional and anatomic stability.  The authors stated that to the best of their knowledge, the case reported here was the first one describing the efficacy of combined therapy of IVT aflibercept 2 mg and PDT in a Caucasian patient refractory to combined therapy with ranibizumab and PDT.  Given the lack of proper studies with aflibercept conducted in Caucasian PCV patients, it is currently unknown whether adding PDT to treatment for such patients would allow their receiving fewer injections or if it would yield greater visual and anatomic improvements.  Should the latter be the case, PDT could be left to non-responders or to cases requiring too frequent injections, thus avoiding the complications associated with the use of PDT.  Moreover, these investigators stated that further research is needed to elucidate the role of aflibercept with and without PDT in Caucasian patients refractory to other anti-VEGF agents.

Aflibercept (Intravitreal) for the Treatment of Radiation Retinopathy

Pooprasert and colleagues (2017) noted that aflibercept is a novel anti-VEGF drug indicated for wARMD and macular edema secondary to retinal vein occlusion and DME.  While only newly introduced on the market, it is growing in popularity and over 5.5 million doses have been prescribed worldwide.  Due to its versatile mechanism, it is indicated for numerous eye pathologies, and in particular, has been adapted to treat various types of retinopathy.  To the authors’ knowledge, this was the first case report of solely using aflibercept to treat cystoid macular edema in radiation retinopathy. 

Furthermore, an UpToDate review on “Delayed complications of cranial irradiation” (Dietrich et al, 2018) does not mention aflibercept as a therapeutic option.

Aflibercept (Intravitreal) for the Treatment of Retinitis Pigmentosa

Strong and colleagues (2016) presented the case of a 38-year old man who had bilateral retinitis pigmentosa (RP)-associated cystoid macular edema that responded on 2 separate occasions to intra-vitreal injections of aflibercept, despite previously demonstrating only minimal response to intra-vitreal ranibizumab.  The authors concluded that aflibercept may provide superior action to other anti-VEGF medications due to its intermediate size (115 kDa) and higher binding affinity; however, these researchers stated that further investigation in a large prospective cohort over an extended time is needed to determine the safety and efficacy of intra-vitreal aflibercept for use in the treatment of RP.

Furthermore, an UpToDate on “Retinitis pigmentosa: Treatment” (Garg, 2019) does not mention aflibercept or vascular endothelial growth factor (VEGF) inhibitor as therapeutic options.

Aflibercept (Intravitreal) for the Treatment of Retinopathy of Prematurity

 In a retrospective, interventional consecutive case-series study, Vedantham (2019) examined the efficacy of intra-vitreal aflibercept in the treatment of ROP.  This trial included 46 Indian eyes that received intra-vitreal injection of aflibercept for high risk pre-threshold ROP, threshold ROP, and aggressive-posterior ROP (AP-ROP).  Aflibercept was effective in achieving the primary end-point, namely regression of ROP following the injection in all 46 eyes (100 %) at 1 week following the injection; 32.6 % (15/46) of eyes achieved secondary end-point namely complete vascularization, with no recurrence of ROP at varying time intervals: as early as 15 weeks to as late as 29 weeks after injection, at intervals ranging from 49 to 64 weeks PCA.  The authors concluded that intra-vitreal aflibercept was effective in inducing complete regression of all types of ROP in all the eyes in this series.  In addition, 32.6 % of cases did not need a secondary intervention, with no recurrence of ROP and complete vascularization of the retina.  In 81.8 % of Zone I ROP eyes, aflibercept facilitated continuation of retinal vascular development following regression of ROP, resulting in less extensive laser during treatment of ROP recurrence.  These researchers acknowledged that only short-term outcomes following intra-vitreal aflibercept in ROP were presented in this study; and an analysis of long-term neurodevelopmental, refractive and structural outcomes in these eyes are needed to shed more light on the role of intra-vitreal aflibercept in ROP.

Bevacizumab (Avastin), Bevacizumab-adcd (Vegzelma), Bevacizumab-awwb (Mvasi) Bevacizumab-bvzr (Zirabev), and Bevacizumab-maly (Alymsys)

Compendial Uses for Ophthalmic Disorders for Avastin, Vegzelma, Mvasi Zirabev, and Alymsys

• Diabetic Macular Edema
• Neovascular (wet) Age-Related Macular Degeneration (AMD)
• Macular Edema following Retinal Vein Occlusion (RVO)
• Proliferative Diabetic Retinopathy
• Choroidal Neovascularization (CNV)
• Neovascular Glaucoma; adjunct
• Retinopathy of Prematurity
• Polypoidal Choroidal Vasculopathy

Bevacizumab is available as Avastin (Genentech, Inc). Bevacizumab-awwb is available as Mvasi (Amgen Inc.). Bevacizumab-bvzr is available as Zirabev (Pfizer Inc.). Bevacizumab-maly is available as Alymsys (Amneal Pharmaceuticals LLC). Bevacizumab-adcd is available as Vegzelma (Celltrion, Inc.). Bevacizumab, given by intravitreal injection, is considered “medically reasonable and necessary for patients diagnosed with neovascular (wet) AMD.” The American Academy of Ophthalmology (AAO) and the American Society of Retinal Specialists (ASRS) support the use of bevacizumab. The NIH‐sponsored Ranibizumab and Bevacizumab for Neovascular Age‐Related Macular Degeneration CATT study suggests that at one year, Avastin (bevacizumab) and Lucentis (ranibizumab) have equivalent effects on visual acuity when administered according to the same schedule for the treatment of age‐related macular degeneration (AMD).

Bevacizumab carries the following warnings and precautions: 

• Gastrointestinal perforations and fistula
• Surgery and wound healing complications
• Hemorrhage
• Arterial thromboembolic events (ATE)
• Venous thromboembolic events (VTE)
• Hypertension
• Posterior reversible encephalopathy syndrome (PRES)
• Renal injury and proteinuria
• Infusion-related reactions
• Embryo-fetal toxicity
• Ovarian failure
• Congestive heart failure (CHF).

The most common adverse reactions incidence (incidence greater than 10%) include epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis. 

Age-related macular degeneration (AMD), characterized as a progressive degenerative disease of the macula, is the leading cause of blindness in developed countries afflicting approximately 15 million people in the United States. There are various options for the treatment of choroidal neovascularization (CNV) in patients with AMD.  Classic CNV responds well to photodynamic therapy (PDT) with "off label" triamcinolone, while occult CNV can be treated by PDT, transpupillary thermotherapy, sub-retinal surgery, macular translocation, and anti-angiostatic therapy.  Ladewig and colleagues (2006) stated that the safety and effectiveness of the therapeutic anti-VEGF concept has already been shown for pegaptanib (Macugen) and ranibizumab (Lucentis).  Bevacizumab acts as an antibody against all VEGF-A isoforms and has been developed for oncological indications with intravenous application.  Initial reports on intra-vitreal administration in patients with neovascular AMD have shown beneficial morphological and functional effects.  In the meantime, bevacizumab has been used off-label in thousands of patients with AMD. 

Fung et al (2006) stated that off-label intra-vitreal injections of bevacizumab have been performed for the treatment of neovascular and exudative ocular diseases since May 2005. Since then, the use of intra-vitreal bevacizumab has spread worldwide, but the drug-related AEs associated with its use have only been reported in a few retrospective reviews.  The International Intra-vitreal Bevacizumab Survey was initiated to gather timely information regarding adverse events from physicians around the world via the internet.  An internet based survey was designed to identify AE associated with intra-vitreal bevacizumab therapy.  The survey web address was disseminated to the international vitreo-retinal community via email.  Rates of AE were calculated from participant responses.  A total of 70 centers from 12 countries reported on 7,113 injections performed on 5,228 patients.  Physician-reported AE included corneal abrasion, lens Injury, endophthalmitis, retinal detachment, inflammation/uveitis, cataract progression, acute vision loss, central retinal artery occlusion, sub-retinal hemorrhage, retinal pigment epithelium tears, blood pressure elevation, transient ischemic attack, cerebrovascular accident and death.  None of the AE rates exceeded 0.21 %.  The authors concluded that intra-vitreal bevacizumab is being used globally for ocular diseases.  Self-reporting of AE following intra-vitreal bevacizumab injections did not reveal an increased rate of potential drug-related ocular or systemic events.  These short-term results suggest that intra-vitreal bevacizumab appears safe. 

Spaide et al (2006) described the short-term anatomical and visual acuity responses after intra-vitreal injection of bevacizumab in patients with CNV secondary to AMD. These investigators performed a retrospective study of patients with CNV secondary to AMD who were treated with intra-vitreal injection of bevacizumab (1.25 mg) during a 3-month period.  Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits.  There were 266 consecutive eyes of 266 patients who received injections, and follow-up information was available for 251 (94.4 %).  The mean age of the patients was 80.3 years, the mean baseline visual acuity was 20/184, and 175 (69.7 %) had inadequate response to alternate methods of treatment.  At the 1-month follow-up (data available for 244 patients), the mean visual acuity was 20/137 (p < 0.001 as compared with baseline), and 74 (30.3 %) of patients had improvement in visual acuity as defined by a halving of the visual angle.  At the 2-month follow-up (data available for 222 patients), the mean visual acuity was 20/122 (p < 0.001), and 78 (31.1 %) of patients had visual improvement.  At the 3-month follow-up (data available for 141 patients), the mean visual acuity was 20/109 (p < 0.001), and 54 (38.3 %) of patients had visual acuity improvement.  The mean central macular thickness at baseline was 340 microm and decreased to a mean of 247 microm at month 1 (p < 0.001) and 213 microm at month 3 (p < 0.001).  At 1 month, two patients had mild vitritis, as did one patient at 2 months, who had a history of recurrent uveitis.  No endophthalmitis, increased intraocular pressure, retinal tear, or retinal detachment occurred.  The risk for thromboembolic disorders did not seem to be different than reported previously in studies concerning macular degeneration.  There were no apparent short-term safety concerns for intra-vitreal bevacizumab injection for CNV.  Treated eyes had a significant decrease in macular thickness and improvement in visual acuity.  The results of this study are in agreement with those of Inturralde et al (2006, 16 eyes/15 patients), Bashshur et al (2006, 17 eyes/17 patients), Rich et al (2006, 53 eyes/50 patients), and Avery et al (2006, 81 eyes/79 patients). 

A German review on new treatments for neovascular AMD (authors not listed, 2006) stated that therapeutic options include laser photocoagulation, PDT with verteporfin, triamcinolone and its possible combination with PDT, anecortave acetate, pegaptanib and ranibizumab. It noted that extra-foveal classic CNV should be treated with thermal laser coagulation.  For sub-foveal lesions with predominantly classic CNV, or occult forms with non-classic CNV, a lesion size less than or equal to 4 macular photocoagulation study (MPS) disc areas (DA) and recent disease progression, PDT with verteporfin is a safe and effective therapy.  For the remaining subtypes, VEGF inhibitors (e.g., pegaptanib, ranibizumab, bevacizumab) for intra-vitreal use are now available as therapeutic alternatives.  The review stated that the results of the phase III studies for pegaptanib and ranibizumab, however, are not comparable, in particular with reference to the outcomes in the control groups.  Since bevacizumab (Avastin) and ranibizumab are comparable in their pharmacological profile, bevacizumab may be an alternative in the off-label treatment of neovascular AMD.  The switch to alternative treatment modalities should be considered in particular when the first line treatment is ineffective.  The recommendations from this review provided evidence-based guidance for non-surgical therapies in the management of neovascular AMD. 

In an editorial on the use of intra-vitreal Avastin as the low cost alternative to Lucentis published in the American Journal of Ophthalmology, Rosenfeld (2006) stated that "[c]urrently, there appears to be a global consensus that the treatment strategy using intravitreal Avastin is logical, the potential risks to our patients are minimal, and the cost-effectiveness is so obvious that the treatment should not be withheld". 

On March 20, 2006, a survey by the American Society of Retinal Specialists of its membership was completed. It found that 92 % of 289 respondents felt intra-vitreal bevacizumab was "somewhat better" or "much better" than other FDA-approved or covered therapies.  Only 4 % of respondents had seen any thromboembolic complications thought to be related to the intra-vitreal bevacizumab, and 96 % thought intra-vitreal bevacizumab was the same or better in terms of overall safety compared to other FDA-approved or covered therapies. 

On April 20, 2006, the American Academy of Ophthalmology (AAO) wrote to the Centers for Medicare and Medicaid Services (CMS) supporting the reimbursement for treating AMD with intra-vitreal injections of bevacizumab, to meet the medical needs of patients who have not responded to therapy with PDT with verteporfin or intra-vitreal pegaptanib. The AAO's support for reimbursement is limited to "such patients who are deemed by their treating physician to have failed FDA-approved therapies, or in the judgment of their treating physician, based on his/her experience, are likely to have greater benefit from the use of intra-vitreal bevacizumab". 

On October 5, 2006, the National Institutes of Health's National Eye Institute said it will fund a multi-center clinical trial to compare Lucentis with Avastin in the treatment of AMD (NIH, 2006). 

Available evidence indicates that anti-VEGF therapy with either ranibizumab or bevacizumab plays an important role in the management of diabetic macular edema.  An NIH-sponsored, multi-center, randomized clinical trial demonstrated that ranibizumab in combination with macular laser photocoagulation is superior to macular laser photocoagulation alone at 12 months of follow-up (Diabetic Retinopathy Clinical Research Network, 2010).  The need for re-treatment was determined by retinal thickness as measured by OCT and visual acuity.  The 1-year mean change in the visual acuity letter score from baseline was significantly greater in the ranibizumab + prompt laser group (+9, p < 0.001) and ranibizumab + deferred laser group (+9, p < 0.001) but not in the triamcinolone + prompt laser group (+4, p = 0.31) compared with the sham + prompt laser group (+3).  Intravitreal ranibizumab with prompt or deferred laser is more effective through at least 1 year compared with prompt laser alone for the treatment of DME involving the central macula.

A second single-center, randomized clinical trial also demonstrated that intravitreal injection of bevacizumab every 6 weeks based on clinical response determined by OCT and visual acuity is superior to macular photocoagulation every 4 months (Michaelides et al, 2010).  The authors reported the odds of gaining greater than or equal to 10 ETDRS letters over 12 months were 5.1 times greater in the bevacizumab group than in the laser group (adjusted odds ratio, 5.1; 95 % CI: 1.3 to 19.7; p = 0.019).

Astam and colleagues (2009) evaluated the short-term effectiveness of intra-vitreal bevacizumab injection for the management of macular edema due to diabetic retinopathy and retinal vein occlusion.  Standardized ophthalmic evaluation, ETDRS visual acuity measurement, and central macular thickness were performed at baseline and 1 month intervals after injection.  There were 23 eyes of 21 patients with macular edema due to diabetic retinopathy (14 eyes of 12 patients), and retinal vein occlusion (9 eyes of 9 patients).  The mean baseline logMAR visual acuity and central macular thickness were 0.82 +/- 0.27 and 604.71 +/- 123.62 mum, respectively, in patients with diabetic retinopathy.  There was no statistically significant difference between the mean logMAR visual acuity (p = 0.22) and central retinal thickness (p = 0.16) measurements at baseline and 3 months follow-up.  The mean baseline logMAR visual acuity and central macular thickness were 0.94 +/- 0.48 and 557 +/- 113.9 mum, respectively, in patients with retinal vein occlusion.  There was a statistically significant difference between the mean logMAR visual acuity and central retinal thickness measurements at baseline and 3 months follow-up (p < 0.01).  Almost all of the eyes (88.8 %) regained normal foveal configuration.  The authors concluded that although the follow-up period was short and the number of patients were limited to provide specific treatment recommendations, intra-vitreal bevacizumab seems to be more effective for macular edema due to retinal vein occlusion than diabetic macular edema.  The favorable short-term findings suggested that further study is needed.  This is in agreement with the observations of Badala (2008) as well as Wu et al (2008). 

In a review on diabetic retinopathy (DR), Cheung et al (2010) noted that although anti-VEGF therapy has promising clinical applications for the management of DR, its long-term safety in patients with diabetes has not yet been established.  Local adverse events of IVB include cataract formation, infection, retinal detachment, vitreous hemorrhage, as well as potential loss of neural retinal cells.  Furthermore, a significant portion of anti-VEGF agents injected into the eye could pass into the systemic circulation.  Thus, systemic inhibition of angiogenesis is a potential risk.  Also, although clinical trials on the use of intra-vitreal anti-VEGF therapy for the treatment of AMD generally show low (0.6 to 1.2 %) rates of stroke, this risk could be increased in patients with DR because of pre-existing diabetes-related vascular disease. 

Nicholson and Schachat (2010) stated that many observational and pre-clinical studies have implicated VEGF in the pathogenesis of DR, and recent successes with anti-VEGF therapy for age-related macular degeneration have prompted research into the application of anti-VEGF drugs to DR.  These investigators reviewed the numerous early studies that suggest an important potential role for anti-VEGF agents in the management of DR.  The authors concluded that for diabetic macular edema, phase II trials of intra-vitreal pegaptanib and intra-vitreal ranibizumab have shown short-term benefit in visual acuity.  Intra-vitreal bevacizumab also has been shown to have beneficial short-term effects on both visual acuity and retinal thickness.  For proliferative diabetic retinopathy (PDR), early studies suggest that IVB temporarily decreases leakage from diabetic neovascular lesions, but this treatment may be associated with tractional retinal detachment.  Furthermore, several studies indicate that bevacizumab is likely to prove a helpful adjunct to diabetic pars plana vitrectomy for tractional retinal detachment.  Finally, 3 small series suggest a potential beneficial effect of a single dose of bevacizumab to prevent worsening of DME after cataract surgery.  The authors noted that use of anti-VEGF medications for any of these indications is off-label.  Despite promising early reports on the safety of these medications, the results of large, controlled trials to substantiate the safety and efficacy of anti-VEGF drugs for diabetic retinopathy are eagerly awaited. 

Badala (2008) noted that intra-vitreal bevacizumab appears to be a safe and effective treatment for macular edema associated with branch retinal vein occlusion, at least in the short-term.  However, further randomized, controlled studies are needed to evaluate long-term safety and effectiveness of this approach.  Wu et al (2008) stated that longer studies are needed to ascertain what role, if any, intra-vitreal injection of bevacizumab may play in the long-term treatment of macular edema secondary to branch retinal vein occlusion.  Furthermore, Fraser-Bell et al (2008) noted that there remains no proven intervention that consistently prevents or reverses visual loss from diabetic macular edema in all patients.  A variety of promising new medical and surgical therapies including intra-vitreal bevacizumab are under investigation, but further research is needed to determine their role alone or in combination. 

An evidence review by Scanlon and Stratton (2008) for the National Library of Health stated that bevacizumab and other vascular endothelial growth factor inhibitors have not been studied in diabetic eye disease and that there are only early reports of their use.  A recent systematic evidence review found insufficient evidence for the use of bevacizumab or other anti-VEGFs in diabetic eye disease (Mohamed et al, 2007).  An ongoing randomized controlled clinical trial sponsored by the National Eye Institute is comparing the effects of laser treatment, intravitreal bevacizumab, and combined intravitreal bevacizumab and laser or sham injection on diabetic macular edema (National Eye Institute, 2008). 

In an interventional, retrospective, multi-center study, Arevalo et al (2009a) determined the feasibility, safety, and clinical effect of intra-vitreal (IVT) bevacizumab in patients with refractory cystoid macular edema (CME) following cataract surgery.  A total of 36 eyes of 31 patients with refractory CME after cataract surgery and with a mean age of 68.2 years (range of 67 to 87 years) were included in this study.  Patients were treated with at least 1 IVT injection of 1.25 or 2.5 mg bevacizumab.  Patients were followed-up for 12 months.  Main outcome measures included best-corrected visual acuity (BCVA) and central macular thickness (CMT) by optical coherence tomography (OCT).  Twenty-six eyes (72.2 %) showed improvement of BCVA (greater than or equal to 2 Early Treatment Diabetic Retinopathy Study [ETDRS] lines), and no eye experienced worsening of visual acuity (greater than or equal to 2 ETDRS lines).  Mean baseline BCVA was 20/200 (0.96 logarithm of the minimum angle of resolution [logMAR] units), and the mean 12-month BCVA was 20/80 (0.62 logMAR units; p < 0.0001).  Optical coherence tomography demonstrated that mean CMT at baseline was 499.9 microm (range of 298 to 784 microm) and decreased to a mean of 286.1 microm (range of 168 to 499 microm) at 12 months (p < 0.0001).  Four (11 %) eyes received 2 injections, 10 (27.8 %) eyes received 3 injections, 10 (27.8 %) eyes received 4 injections, 1 (2.8 %) eye received 5 injections, and 1 (2.8 %) eye received 6 injections.  The mean number of injections was 2.7 (range of 1 to 6), and the mean interval between injections was 15.1 weeks (range of 4 to 45 weeks).  No ocular or systemic adverse events were observed.  The authors concluded that short-term results suggest that IVT bevacizumab is well-tolerated in patients with refractory pseudophakic CME.  Treated eyes had a significant improvement in BCVA and decrease in macular thickness by OCT at 12 months.  They stated that these results are promising and suggested the need for further evaluation with longer follow-up and a larger series of patients. 

In a retrospective, multi-center, interventional, comparative case series, Arevalo et al (2009b) reported the 24-month anatomic and ETDRS BCVA response following primary intra-vitreal bevacizumab ([IVB] 1.25 or 2.5 mg) in patients with diffuse diabetic macular edema (DDME).  In addition, a comparison of the 2 different doses of IVB used was presented.  The clinical records of 115 consecutive patients (139 eyes) with DDME at 11 centers from 8 countries were reviewed.  Patients were treated with at least 1 IVT injection of 1.25 or 2.5 mg of bevacizumab.  All patients were followed-up for 24 months.  Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, OCT, and FA at the baseline, 1-, 3-, 6-, 12-, and 24-month visits.  Main outcome measures included changes in BCVA and OCT results.  The mean age of the patients was 59.4 +/- 11.1 years.  The mean number of IVB injections per eye was 5.8 (range of 1 to 15 injections).  In the 1.25-mg group at 1 month, BCVA improved from 20/150 (0.88 logarithm of the minimum angle of resolution [logMAR] units) to 20/107, 0.76 logMAR units (p < 0.0001).  The mean BCVA at 24 months was 20/75 (0.57 logMAR units; p < 0.0001).  Similar BCVA changes were observed in the 2.5-mg group: at 1 month, BCVA improved from 20/168 (0.92 logMAR units) to 20/118 (0.78 logMAR units; p = 0.02).  The mean BCVA at 24 months was 20/114 (0.76 logMAR units; p < 0.0001).  In the 1.25-mg group, the mean CMT decreased from 466.5 +/- 145.2 microm at baseline to 332.2 +/- 129.6 microm at 1 month and 286.6 +/- 81.5 microm at 24 months (p < 0.0001).  Similar results were obtained in the 2.5-mg group.  The authors concluded that primary IVB at doses of 1.25 to 2.5 mg seem to provide stability or improvement in BCVA, OCT, and FA in DDME at 24 months.  The results show no evident difference between IVB at doses of 1.25 or 2.5 mg.  Moreover, they stated that the results are promising and suggested the need for further investigation especially randomized controlled trials comparing IVB and focal or grid photocoagulation. 

In a Cochrane review on anti-angiogenic therapy with anti-VEGF modalities for diabetic macular edema, Parravano and colleagues (2009) concluded that there is insufficient high quality evidence from large randomized controlled trials (RCTs) supporting the use of either single or multiple anti-VEGF intra-vitreal injections to treat diabetic macular edema.  Results from ongoing studies on several compounds should assess not only treatment efficacy but also, if a benefit is found, the number of injections needed for maintenance and long-term safety.  Furthermore, the Spanish Retina and Vitreous Society's guidelines on management of diabetic retinopathy and macular oedema (Pareja-Ríos et al, 2009) stated that the role of anti-angiogenics is not yet sufficiently defined. 

In a prospective, randomized, masked cohort study, Takamura et al (2009) determined the feasibility and clinical effectiveness of IVB combined with cataract surgery for management of the post-operative increase of retinal thickness in patients with diabetic maculopathy.  A total of 42 eyes with DME of 42 patients with type 2 diabetes mellitus were included in this analysis.  Patients were randomly assigned to receive either cataract surgery only (control; 21 eyes) or combined with IVT injection of 1.25 mg bevacizumab (21 eyes).  Efficacy measures included BCVA testing, OCT, and ophthalmoscopic examination.  Retinal thickness (RT) on OCT and BCVA were measured at baseline and 1 and 3 months after surgery.  There were no significant differences in RT, BCVA, severity of cataract, or systemic condition between the control and bevacizumab groups at the baseline.  One and 3 months after surgery, the control group showed a significant increase in RT, whereas the bevacizumab group showed a significant decrease.  Although post-operatively the eyes in both groups showed a significant improvement of BCVA, bevacizumab-treated eyes showed significantly better results (mean logarithm of the minimum angle of resolution, 0.38) than the control group (0.51) at month 3.  There was a significant relationship between RT and VA post-operatively in the control (p = 0.0001) and bevacizumab (p = 0.0141) groups.  No systemic or ocular adverse events were observed.  The authors concluded that short-term results suggested that IVT bevacizumab has the potential not only to prevent the increase in RT, but also reduce the RT of eyes with DME following cataract surgery.  Moreover, they stated that these results seem promising and further investigation with a longer follow-up and a larger series of patients may be needed. 

Schaal and associates (2009) evaluated the short-term safety and efficacy of intra-vitreal bevacizumab for the treatment of intra-retinal or sub-retinal fluid accumulation secondary to chronic central serous chorioretinopathy (CSC).  A total of 12 patients were treated with intra-vitreal injections of 2.5 mg bevacizumab at 6- to 8-week intervals until intra-retinal or sub-retinal fluid resolved.  Observation procedures were Early Treatment Diabetic Retinopathy Study BCVA, ophthalmic examination, and OCT, performed at 6- to 8-week intervals.  Fluorescein angiography was performed at baseline visit and thereafter depending on clinical and OCT findings.  Multi-variate analysis of variance with repeated measures was used to calculate a statistical significance of change in BCVA and mean central retinal thickness, which were the main outcome measures.  Patients received 2 +/- 1 intra-vitreal injections of bevacizumab on average during a follow-up of 24 +/- 14 weeks.  Mean BCVA increased by 2 +/- 2 lines; the change in BCVA (logMAR) was significant (p < 0.02).  Mean central retinal thickness decreased significantly over follow-up (p < 0.05), with 6 patients (50 %) showing complete resolution of sub-retinal fluid.  The authors concluded that anatomical and functional improvement following intra-vitreal bevacizumab injections suggest that VEGF may be involved in fluid leakage in patients with chronic CSC.  The results suggested a possible role for anti-VEGF agents in the treatment of chronic CSC.  They stated that further evaluation of intra-vitreal bevacizumab for chronic CSC in controlled randomized studies is warranted. 

In a prospective, controlled clinical study, Artunay et al (2010) examined the effect of IVB in treatment of persistent CSC.  A total of 30 eyes of 30 patients with persistent, symptomatic CSC of 3 months' duration or more were included in this study.  Fifteen eyes of 15 patients were treated with intra-vitreal injections of 2.5 mg (0.1 ml) bevacizumab (treatment group).  Fifteen eyes of 15 patients with the same characteristics who declined treatment were an acceptable control group.  The visual and anatomical responses were observed with BCVA and central foveal thickness measured by OCT at baseline,1, 3, and 6 months after treatment.  Twelve (80 %) eyes in the IVB group compared with 8 (53.3 %) eyes in the control group showed morphological restitution at 6 months (p < 0.01).  All 15 (100 %) treated eyes had stable or improved vision, compared with 10 (66.6 %) eyes in the control group (p < 0.01).  At 6 months, the mean +/- SD central foveal thickness for the treatment group remained significantly lower compared to the control group, with 174 +/- 68 microm and 297 +/- 172 microm, respectively (p < 0.001).  Injection-related complications were not encountered.  The authors concluded that these findings indicate that intra-vitreal bevacizumab injection may be a new, promising treatment option for select patients with idiopathic persistent CSC.  They stated that continued studies with IVB in this population will help to establish its long-term efficacy. 

Teng and co-workers (2009) examined the effect of sub-conjunctival bevacizumab on primary pterygium.  A patient with an inflamed nasal primary pterygium refractory to artificial tears and naphazoline was enrolled in this study.  After pre-treatment with topical proparacaine and moxifloxacin, 0.05 ml bevacizumab (1.25 mg/0.05 ml) was injected sub-conjunctivally at the limbus.  Clinical signs of irritation, redness, and vascularization were monitored over 7 weeks.  At 1 week post-injection, irritation and hyperemia showed near-total regression.  At week 2, the pterygium maintained this appearance.  By week 7, the degree of vascularity and symptoms of irritation had regressed to its pre-injection state.  The authors concluded that treatment of primary pterygium with sub-conjunctival bevacizumab results in a short-term decrease in vascularization and irritation.  They stated that further long-term studies should investigate the efficacy of bevacizumab as an adjunct to surgical excision or combined topical treatment targeting other growth factors involved in pterygium pathogenesis. 

Razeghinejad and associates (2010) assessed the effectiveness of sub-conjunctival bevacizumab as an adjunctive therapy for primary pterygium surgery.  This randomized prospective clinical study was conducted on 30 eyes of 30 patients.  After pterygium excision and accomplishing a rotational conjunctival flap, 15 patients (case group) received 1.25 mg (0.1 ml) bevacizumab, and 15 other patients (control group) received 0.1 ml balanced salt solution subconjunctivally.  The main outcome measures were recurrence of pterygia, horizontal length of the corneal epithelial defect, conjunctival erythema, lacrimation and photophobia during the first post-operative week.  There were no statistically significant differences regarding age, sex or recurrence risk factors between the 2 groups (p > 0.05).  The pterygia resolved in 13 (86.6 %) of 15 eyes in both groups, with a recurrence rate of 13.4 % during a mean follow-up period of 8 +/- 1.4 months in the case group and 7.4 +/- 1.5 months in the control group (p = 0.2).  There were no statistically significant differences regarding reduction in refractive astigmatism, improvement in visual acuity, corneal epithelial defects, conjunctival erythema, lacrimation or photophobia between the case and control groups (p > 0.05).  The authors concluded that a single intra-operative subconjunctival bevacizumab injection had no effect on recurrence rate or early post-operative conjunctival erythema, lacrimation, photophobia or healing of corneal epithelial defects following pterygium excision. 

In a case series study, Ghanem and associates (2009) evaluated the effect of intra-vitreal injection of bevacizumab (2.5 mg) in cases of neovascular glaucoma.  A total of 16 eyes of 16 patients with rubeosis iridis (RI) and secondary glaucoma were included in this study.  The patients were followed for 2 months.  These researchers noted partial or complete regression of iris neovascularization 1 week after injection of bevacizumab.  Re-proliferation of new vessels was detected in 25 % of the cases after 2 months.  The mean IOP before injection was 28 +/-  9.3 mm Hg under topical ss-blocker and systemic acetazolamide.  One week after injection, the IOP decreased to 21.7 +/- 11.5 mm Hg (5 cases without anti-glaucoma drugs, 6 cases with topical ss-blocker, and 5 cases with both topical ss-blocker and systemic acetazolamide).  The authors concluded that intra-vitreal bevacizumab injection leads to regression of iris neovascularization with subsequent drop of IOP in eyes with neovascular glaucoma.  This was a small study with short-term follow-up; its finding was also confounded by the concomitant use of anti-glaucoma drugs in some cases.  These findings need to be validated by well-designed studies. 

Batman and Ozdamar (2010) reported the outcomes of the use of intra-cameral bevacizumab for iris neovascularization occurring after silicone oil (SO) removal in eyes undergoing vitre-oretinal surgery (VRS).  This study included 12 eyes that had iris neovascularization after SO removal.  There were 8 men and 4 women with an average age of 41.6 +/- 12.7 years.  All eyes had VRS for various vitreo-retinal diseases.  After the mean follow-up period of 9.7 +/- 5.3 months, SO removal was performed.  Then, patients were followed for more than 2 months and detailed retinal examinations and IOP were normal during this period, but RI developed.  Rubeosis iridis was treated with 1 dose of 1.25 mg bevacizumab into the anterior chamber.  After a mean follow-up period of 4.8 +/- 2.2 months, the regression of iris neovascularization was detected and IOP was below 21 mmHg in all eyes.  The authors concluded that anterior segment neovascularization (ASNV) may develop through various mechanisms in patients with VRS after SO removal, and anterior chamber injection of bevacizumab may lead to regression of ASNV.  Again, this was a small study with short-term follow-up; its findings need to be validated by well-designed studies. 

In a prospective, randomized, clinical trial, Ahn et al (2011) evaluated the effects of pre-operative and IVB injection on the incidence of post-operative vitreous hemorrhage (VH) after vitrectomy for PDR.  A total of 107 eyes of 91 patients undergoing pars plana vitrectomy (PPV) for the management of PDR-related complications were enrolled.  A total of 107 cases were assigned randomly to either group 1 (intra-vitreal 1.25 mg/0.05 ml bevacizumab injection 1 to 14 days before PPV), group 2 (intra-vitreal 1.25 mg/0.05 ml bevacizumab injection at the end of PPV), or group 3 (no IVB injection).  The primary outcome was the incidence of early (less than or equal to 4 weeks) and late (greater than 4 weeks) recurrent VH.  Secondary outcome measures were the initial time of vitreous clearing (ITVC) and BCVA at 6 months after surgery.  The incidences of early recurrent VH were 22.2 %, 10.8 %, and 32.4 % in groups 1, 2, and 3, respectively (p = 0.087).  A subgroup pair-wise analysis showed significantly decreased early VH incidence in group 2 compared with that of group 3 (p = 0.026).  The incidences of late recurrent VH were 11.1 %, 16.2 %, and 14.7 % in groups 1, 2, and 3, respectively (p = 0.813).  The ITVC in groups 1, 2, and 3 were 26.4 +/- 42.5 days, 10.3 +/- 8.2 days, and 25.2 +/- 26.1 days, respectively.  The ITVC was significantly shorter in group 2 compared with that in groups 1 and 3 (p = 0.045 and p = 0.015, respectively).  The BCVA at 6 months after surgery did not differ significantly among the 3 groups (p = 0.418).  The authors concluded that this study found no substantial evidence to support the adjunctive use of pre-operative IVB to reduce post-operative recurrence of VH in vitrectomy for PDR.  For select cases in which adjunctive IVB use is considered, intra-operative administration seems to be the better option for reducing post-operative VH. 

Farahvash et al (2011) evaluated the effect of pre-operative IVB on surgery and on the early post-operative course in diabetic patients undergoing vitrectomy for dense VH.  A total of 35 patients with dense diabetic VH were randomly assigned to a group that received 1.25 mg of IVB 1 week before vitrectomy (18 patients) or the control group (17 patients).  To compare the complexity of 2 groups, intra-operative complexity score and proliferative diabetic vitreo-retinopathy stage were recorded.  Intra-operative bleeding, break formation, number of endodiathermy applications, BCVA, anatomical outcome at month 3 and at final follow-up, and post-operative complications were evaluated.  Mean complexity scores and proliferative diabetic vitreo-retinopathy stages of both groups were similar.  The mean score of bleeding was 1.05 in the IVB group versus 1.76 in the control group (p = 0.35); endodiathermy applications and break formations were 0.44 versus 0.52 (p = 0.68) and 0.22 versus 0.29 (p = 0.60) in the IVB and control groups, respectively.  Anatomical outcome and visual acuity at month 3 and at the final follow-up were similar.  The authors concluded that these findings suggested that IVB before vitrectomy for dense diabetic VH has no significant effect on facilitation of surgery or on the early post-operative course. 

In a Cochrane review, Smith and Steel (2011) assessed the effect of peri-operative anti-VEGF in reducing the incidence of post-operative vitreous cavity hemorrhage (POVCH).  These investigators searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2011, Issue 2), MEDLINE (January 1950 to March 2011), PubMed (10 March 2011), EMBASE (January 1980 to March 2011), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to March 2011), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com) and ClinicalTrials.gov (www.clinicaltrial.gov).  There were no date or language restrictions in the electronic searches for trials.  The electronic databases were last searched on March 10,  2011.  These researchers included all RCTs that looked at the use of anti-VEGFs and the incidence of POVCH in people undergoing vitrectomy for PDR.  Both review authors independently assessed and extracted the data using a standardized form based on the CONSORT statement.  They included 4 studies (202 eyes of 198 participants) in this review.  The 4 RCTs met the inclusion criteria, but the authors were unable to conduct a meta-analysis due to methodological issues in 3 of the trials. They have provided a summary of the effects of the interventions; and have also provided a summary of the current literature addressing each primary and secondary outcome.  The authors concluded that results from 1 of the included studies support the use of pre-operative IVB to reduce the incidence of early POVCH.  There are currently no other high-quality RCTs that support the use of anti-VEGF agents peri-operatively to reduce the incidence of early or late POVCH.  The remaining studies identified by the search suggested that the pre-operative use of bevacizumab may reduce the incidence of early POVCH, but it should be recognized that there are a number of significant methodological issues in these studies that lead us to be cautious when interpreting their findings and make any definitive conclusions unwarranted.

Intravitreal bevacizumab is one form of treatment for rare causes of choroidal neovascularization such as degenerative myopia, idiopathic, angioid streaks, trauma, choroiditis and retinal dystrophies.  Because these are rare conditions, it is not possible to perform definitive clinical trials.  These diseases are characterized by a subretinal neovascular process which is similar to that seen in neovascular age-related macular degeneration.  Therefore, there is strong biologic plausibility that intravitreal bevacizumab may be effective in these conditions.  For these conditions, intravitreal bevacizumab would be indicated in persons with visual loss due to the presence of active choroidal neovascular as seen on fluorescein angiography or ocular coherence tomography.

In a pilot study, Lo Giudice et al (2009) evaluated the efficacy of single-session PDT combined with intra-vitreal bevacizumab (IVB) in the treatment of retinal angiomatous proliferation (RAP) in age-related macular degeneration.  A total of 8 patients with RAP underwent ICGA-guided single-session verteporfin PDT followed by IVB (1.25 mg) within a 0-day +/- 1-day interval.  All patients were naïve to treatment.  Best-corrected visual acuity, fluorescein angiography, ICGA, and OCT were performed at baseline and at each follow-up visit.  All patients received 3 consecutive monthly IVB injections; thereafter, retreatment with bevacizumab was performed in the case of worsening BCVA or a deterioration of angiographic or OCT findings.  All patients had 9 months of follow-up.  Complete resolution of angiographical leakage was achieved in all eyes at 9 months.  A significant improvement in the mean BCVA was observed at 1 month, 3 months, 6 months, and 9 months after combined treatment (p = 0.004).  Visual acuity improved in 62.5 % and was stable in 37.5 % of cases.  No patients had a decrease in BCVA of 3 or more lines during follow-up.  Mean central macular thickness was significantly reduced in all patients (p < 0.0001) as controlled at 1-month, 3-month, 6-month, and 9-month intervals from initial treatment.  The mean number of injections for the 9 months were 3.2 +/- 0.4.  No ocular complications or systemic events developed.  The authors concluded that sequenced combined treatment with single-session PDT and IVB injections may be useful in treating RAP, reducing or eliminating retinal edema, and improving or stabilizing visual acuity.  They stated that further investigations are warranted to outline the appropriate treatment paradigm for combination therapy.

Ishikawa et al (2009) evaluated the safety and effectiveness of IVB as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy (PDR).  A total of 8 eyes of 6 patients (33 to 64 years old, all male subjects) with severe PDR were investigated.  An intra-vitreal injection of 1.25 mg bevacizumab was carried out 3 to 30 days before planned vitrectomy.  All cases showed minimum bleeding during surgical dissection of fibro-vascular membrane.  Two cases receiving bevacizumab 7 days before the surgery showed strong fibrosis and adhesion of fibro-vascular membrane, resulted in some surgical complications.  The cases having IVB for shorter time did not show extensive fibrosis.  The authors concluded that pre-treatment of bevacizumab is likely effective in the vitrectomy for severe PDR.  The appropriate timing of vitrectomy after bevacizumab injection should be further evaluated.

In a prospective, comparative case series, El-Sabagh and colleagues (2011) evaluated the effects of intervals between pre-operative IVB and surgery on the components of removed diabetic fibro-vascular proliferative membranes.  A total of 52 eyes of 49 patients with active diabetic fibro-vascular proliferation with complications necessitating vitrectomy were included in this study.  Participant eyes that had IVB were divided into 8 groups in which vitreo-retinal surgery was performed at days 1, 3, 5, 7, 10, 15, 20, and 30 post-injection.  A group of eyes with the same diagnosis and surgical intervention without IVB injection was used for comparison.  In all eyes, proliferative membrane specimens obtained during vitrectomy were sent for histopathologic examination using hematoxylin-eosin stain, immunohistochemistry (CD34 and smooth muscle actin), and Masson's trichrome stain.  Main outcome measure was comparative analysis of different components of the fibro-vascular proliferation (CD34, smooth muscle actin, and collagen) among the study groups.  Pan-endothelial marker CD34 expression levels starting from day 5 post-injection were significantly less than in the control group (p < 0.001), with minimum expression (1+) in all specimens removed at or after day 30 post-injection.  Positive staining for smooth muscle actin was barely detected in the control eyes at day 1, and consistently intense at day 15 and beyond (p < 0.001).  The expression level of trichrome staining was significantly high at day 10, compared with control eyes (p < 0.001), and continued to increase at subsequent surgical time points.  The author concluded that a pro-fibrotic switch was observed in diabetic fibro-vascular proliferation after IVB, and these findings suggest that at approximately 10 days post-IVB the vascular component of proliferation is markedly reduced, whereas the contractile components (smooth muscle actin and collagen) are not yet abundant.  Moreover, the authors noted that their histologic findings are in agreement with many published clinical findings and might be predictive of an optimal time interval for the pre-operative use of adjunctive IVB, which makes surgery more successful with less intra-operative bleeding and complications; thus resulting in better visual outcomes.  However, such favorable outcomes need validation from large-scale clinical studies.

In a comparative, retrospective case series, Fong et al (2010) compared VA outcomes after bevacizumab or ranibizumab treatment for AMD.  These researchers followed 452 patients in a retrospective study of exudative AMD treated with anti-VEGF drugs; 324 patients were treated with bevacizumab and 128 patients with ranibizumab.  All treatment-naive patients who received either bevacizumab or ranibizumab were followed for 1 year.  Baseline characteristics and VA were recorded using standard descriptive statistics.  Main outcome measure was VA.  At 12 months, the distribution of VA improved in both groups with 22.9 % of bevacizumab and 25.0 % of ranibizumab attaining greater than or equal to 20/40.  Improvement in vision was observed in 27.3 % of the bevacizumab group and 20.2 % of the ranibizumab group.  The mean number of injections at 12 months was 4.4 for bevacizumab and 6.2 for ranibizumab.  There were 8 (2 %) deaths in the bevacizumab group and 4 (3 %) in the ranibizumab group.  Two patients developed endophthalmitis in the bevacizumab group and the ranibizumab group.  The bevacizumab group had slightly worse acuity at baseline, but both groups showed improvement and stability of vision over time.  The authors concluded that both treatments seem to be effective in stabilizing VA loss.  There was no difference in VA outcome between the 2 treatment groups.  Because the study is a non-randomized comparison, selection bias could mask a true treatment difference.  Results from the Comparison of the Age-related Macular Degeneration Treatment Trials (CATT) will provide more definitive information about the comparative effectiveness of these drugs.

In a multi-center, single-blind, non-inferiority trial, Martin and colleagues/the CATT Research Group (2011) randomly assigned 1,208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation.  The primary outcome was the mean change in VA at 1 year, with a non-inferiority limit of 5 letters on the eye chart.  Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively.  Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively.  Ranibizumab as needed was equivalent to monthly ranibizumab, although the comparison between bevacizumab as needed and monthly bevacizumab was inconclusive.  The mean decrease in central retinal thickness was greater in the ranibizumab-monthly group (196 μm) than in the other groups (152 to 168 μm, p = 0.03 by analysis of variance).  Rates of death, myocardial infarction, and stroke were similar for patients receiving either bevacizumab or ranibizumab (p > 0.20).  The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1 % versus 19.0 %; risk ratio, 1.29; 95 % confidence interval [CI]: 1.01 to 1.66), with excess events broadly distributed in disease categories not identified in previous studies as areas of concern.  The authors concluded that at 1 year, bevacizumab and ranibizumab had equivalent effects on VA when administered according to the same schedule.  Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly.  Differences in rates of serious adverse events require further study.

In an editorial that accompanied the afore-mentioned study, Rosenfeld (2011) stated that "The CATT results, together with the totality of global experience, support the use of either bevacizumab or ranibizumab for the treatment of neovascular AMD ... The CATT data support the continued global use of intravitreal bevacizumab as an effective, low-cost alternative to ranibizumab".

Schmucker and associates (2011) performed a systematic review to compare adverse effects (AE) and the reporting of harm in RCTs and non-RCTs evaluating intravitreal ranibizumab and bevacizumab in AMD.  Medline, Embase and the Cochrane Library were searched with no limitations of language and year of publication.  Studies which compared bevacizumab or ranibizumab as monotherapy with any other control group were included.  Case series were included if they met pre-defined quality standards. The results of phase III trials evaluating ranibizumab showed that the rates of serious ocular AE were low (less than or equal to 2.1 %) but indicated major safety concerns (risk ratio [RR] 3.13, 95 % CI: 1.10 to 8.92).  A possible signal with regard to thrombo-embolic events (RR 1.35, 95 % CI: 0.66 to 2.77) and a significant increase in non-ocular hemorrhage (RR 1.62, 95 % CI: 1.03 to 2.55) were also noted.  In contrast to ranibizumab trials, the RCTs evaluating bevacizumab were of limited value.  The main shortcomings are small sample sizes and an apparent lack of rigorous monitoring for AE.  A critical assessment of the large number of published case series evaluating bevacizumab also showed that no reliable conclusions on safety can be drawn using this study design.  Therefore, any perception that intravitreal bevacizumab injections are not associated with major ocular or systemic AE are not supported by reliable data.  The authors concluded that bevacizumab studies showed too many methodological limitations to rule out any major safety concerns.  Higher evidence from ranibizumab trials suggested signals for an increased ocular and systemic vascular and hemorrhagic risk that warrants further investigation.

Bevacizumab (Intravitreal) for Macular Edema Secondary to Branch Retinal Vein Occlusion

Ehlers and colleagues (2017) evaluated the available evidence on the safety and effectiveness of current therapeutic alternatives for the management of ME secondary to BRVO.  Literature searches were last conducted on January 31, 2017, in PubMed with no date restrictions and limited to articles published in English, and in the Cochrane Database without language limitations.  The searches yielded 321 citations, of which 109 were reviewed in full text and 27 were deemed appropriate for inclusion in this assessment.  The panel methodologist assigned ratings to the selected studies according to the level of evidence.  Level I evidence was identified in 10 articles that addressed anti-VEGF pharmacotherapies for ME, including intravitreal bevacizumab (5 studies), aflibercept (2 studies), and ranibizumab (4 studies).  Level I evidence was identified in 6 studies that examined intravitreal corticosteroids, including triamcinolone (4 studies) and the dexamethasone implant (2 studies).  Level I evidence also was available for the role of macular grid laser photocoagulation (7 studies) and scatter peripheral laser surgery (1 study).  The inclusion of level II and level III studies was limited given the preponderance of level I studies.  The number of studies on combination therapy is limited.  The authors concluded that current level I evidence suggested that intravitreal pharmacotherapy with anti-VEGF agents is safe and effective for ME secondary to BRVO.  Prolonged delay in treatment is associated with less improvement in VA.  Level I evidence also indicated that intravitreal corticosteroids are safe and effective for the management of ME associated with BRVO; however, corticosteroids are associated with increased potential ocular side effects (e.g., elevated IOP, cataracts); laser photocoagulation remains a safe and effective therapy, but VA results lag behind the results for anti-VEGF therapies.

Bevacizumab (Intravitreal) for the Treatment of Amelanotic Melanoma / "Leakage" from an Amelanotic Choroid Malignancy

Canal-Fontcuberta et al (2012) stated that photodynamic therapy (PDT) has been used occasionally as an alternative treatment for uveal melanomas.  These researchers described the clinical and histopathologic features of 5 choroidal melanomas after PDT.  A total of 3 patients with pigmented choroidal melanomas were treated with PDT and intravitreal bevacizumab 1 week before undergoing biopsy and brachytherapy to minimize the risks of bleeding during the biopsy.  Another 2 patients received PDT as a primary treatment for peri-papillary amelanotic melanomas, 1 of them also in combination with bevacizumab.  The tumors treated with PDT and bevacizumab showed a marked reduction in tumor vascularity assessed by indocyanine angiography (ICA), and the biopsies were conducted without recognizable bleeding, showing viable tumor cells.  The tumors receiving PDT as a primary treatment were followed by progressive tumor growth that led to enucleation years after.  The histopathology revealed overlying fibrosis with invasion of sclera and optic nerve.  The authors concluded that PDT and bevacizumab could induce closure of the superficial vasculature of a pigmented choroidal melanoma, but in none of these cases, there was evidence of tumor destruction from this treatment.  Pre-operative PDT may be useful to reduce the potential of bleeding at the time of tumor biopsy.  The authors concluded that their cases did not support the use of a single session of PDT as a primary treatment for pigmented small choroidal melanomas. 

Francis et al (2020) stated that cutaneous melanoma metastatic to the vitreous is very rare.  In a retrospective, multicenter, cohort study, these investigators examined the clinical findings, treatment, and outcome of patients with metastatic cutaneous melanoma to the vitreous.  Most patients received checkpoint inhibition for the treatment of systemic disease, and the significance of this was examined.  A total of 14 eyes of 11 patients with metastatic cutaneous melanoma to the vitreous.  Clinical records, including fundus photography and ultrasound (US) results, were reviewed retrospectively, and relevant data were recorded for each patient eye.  Main outcome measures were clinical features at presentation, ophthalmic and systemic treatments, and outcomes.  The median age at presentation of ophthalmic disease was 66 years (range of 23 to 88 years), and the median follow-up from diagnosis of ophthalmic disease was 23 months; 10 of 11 patients were treated with immune checkpoint inhibition at some point in the treatment course.  The median time from starting immunotherapy to ocular symptoms was 17 months (range of 4.5 to 38 months).  Half of eyes demonstrated amelanotic vitreous debris; 5 eyes demonstrated elevated intra-ocular pressure (IOP), and 4 eyes demonstrated a retinal detachment; 6 patients showed metastatic disease in the central nervous system (CNS).  Ophthalmic treatment included external beam radiation (30 to 40 Gy) in 6 eyes, intra-vitreous melphalan (10 to 20 μg) in 4 eyes, enucleation of 1 eye, and local observation while receiving systemic treatment in 2 eyes; 3 eyes received intravitreal bevacizumab for neovascularization.  The final Snellen visual acuity (VA) ranged from 20/20 to no light perception.  The authors concluded that the differential diagnosis of vitreous debris in the context of metastatic cutaneous melanoma included intravitreal metastasis, and this appeared to be particularly apparent during this era of treatment with checkpoint inhibition.  External beam radiation, intravitreal melphalan, and systemic checkpoint inhibition could be used in the treatment of ophthalmic disease.  Neovascular glaucoma and retinal detachments may occur, and most eyes showed poor visual potential.  Approximately 1/4 of patients demonstrated ocular disease that preceded CNS metastasis.  Patients with visual symptoms or vitreous debris in the context of metastatic cutaneous melanoma would benefit from evaluation by an ophthalmic oncologist.

Bevacizumab (Intravitreal) for the Treatment of Radiation Maculopathy

In a retrospective, comparative, non-randomized study, Eandi et al (2021) examined 18 months' results of a strict anti-VEGF protocol for radiation maculopathy following proton radiotherapy (RT) in choroidal melanoma. This trial included of 74 radiation maculopathy patients presenting macular lipid deposits, hemorrhages, microaneurysms, cystoid edema, nerve layer infarction, telangiectasia, or capillary nonperfusion. The study group included 52 consecutive patients injected with intravitreal bevacizumab/ranibizumab (46/6) every 2 months for the 1st and every 3 months for the 2nd year, with minimum 12 months' follow-up. The control group consisted of 22 patients having declined this treatment. BCVA, spectral domain-OCT (SD-OCT) and OCT angiography (OCT-A) were recorded at baseline, 6, 12, and 18 months. The foveal avascular zone and capillary density were measured at the superficial capillary plexus. Radiation maculopathy was diagnosed at 2 years (1.5 to 3.5) following proton RT. BCVA at baseline, 12 and 18 months improved in the study group from 0.45, 0.3 to 0.2 logarithm of the minimum angle of resolution, but decreased in the control group from 0.5, 0.9 to 1.0 logarithm of the minimum angle of resolution respectively (p < 0.001 at 12 months). Simultaneously, foveal avascular zone enlargement was less in the study (from 0.377, 0.665 to 0.744 mm2) than control group (from 0.436, 1.463 to 2.638 mm2) (p = 0.05 at 12 months). CMT (280 and 276 µm) and capillary density (37 % and 38 %, at baseline, respectively) did not evolve significantly different. The authors concluded that intravitreal anti-VEGF, every 2 months for the 1st and every 3 months for the 2nd year, slowed down, over up to 18 months, vision loss and anatomical degradation in radiation maculopathy following proton RT for choroidal melanoma.

The authors stated that drawbacks of this study included its retrospective design and the insufficient number of eyes with an 18-month follow-up, not allowing a conclusive statistical analysis at this time-point. The statistically significant difference in the median age between the 2 groups was another drawback. In fact, visual prognosis was less favorable in elder patients, which were also those who refused the strict treatment regimen. Moreover, for a single-center study with its own specific treatment regimen, a comparison with published results was delicate. The use of 2 different anti-VEGF drugs (bevacizumab and ranibizumab) represented another drawback allowing only to examine the general effect of a VEGF inhibition rather than the effectiveness of a specific molecule. Finally, OCT-A examination presented still limitations in both acquisitions, although low quality scans were discarded, and interpretation, because there is still debate whether to use the superficial capillary plexus (SCP) or deep capillary plexus (DCP) for foveal avascular zone (FAZ) analysis. In addition, the presence of macular edema could affect the quality and segmentation of the OCT-A images. However, for this reason, a trained ophthalmologist controlled the correct segmentation of each examination, to reduce this bias that could have affected the OCT-A quantitative data and therefore the results.

Fallico et al (2021) noted that radiation maculopathy and radiation-induced macular edema are common, sight-threatening complications following RT, especially that used for uveal melanoma. While many treatment and preventive strategies have been proposed, management of these conditions is still challenging. Initially, treatments were based on the use of retinal laser, but the outcomes were poor. Subsequently, management has shifted toward injection of intravitreal anti-VEGF or corticosteroids. These investigators examined available evidence, which mostly relied on small sample-sized and retrospective studies, for the management of radiation maculopathy and, in particular, radiation-induced macular edema. Currently, the 1st-line approach is usually intravitreal anti-VEGF. Intravitreal dexamethasone implantation may be an option for those with suboptimal response or contraindications to anti-VEGF agents. Possible preventive treatments that require future study are intravitreal bevacizumab and ranibizumab, peripheral laser photocoagulation, and subtenon triamcinolone acetonide.

Furthermore, the American Academy of Ophthalmology (AAO) “Eyewiki” on “Radiation retinopathy” (Wen et al, 2021) stated that VEGF is a secreted protein that promotes vascular leakage and angiogenesis. Bevacizumab is a humanized monoclonal antibody to VEGF and intravitreal bevacizumab is currently used to treat numerous ophthalmologic disorders including diabetic retinopathy, retinal vein occlusion and macular degeneration. Several studies have examined the use of intravitreal bevacizumab in the treatment of radiation retinopathy and maculopathy. Many of the studies demonstrated an improvement in macular edema following intravitreal bevacizumab though a sustained decrease often required multiple injections. However, VA was not found to improve significantly in most of the studies.

Bevacizumab (Intravitreal) for the Treatment of Radiation Retinopathy

In a retrospective, uncontrolled study, Finger and colleagues (2016) reported long-term experience with intravitreal anti-VEGF treatment for radiation maculopathy.  From 2005 to 2015, a total of 120 consecutive patients underwent intravitreal anti-VEGF therapy for radiation maculopathy.  Inclusion criteria included a diagnosis of uveal melanoma treated with plaque radiotherapy and subsequent macular radiation vasculopathy (exudate, retinal hemorrhage, intra-retinal microangiopathy, neovascularization, edema).  Anti-VEGF therapy involved continuous injections in 4- to 12-week intervals with doses of 1.25 mg/0.05 ml (n = 44), 2.0 mg/0.08 ml 9n = 21), 2.5 mg/0.1 ml (n = 21), or 3.0 mg/0.12 ml (n = 6) of bevacizumab as well as 0.5 mg/0.05 ml or 2.0 mg/0.05 ml of ranibizumab.  Goals were maintenance of visual acuity (VA) and normative macular anatomy.  Safety and tolerability (retinal detachment, hemorrhage, infection), VA, CFT on OCT imaging, and clinical features of radiation maculopathy were analyzed.  A total of 99 patients were available for analysis of the main outcome measures of VA and CFT.  Progressive reductions in macular edema, hemorrhages, exudates, cotton-wool spots, and microangiopathy were noted.  At last follow-up, 80 % remained within 2 lines of their initial VA or better, with a mean treatment interval of 38 months (range of 6 to 108 months).  Kaplan-Meier analysis of the probability of remaining within 2 lines of initial VA was 69 % at 5 years and 38 % at 8 years of anti-VEGF therapy.  Discontinuation of therapy was rare.  Relatively few acute or long-term side effects were noted, allowing for good long-term patient accrual.  The authors concluded that the findings of this study suggested that continuous periodic intravitreal anti-VEGF therapy offers suppression of radiation maculopathy edema and long-term preservation of vision.

The authors stated that drawbacks of this study were mostly due to the 10-year span and evolution of techniques/technology over time.  This resulted in a retrospective, uncontrolled, all-inclusive study design providing difficulties with respect to outcome assessment.  For example, 15 patients were excluded from the outcome assessments (of VA and CFT) due to receiving only 1 to 2 injections before discontinuation.  Although these researchers had an intention-to-treat, the results clearly demonstrated that only sustained suppression of this progressive disease is effective.  In addition, dose escalation was only offered in the last 4 years of the study due to the availability of higher doses of anti-VEGF medications.  They chose to report only OCT findings over the last 5 years due to the superiority of the spectral-domain versus the prior time domain technology and their relative abilities to measure CFT.  Finally, due to the numerous factors affecting VA outcomes, these investigators reported on how foveal radiation dose (and not tumor location) affected VA.

Haji Mohd Yasin et al (2016) reviewed the Dunedin Hospital (DH) experience in the treatment of choroidal melanoma (CM) with stereotactic fractionated radiotherapy (SRT) and the outcome of prophylactic use of intravitreal injection bevacizumab (PIB) in preventing radiation retinopathy.  These researchers carried out a retrospective study of patients at DH who underwent SRT for CM with and without PIB from January 1, 2001 to January 31, 2012.  In DH, some patients who had SRT following the introduction of intravitreal bevacizumab in December 2006 were also treated with PIB with the expectation that this might reduce the risk of developing radiation retinopathy, although the evidence of its effectiveness in this respect is not clear.  The primary outcome measure was local progression as monitored with regular ultrasound; secondary outcome measures were metastatic progression incidence, enucleation incidence, no functional vision incidence, overall survival (OS), disease-specific mortality, incidence of radiation retinopathy, and radiotherapy to clinical diagnosis of radiation retinopathy time.  A total of 27 patients who were followed-up at DH were reviewed after a mean follow-up of 5.1 years (range of 0.4 to 12.6); 14 patients received PIB.  The local progression, metastatic progression and enucleation rate were 4 %, 8 % and 11 %, respectively.  The no functional vision (hand movements or less) rate was 62 %; OS was 63 %, but only 3 (11 %) deaths were due to metastatic CM.  Incidence of radiation retinopathy was 57 % and 54 % for those that received PIB and those who did not, respectively; PIB did not reduce the rate of radiation retinopathy (p = 1.00).  The authors concluded that the findings of this study re-affirmed that SRT achieved very good local control and eye retention rates; PIB did not appear to reduce the radiation retinopathy rate in this study, and more studies are needed especially phase-II and phase-III clinical trials to determine PIB efficacy in preventing RR.

Furthermore, an UpToDate review on “Initial management of uveal and conjunctival melanomas” (Harbour and Shih, 2018) states that “The management of radiation retinopathy, optic neuropathy, and neovascular glaucoma has been more challenging.  Radiation causes endothelial cell loss and capillary closure, leading to retinal ischemia and the elaboration of vascular endothelial growth factor (VEGF) and other pro-angiogenic factors.  Attempted treatments have included photodynamic therapy, laser photocoagulation, oral pentoxyphylline, hyperbaric oxygen, periocular or intravitreal injection of corticosteroids, and more recently, intravitreal injection of anti-VEGF agents such as bevacizumab, ranibizumab, and aflibercept.  While none of these treatments is curative or preventative, promising results have been observed for intravitreal anti-VEGF therapy in maintaining or improving visual function in some patients with radiation maculopathy.  Intraocular anti-VEGF therapy, often combined with pan-retinal laser photocoagulation to reduce the production of pro-angiogenic factors from an ischemic retina, has also improved the management of neovascular glaucoma and decreased the rate of secondary enucleation.  The risk of neovascular glaucoma can also be reduced by prompt surgical repair of post-radiation retinal detachment using vitrectomy techniques”.

Also, an UpToDate review on “Delayed complications of cranial irradiation” (Dietrich et al, 2018) states that “The optimal dose and duration of bevacizumab for treatment of radiation necrosis have not been established.  In small series, symptomatic and/or radiographic relapse after discontinuation of bevacizumab has been described in 2 of 5 and 11 of 20 patients.  Some of these patients may respond to retreatment with bevacizumab.  While no serious adverse events were reported in the randomized trial, additional studies are needed to better determine the safety profile of bevacizumab in the management of radiation necrosis as well as the optimal dose and duration of treatment”.

Bevacizumab (Intravitreal) for the Treatment of Sickle Cell Retinopathy

In a case-report, Moshiri and colleagues (2013) discussed the use of pre-surgical intra-vitreal bevacizumab in the context of proliferative sickle-cell retinopathy with retinal detachment.  Intra-vitreal bevacizumab was injected 3 days before the surgical procedure for traction retinal detachment.  Vitrectomy, membrane peeling, endolaser, and SF6 gas tamponade were performed.  A 37-year old woman presented with hemoglobin sickle-cell disease and temporal retinal detachment with bullous sub-retinal fluid extending through the fovea associated with an area of active sea-fan retinal neovascularization with pre-retinal hemorrhage and retinal traction, with 3 associated retinal breaks. The sea-fan neovascularization associated with the traction retinal detachment and the resultant retinal breaks appeared more fibrotic and less vascular than was noted prior to the pre-operative bevacizumab injection.  Segmentation and dissection were performed with minimal bleeding, and retinal traction was relieved without difficulty.  This was believed to be atypical in the experience of the surgeons.  One month post-operatively, vision measured 20/50, and the retina remained attached.  The authors concluded that further study is needed to clarify the role of anti-VEGF in the treatment of proliferative sickle cell retinopathy associated retinal detachment.

Furthermore, UpToDate reviews on “Overview of the clinical manifestations of sickle cell disease” (Vichinsky, 2018) and “Overview of the management and prognosis of sickle cell disease” (Field et al, 2018) do not mention bevacizumab for treatment of sickle cell retinopathy.

Bevacizumab (Intravitreal) for Type 1 Retinopathy of Prematurity

VanderVeen and associates (2017) reviewed the available evidence on the safety and effectiveness of anti- VEGF agents for the treatment of retinopathy of prematurity (ROP) compared with laser photocoagulation therapy.  These investigators performed a literature search of the PubMed and Cochrane Library databases was conducted last on September 6, 2016, with no date restrictions and limited to articles published in English.  This search yielded 311 citations, of which 37 were deemed clinically relevant for full-text review; 13 of these were selected for inclusion in this assessment.  The panel methodologist assigned ratings to the selected articles according to the level of evidence.  Of the 13 citations, 6 articles on 5 randomized clinical trials provided level II evidence supporting the use of anti-VEGF agents, either as monotherapy or in combination with laser therapy.  The primary outcome for these articles included recurrence of ROP and the need for re-treatment (3 articles), retinal structure (2 articles), and refractive outcome (1 article); 7 articles were comparative case series that provided level III evidence.  The primary outcomes included the effects of anti-VEGF treatment on development of peripheral retinal vessels (1 article), refractive outcomes (1 article), or both structural and refractive or visual outcomes (5 articles).  The authors concluded that current level II and III evidence indicated that intravitreal anti-VEGF therapy is as effective as laser photocoagulation for achieving regression of acute ROP.  Although there are distinct ocular advantages to anti-VEGF pharmacotherapy for some cases (such as eyes with zone I disease or aggressive posterior ROP), the disadvantages are that the ROP recurrence rate is higher, and vigilant and extended follow-up is needed because retinal vascularization is usually incomplete.  After intravitreal injection, bevacizumab can be detected in serum within 1 day, and serum VEGF levels are suppressed for at least 8 to 12 weeks.  The effects of lowering systemic VEGF levels on the developing organ systems of premature infants are unknown, and there are limited long-term data on potential systemic and neurodevelopmental effects after anti-VEGF use for ROP treatment.  Anti-VEGF agents should be used judiciously and with awareness of the known and unknown or potential side effects.

Furthermore, an UpToDate review on “Retinopathy of prematurity: Treatment and prognosis” (Coats, 2017) states that “For patients with type I ROP or more severe disease, we recommend treatment rather than ongoing surveillance (Grade 1B).  Effective treatments for ROP include laser photocoagulation and intravitreal injection of an anti-vascular endothelial growth factor (VEGF) agent (e.g., bevacizumab, ranibizumab).  The choice of therapy depends upon the severity of ROP, medical condition of the infant, experience and preference of the treating ophthalmologist, and the preferences of the patient's caregivers”.

Bavacizumab (Intravitreal Injection) in Vitrectomy for Proliferative PVR-Related Retinal Detachment

In a meta-analysis, Zhao and colleagues (2017) examined the effect of intra-vitreal injection of bevacizumab in vitrectomy for patients with proliferative vitreo-retinopathy (PVR)-related retinal detachment.  PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from their earliest entries through October, 2016, to identify the studies that had evaluated the effects of intra-vitreal injection of bevacizumab in vitrectomy for eyes with PVR-related retinal detachment.  The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed.  The relevant data were analyzed using Stata 12.0 software.  The weighted mean difference (WMD), relative risk, and their 95 % CIs were used to assess the strength of the association.  These investigators’ search yielded 133 records from which 3 studies that have examined the effects of intra-vitreal injection of bevacizumab (120 eyes with PVR-related retinal detachment) were included for review and analysis.  Their meta-analyses showed that neither the best-corrected visual acuity (BCVA) nor retinal re-detachment rate showed any clinically or statistically important difference between the non-bevacizumab and bevacizumab groups (p > 0.05).  In addition, bevacizumab did not influence the interval between vitrectomy and retinal re-detachment (p > 0.05).  The authors concluded that based on the available evidence, intra-vitreal injection of bevacizumab in vitrectomy for patients with PVR-related retinal detachment did not decrease retinal re-detachment rate or improve VA.  They stated that better-designed studies with larger simple sizes and longer follow-up periods are needed to reach valid conclusions regarding benefits and harms of intra-vitreal injection of bevacizumab in these cases.  Moreover, evaluation of anti-VEGF therapy on surgical outcomes in eyes with milder sub-types of PVR or no PVR, but deemed at high risk of PVR, may be worthy of future consideration.

Bevacizumab (Subconjunctival Injection) for the Management of Bleb Encapsulation / Needling Following Trabeculectomy

Tai and colleagues (2015) reported the findings of patients who underwent bleb needle revision procedures.  All patients received a subconjunctival injection of 0.1-ml mitomycin C (MMC; 0.4 mg/ml) mixed with 0.1-ml preservative-free lidocaine (1 %) at the beginning of the procedure.  Subjects were randomized into 2 cohorts to receive either 1.0-mg (0.04 ml of 25 mg/ml) subconjunctival bevacizumab (treatment group) or 0.04-ml of balanced salt solution (BSS; control group) injected in an identical manner posterior to the bleb after the bleb needling.  Success was defined as greater than or equal to 20 % reduction in IOP without any IOP-lowering medications.  Qualified success was defined as greater than or equal to 20 % reduction of IOP with IOP-lowering medications.  Failure was defined as IOP of greater than 21 mm Hg, IOP reduction of less than 20 %, or need for additional surgery.  Bleb morphology was classified using the Indiana Bleb Appearance Grading Scale.   At 6-month follow-up, in treatment group (n = 29), 57 % of patients achieved complete success, and 43 % failed.  In control group (n = 29), 41 % of patients achieved complete success, 7 % achieved qualified success, and 52 % failed.  The difference in success rates between the 2 groups was not statistically significant (p = 0.35).  At 6-month follow-up, the mean IOP was 11.52 in treatment group and 12.83 in control group (p = 0.45); patients in treatment group were on a mean of 0.16 medications as compared with 0.58 medications in control group (p = 0.058).  For bleb morphology of treatment group compared with control group, the blebs had less vascularity (0.76 versus 1.20, respectively, on a scale of 0 to 4, p < 0.05) and greater extent (2.68 versus 2.36, on a scale of 0 to 3, p = 0.022) in treatment group.  The authors concluded that there was no significant difference between the success rates and IOPs at post-operative month 6 between treatment and control groups; and post-operative blebs in the treatment group were less vascular and had greater extent. 

In a prospective, randomized, placebo-controlled study, Kiddee and associates (2015) examined the efficacy of subconjunctival bevacizumab (ScB) as adjuvant therapy to primary trabeculectomy with MMC in primary open-angle glaucoma (POAG).  A total of 46 eyes of POAG patients were randomized to receive ScB (1.25 mg/0.05 ml) injections (the MMC+ScB group) at the end of the operations, or sham-treated controls (the MMC group); IOP was the primary outcome and secondary outcomes included bleb appearance, VA, number of medications, complications, and proportion of eyes achieving successful outcomes at the 12-month follow-up.  Of 39 eyes, 20 eyes from the MMC+ScB group, and 19 eyes from the MMC group completed the follow-up.  The mean post-operative IOP was 15.5 ± 4.1 mm Hg in the MMC+ScB group (p < 0.01; 40 % reduction), and 14.7 ± 4.3 mm Hg in the MMC group (p < 0.01; 44 % reduction).  The differences in IOPs, at all follow-up visits, were not significant (p > 0.05).  The mean bleb vascularity score, at 1 month, in the MMC+ScB group was lower than the MMC group (1.55 ± 0.51 versus 2.26 ± 0.6, respectively, p = 0.01), but was not retained at follow-ups.  The success rates at 12 months following surgery were 85 % in the MMC+ScB group and 89.5 % in the MMC group (p = 0.53).  The cumulative probabilities of surgical success were 80 % and 73.7 % in the MMC+ScB and in the MMC group, respectively (p = 0.52).  The authors concluded that single adjunctive ScB injection did not appear to have an additive benefit on outcomes of MMC trabeculectomy, in terms of IOPs and success rates. 

In an in-vitro study, Zhang and co-workers (2019) examined the safety and anti-scarring effects of combined application of bevacizumab (BVZ) and 5-fluorouracil (5-Fu) or BVZ and MMC during glaucoma filtration surgery (GFS).  The cytotoxicity of drug combinations in human Tenon's fibroblasts (HTFs) and human umbilical vein endothelial cells (HUVECs) was evaluated.  Their effects on the levels of VEGF in HUVECs, cell proliferation and migration in HTFs, and the expression of collagen type I alpha 1 (Col1A1) gene in HTFs were examined.  Furthermore, the effects of combined drugs on VEGF receptor (VEGF(R)) mRNA in HTFs were detected to examine the possible underlying drug mechanisms.  The findings showed that BVZ combined with 5-Fu demonstrated more significant anti-scarring effects than BVZ or 5-Fu alone.  However, the inhibitory effects of BVZ combined with MMC were similar to those of MMC alone.  The cytotoxicity of the drug combinations was significantly greater than that of single drug, suggesting that combined application of BVZ and anti-metabolites after GFS was safer when applied at different sites (such as subconjunctival injection at bilateral sides of the filtering bleb) or at varied time-points. 

In a prospective, randomized, placebo-control, single-center study, Muhsen and colleagues (2019) compared the effectiveness of post-operative adjunctive use of subconjunctival bevacizumab in altering the outcome of primary trabeculectomy in terms of sustained lowering of IOP and reduction of post-operative bleb vascularization and fibrosis.  A total of 59 patients (59 eyes) with uncontrolled IOP under maximal tolerated medical treatment (MTMT) were recruited.  A primary trabeculectomy with MMC was carried out and the patients were randomized to either post-operative subconjunctival injection of bevacizumab (1.25 mg/0.05 ml) or BSS; 47 patients (47 eyes) completed at least 1 year of follow-up and were included in the study.  The main outcome measure was the IOP, and secondary outcome measures include bleb morphology, vascularization, and fibrosis, as well as the need for glaucoma medications and 5-FU needling.  At 1-year follow up, there was no significant difference between groups for IOP (p = 0.65), bleb morphology (p = 0.65), and the need for glaucoma medications (p = 0.65) or 5-FU needling requirements (p = 0.11); however, the bevacizumab group had a higher rate of success results, lower use of glaucoma medications following surgery, and optimal bleb aspect in more patients, but more 5-FU needling procedures required.  The authors concluded that a bigger sample size is needed in order to examine if the differences found in the bevacizumab group are statistically significant.

Brolucizumab-dbll (Beovu)

U.S. Food and Drug Administration (FDA)-Approved Indications

Beovu is indicated for:

• Neovascular (wet) age-related macular degeneration
• Diabetic macular edema.

Brolucizumab-dbll is available as Beovu (Novartis Pharmaceuticals Corporation). Brolucizumab-dbll is a recombinant human vascular endothelial growth factor (VEGF) inhibitor. Brolucizumab binds to the three major isoforms of VEGF-A (e.g., VEGF110, VEGF121, and VEGF165), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability.

Beovu is contraindicated in ocular or perocular infections, active intraocular inflammation and hypersensitivy. Beovu carries warnings and precautions for risk of endophthalmitis and retinal detachment following intravitreal injections, retinal vasculitis and/or retinal vascular occlusion, typically in the presense of intraocular inflammation, increases in intraocular pressure (IOP), which has been seen withing 30 minutes of an intravitreal injection, and there is a potential risk of arterial thromboembolic events (ATE) following intravitreal use of VEGF inhibitors. The most common adverse reactions (5% or more) reported in patients receiving Beovu are vision blurred (10%), cataract (7%), conjunctival hemorrhage (6%), eye pain (5%), and vitreous floaters (5%) (Novartis, 2020).

On October 7, 2019, the FDA approved Beovu for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD). 

The safety and efficacy of Beovu were assessed in two randomized, multi-center, double-masked, active-controlled studies (HAWK - NCT02307682 and HARRIER - NCT02434328) in patients with neovascular AMD. A total of 1817 patients were treated in these studies for two years (1088 on brolucizumab and 729 on control). Patient ages ranged from 50 to 97 years with a mean of 76 years. In both studies, after three initial monthly doses (Week 0, 4, and 8), treating physicians decided whether to treat each individual patient on an every 8 week or 12 week dosing interval guided by visual and anatomical measures of disease activity, although the utility of these measures has not been established. In HAWK, patients were randomized in a 1:1:1 ratio to the following dosing regimens: (1) brolucizumab 3 mg administered every 8 or 12 weeks after the first 3 monthly doses, (2) brolucizumab 6 mg administered every 8 or 12 weeks after the first 3 monthly doses, or (3) aflibercept 2 mg administered every 8 weeks after the first 3 monthly doses. In HARRIER, patients were randomized in a 1:1 ratio to the following dosing regimens: (1) brolucizumab 6 mg administered every 8 or 12 weeks after the first 3 monthly doses, or (2) aflibercept 2 mg administered every 8 weeks after the first 3 monthly doses. Patients on 12 week dosing intervals could be changed based on the same measures to an 8 week schedule after subsequent treatment visits. Any patient placed on an 8 week schedule, remained on the 8 week dosing interval until the end of the study. Protocol-specified visits in the initial three months occurred every 28 ± 3 days followed by every 28 ± 7 days for the remainder of the studies. Baseline anatomical measures may have contributed to the regimen selection because the majority of patients on the 12-week dosing schedule at the end of the trial had less baseline macular edema and/or smaller baseline lesions (Dugel et al., 2020).

The primary hypothesis for both studies was noninferiority in mean best-corrected visual acuity (BCVA) change from baseline to Week 48 (margin: 4 letters). Other key end points included the percentage of patients who maintained q12w dosing through Week 48 and anatomic outcomes. Both studies demonstrated efficacy in the primary endpoint defined as the change from baseline in Best Corrected Visual Acuity (BCVA) at Week 48, measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score. At Week 48, each brolucizumab arm demonstrated noninferiority to aflibercept in BCVA change from baseline (least squares [LS] mean, +6.6 [6 mg] and +6.1 [3 mg] letters with brolucizumab vs. +6.8 letters with aflibercept [HAWK]; +6.9 [brolucizumab 6 mg] vs. +7.6 [aflibercept] letters [HARRIER]; P < 0.001 for each comparison).  At Week 16, after identical treatment exposure, fewer brolucizumab 6 mg-treated eyes had disease activity versus aflibercept in HAWK (24.0% vs. 34.5%; P = 0.001) and HARRIER (22.7% vs. 32.2%; P = 0.002). Greater central subfield thickness reductions from baseline to Week 48 were observed with brolucizumab 6 mg versus aflibercept in HAWK (LS mean -172.8 μm vs. -143.7 μm; P = 0.001) and HARRIER (LS mean -193.8 μm vs. -143.9 μm; P < 0.001). Anatomic retinal fluid outcomes favored brolucizumab over aflibercept.  

Greater than 50% of brolucizumab 6 mg-treated eyes were maintained on q12w dosing through Week 48 (56% [HAWK] and 51% [HARRIER]).The probability of remaining on every 12 week dosing from Week 20 to Week 48 was 85% and 82%, and from Week 48 to Week 96 was 82% and 75% in HAWK and HARRIER, respectively. Treatment effects in evaluable subgroups (e.g., age, gender, race, baseline visual acuity) in each study were generally consistent with the results in the overall populations. Overall, adverse event rates were generally similar with brolucizumab and aflibercept. The proportion of patients who were maintained on every 12 week dosing through Week 96 was 45% and 39% in HAWK and HARRIER, respectively.  

The authors, Dugel et al. (2020), concluded brolucizumab was noninferior to aflibercept in visual function at Week 48, and greater than 50% of brolucizumab 6 mg-treated eyes were maintained on q12w dosing interval through Week 48. Anatomic outcomes favored brolucizumab over aflibercept. Overall safety with brolucizumab was similar to aflibercept.

On June 1, 2022, the U.S. Food and Drug Administration (FDA) approved Beovu (brolucizumab-dbll) 6 mg for the treatment of diabetic macular edema (DME). The FDA approval was based on supporting data from the KESTREL and KITE studies (FDA, 2022b).

In the KESTREL and KITE studies, double-masked, 100 week, multicenter, active-controlled, randomized phase 3 trials, Brown and colleagues (2022) compared the efficacy and safety of brolucizumab with aflibercept in patients with DME. Patients were randomized 1:1:1 to receive brolucizumab 3 mg/6 mg or aflibercept 2 mg in KESTREL (n = 566) or 1:1 to brolucizumab 6 mg or aflibercept 2 mg in KITE (n = 360). Brolucizumab groups received 5 loading doses every 6 weeks (q6w) followed by 12-week (q12w) dosing, with optional adjustment to every 8 weeks (q8w) if disease activity was identified at predefined assessment visits; aflibercept groups received 5 doses every 4 weeks (q4w) followed by fixed q8w dosing, The primary endpoint was best-corrected visual acuity (BCVA) change from baseline at Week 52 and secondary endpoints included the proportion of subjects maintained on q12w dosing, change in Diabetic Retinopathy Severity Scale score, and anatomical and safety outcomes. The results were noted at week 52 as follows:  brolucizumab 6 mg was noninferior (NI margin 4 letters) to aflibercept in mean change in BCVA from baseline (KESTREL: +9.2 letters vs +10.5 letters; KITE: +10.6 letters vs +9.4 letters; p < 0.001), more patients achieved central subfield thickness (CSFT) <280 µm, and fewer had persisting subretinal and/or intraretinal fluid vs aflibercept, with more than half of brolucizumab 6 mg subjects maintained on q12w dosing after loading. In KITE, brolucizumab 6 mg showed superior improvements in change of CSFT from baseline over Week 40 to Week 52 vs aflibercept (p = 0.001). The occurrence of ocular serious adverse events was 3.7% (brolucizumab 3 mg), 1.1% (brolucizumab 6 mg), and 2.1% (aflibercept) in KESTREL; and 2.2% (brolucizumab 6 mg) and 1.7% (aflibercept) in KITE. The investigators concluded that brolucizumab 6 mg resulted in strong visual gains and anatomical improvements with an overall favorable benefit/risk profile in patients with DME.

Faricimab-svoa (Vabysmo)

U.S. Food and Drug Administration (FDA)-Approved Indications

Vabysmo is indicated for the treatment of:

• Diabetic macular edema
• Neovascular (wet) age-related macular degeneration.

Faricimab-svoa is available as Vabysmo (Genentech, Inc.) and is a humanized bispecific immunoglobulin GI (IgGI) antibody that works through inhibition of two pathways by binding both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). The inhibition of VEGF-A results in the suppression of endothelial proliferation, neovascularization and vasular permeability, whereas Ang-2 inhibition has been proposed to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. Some patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD) have increased Ang-2 levels. The significance of Ang-2 inhibition to the treatment effect and clinical response for DME and nAMD is yet to be determined (Genentech, 2022).

Per the presribing information, faricimab-svoa (Vabysmo) carries the following contraindications:

• Ocular or periocular infection
• Active intraocular inflammation
• Hypersensitivity.

Per the prescribing information, faricimab-svoa (Vabysmo) carries the following warnings and precautions:

• Endophthalmitis and retinal detachments
• Increase in intraocular pressure
• Thromboembolic: The occurrence of arterial thromboembolic events (ATEs) in the neovascular (wet) age-related macular degeneration studies during the first year was 1% (7 out of 664) in patients treated with Vabysmo compared with 1% ( 6 out of 662) in patients treated with aflibercept.

The most frequent adverse reaction (≥5%) noted in patients receiving Vabysmo was conjunctival hemorrhage (7%) (Genentech, 2022).

On January 28, 2022, the U.S. Food and Drug Administration (FDA) approved Vabysmo (faricimab-svoa) for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA approval was based on supporting data from four phase 3 studies in nAMD and DME. 

Heier and colleagues (2022) reported primary results from the TENAYA and LUCERNE studies evaluating the efficacy, durability, and safety of intravitreal faricimab-svoa (Vabysmo) with extension up to every 16 weeks for nAMD. Both studies were randomized, multi-center, double-masked, active comparator-controlled, 2-year phase 3 trials. Participants were aged 50 years or older and treatment-naive with nAMD. Randomization occurred (1:1) to intravitreal Vabysmo  6 mg up to every 16 weeks, based on protocol-defined disease activity assessments at weeks 20 and 24, or aflibercept 2 mg every 8 weeks. A total of 1329 participants, across the two studies, were randomly assigned [(TENAYA n=334 Vabysmo and n=337 aflibercept) and (LUCERNE n=331 Vabysmo and n=327 aflibercept)]. Participants, investigators, those assessing outcomes, and the funder were masked to group assignments. "The primary endpoint was mean change in best-corrected visual acuity (BCVA) from baseline averaged over weeks 40, 44, and 48 (prespecified non-inferiority margin of four letters), in the intention-to-treat population. Safety evaluation was conducted in participants who received at least one dose of study treatment. The results showed BCVA difference from baseline with Vabysmo was non-inferior to aflibercept in both TENAYA (adjusted mean change 5.8 letters [95% Confidence Interval (CI) 4.6 to 7.1] and 5.1 letters [3.9 to 6.4]; treatment difference 0.7 letters [-1.1 to 2.5]) and LUCERNE (6.6 letters [5.3 to 7.8] and 6.6 letters [5.3 to 7.8]; treatment difference 0.0 letters [-1.7 to 1.8]). Frequency of ocular adverse events were comparable between Vabysmo and aflibercept (TENAYA n=121 [36.3%] vs n=128 [38.1%] and LUCERNE n=133 [40.2%] vs n=118 [36.2%]). The investigators concluded that visual benefits with Vabysmo given at up to 16-week intervals showed its potential to significantly prolong the time between treatments with sustained efficacy. 

Wykoff and colleagues (2022) reported 1-year results from an evaluation of the efficacy, durability, and safety of intravitreal faricimab-svoa (Vabysmo) with extended dosing up to every 16 weeks for DME in the YOSEMITE and RHINE studies. Both studies were randomized, multi-center, double-masked, active comparator-controlled 2-year phase 3 trials. Adult participants (n=1891) with vision loss due to center-involving diabetic macular edema were eligible [YOSEMITE (n=940) and RHINE (n=951)]. These participants were randomly assigned (1:1:1) to Vabysmo 6 mg every 8 weeks (YOSEMITE n=315, RHINE n=317), Vabysmo 6 mg personalized treatment interval (PTI) (n=313, n=319), or aflibercept 2 mg every 8 weeks up to the final study visit at week 100 (n=312, n=315). PTI dosing intervals were extended, maintained or reduced (every 4 weeks up to every 16 weeks) based on disease activity at active dosing visits. "The primary endpoint was mean change in best-corrected visual acuity at 1 year, averaged over weeks 48, 52, and 56. Efficacy evaluation included intention-to-treat population (non-inferiority margin 4 Early Treatment Diabetic Retinopathy Study [ETDRS] letters); safety evaluation included participants with at least one dose study treatment. Non-inferiority for the primary endpoint was noted with Vabysmo every 8 weeks (adjusted mean vs aflibercept every 8 weeks in YOSEMITE 10.7 ETDRS letters [97.52% Confidence Interval (CI) 9.4 to 12.0] vs 10.9 ETDRS letters [9.6 to 12.2], difference -0.2 ETDRS letters [-2.0 to 1.6]; RHINE 11.8 ETDRS letters [10.6 to 13.0] vs 10.3 ETDRS letters [9.1 to 11.4] letters, difference 1.5 ETDRS letters [-0.1 to 3.2]) and Vabysmo PTI (YOSEMITE 11.6 ETDRS letters [10.3 to 12.9], difference 0.7 ETDRS letters [-1.1 to 2.5]; RHINE 10.8 ETDRS letters [9.6 to 11.9], difference 0.5 ETDRS letters [-1.1 to 2.1]). Frequency of ocular adverse events was comparable between Vabysmo every 8 weeks (YOSMITE n=98 [31%], RHINE n=137 [43%], Vabysmo PTI (n=106 [34%], n=119 [37%]), and aflibercept every 8 weeks (n=102 [33%], n=113 [36%]). The investigators concluded that participants achieved strong vision gains and anatomical improvements with Vabysmo and adjustable dosing up to every 16 weeks, thus showing the potential for Vabysmo to extend the durability of treatment for patients with DME.

Pegaptanib Sodium (Macugen)

U.S. Food and Drug Administration (FDA)-Approved Indications

• Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration.

Pegaptanib sodium is available as Macugen (Bausch + Lomb). Pegaptanib octasodium is an aptamer, a pegylated modified oligonucleotide. Pegaptanib is a selective vascular endothelial growth factor (VEGF) antagonist, a type of signal transduction inhibitor (STI) and angiogenesis inhibitor. Pegaptanib binds to VEGF and inhibits its binding to cellular receptors. Macugen’s anti-VEGF activity is expected to inhibit abnormal blood vessel proliferation and therefore decrease the vision loss associated with the proliferation of abnormal blood vessels.

In 2004, Macugen (pegaptanib sodium intravitreal injection) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of neovascular (wet) age-related macular degeneration.

Gragoudas et al (2004) reported the results of 2 concurrent, prospective, randomized, double-blind, multi-center, dose-ranging, controlled clinical trials (n = 1,186) on the use of pegaptanib in the treatment of neovascular AMD.  Intravitreous injection into 1 eye per patient of pegaptanib (at a dose of 0.3 mg, 1.0 mg, or 3.0 mg) or sham injections were administered every 6 weeks over a period of 48 weeks, for a total of 9 treatments.  The primary end point was the proportion of patients who had lost fewer than 15 letters of visual acuity at 54 weeks. 

In the combined analysis of the primary end point, efficacy was demonstrated, without a dose-response relationship, for all 3 doses of pegaptanib (p < 0.001 for the comparison of 0.3 mg with sham injection; p < 0.001 for the comparison of 1.0 mg with sham injection; and p = 0.03 for the comparison of 3.0 mg with sham injection).  Verteporfin photodynamic therapy (PDT) usage was permitted at the discretion of the investigators in patients with predominantly classic lesions.  Concomitant use of PDT overall was low.  More sham treated patients (25 %) received PDT than Macugen 0.3 mg treated patients (20 %).  In the group given pegaptanib at 0.3 mg, 70 % of patients lost fewer than 15 letters of visual acuity, as compared with 55 % among the controls (p < 0.001).  The risk of severe loss of visual acuity (loss of 30 letters or more) was reduced from 22 % in the sham-injection group to 10 % in the group receiving 0.3 mg of pegaptanib (p < 0.001).  More patients receiving pegaptanib (0.3 mg), as compared with sham injection, maintained their visual acuity or gained acuity (33 % versus 23 %; p = 0.003).  As early as 6 weeks after beginning therapy with the study drug, and at all subsequent points, the mean visual acuity among patients receiving 0.3 mg of pegaptanib was better than in those receiving sham injections (p < 0.002).  Dose levels above 0.3 mg did not demonstrate any additional benefit.  On average, Macugen (0.3) mg treated patients and sham treated patients continued to experience vision loss.  However, the rate of vision decline in the Macugen treated group was slower than the rate in the patients who received sham treatment.  Among the adverse events that occurred, endophthalmitis (1.3 % of patients), traumatic injury to the lens (0.7 %), and retinal detachment (0.6 %) were the most serious and required vigilance.  These events were associated with a severe loss of visual acuity in 0.1 % of patients.  The authors concluded that pegaptanib appears to be an effective therapy for neovascular AMD; however, its long-term safety is not known.

Pegaptanib octasodium is available as Intraocular Solution: 0.3 MG/0.09 ML. Macugen 0.3 mg should be administered once every 6 weeks by intravitreous injection into the eye to be treated.  The safety and efficacy of Macugen therapy administered to both eyes concurrently have not been studied.

Macugen should not be used in the following:

• Hypersensitivity to pegaptanib octasodium or any component of the product, may manifest as severe intraocular inflammation
• Patients with ocular or periocular infection.

In a short-term phase II clinical trial, Cunningham et al (2005) assessed the safety and effectiveness of pegaptanib sodium injection (pegaptanib) in the treatment of diabetic macular edema (DME).  Subjects were individuals with a best-corrected visual acuity (VA) between 20/50 and 20/320 in the study eye and DME involving the center of the macula for whom the investigator judged photocoagulation could be safely withheld for 16 weeks.  Intravitreous pegaptanib (0.3 mg, 1 mg, 3 mg) or sham injections were administered at study entry, week 6, and week 12 with additional injections and/or focal photocoagulation as needed for another 18 weeks.  Final assessments were conducted at week 36.  Main outcome measures include best-corrected VA, central retinal thickness at the center point of the central subfield as assessed by optical coherence tomography measurement, and additional therapy with photocoagulation between weeks 12 and 36.  A total of 172 patients appeared balanced for baseline demographic and ocular characteristics.  Median VA was better at week 36 with 0.3 mg (20/50), as compared with sham (20/63) (p = 0.04).  A larger proportion of those receiving 0.3 mg gained VAs of greater than or equal to 10 letters (approximately 2 lines) (34 % versus 10 %, p = 0.003) and greater than or equal to 5 letters (18 % versus 7 %, p = 0.12). Mean central retinal thickness decreased by 68 micron with 0.3 mg, versus an increase of 4 micron with sham (p = 0.02).  Larger proportions of those receiving 0.3 mg had an absolute decrease of both greater than or equal to 100 micron (42 % versus 16 %, p = 0.02) and greater than or equal to 75 micron (49 % versus 19 %, p = 0.008).  Photocoagulation was deemed necessary in fewer subjects in each pegaptanib arm (0.3 mg versus sham, 25 % versus 48 %; p = 0.04).  All pegaptanib doses were well-tolerated.  Endophthalmitis occurred in 1 of 652 injections (0.15 %/injection; i.e., 1/130 [0.8 %] pegaptanib subjects) and was not associated with severe visual loss.  Subjects assigned to pegaptanib had better VA outcomes, were more likely to show reduction in central retinal thickness, and were deemed less likely to need additional therapy with photocoagulation at follow-up.  These investigators noted that confirmation of these preliminary results across a broad spectrum of patients with DME in sufficiently powered prospective clinical trials is being planned.

A 2-year phase III study demonstrated that pegaptanib sodium improved vision in persons with diabetic macular edema (Pfizer, 2010).  The study included 260 subjects who received 0.3 mg pegaptanib sodium or a sham procedure consisting of anesthesia and a simulated injection in the eye every 6 weeks for a total of 9 injections in year 1.  In year 2, subjects received injections as often as every 6 weeks based on pre-specified criteria.  Up to 3 focal or grid laser treatments per year were permitted beginning at week 18, at the investigator’s discretion.  The primary outcome measure of the study was the proportion of subjects who, after 1 year, experienced an improvement in vision from baseline of 2 lines, or 10 letters, on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart.  The investigators reported that 37 % of subjects treated with pegaptanib sodium gained 2 lines, or 10 letters, of vision on the ETDRS eye chart at 54 weeks, versus 20 % of subjects who received the sham procedure (p = 0.0047).  On average, subjects treated with pegaptanib sodium gained 5.2 letters of vision at year 1 compared to 1.2 letters for subjects receiving sham (p < 0.05).  At the end of year 2, subjects receiving pegaptanib sodium had gained on average 6.1 letters of vision compared to 1.3 letters for subjects in the sham arm of the study (p < 0.01).  The investigators reported that adverse events were consistent with those observed in clinical trials of pegaptanib sodium in persons with neovascular age-related macular degeneration and similar to clinical experience with pegaptanib sodium. 

In a pilot study, Dahr et al (2007) examined the safety and effectiveness of pegaptanib for patients with juxtapapillary or large peripheral angiomas secondary to von Hippel-Lindau (VHL) disease.  A total of 5 patients with severe ocular VHL lesions received intravitreal injections of pegaptanib (3 mg/100 microL), given every 6 weeks for minimum of 6 injections.  The primary outcome of this study was a change of greater than or equal to 15 letters (3 lines) in best-corrected VA by 1 year.  Secondary outcomes included changes in macular thickness, as determined by optical coherence tomography, and changes in fluorescein leakage.  Two of 5 patients completed the course of treatment and 1 year of follow-up.  These 2 patients had progressive decrease in retinal hard exudate and reduction in central retinal thickness measured by optical coherence tomography.  One of these 2 patients had improvement in VA of 3 lines.  No significant change in fluorescein leakage or tumor size was detected in either patient.  Lesions in the other 3 patients continued to progress despite treatment, and these patients did not complete the entire treatment course.  One patient developed a tractional retinal detachment.  Additional serious adverse events included transient post-injection hypotony in 2 eyes.  The authors concluded that intravitreal injections of pegaptanib may decrease retinal thickening minimally and reduce retinal hard exudates in some patients with advanced VHL angiomas.  This finding may be related to a reduction in vasopermeability, because there was no apparent effect of treatment on the size of the primary retinal angiomas in this small pilot study.

According to the U.S. FDA website (FDA, 2021), Macugen was withdrawn from the U.S. market.

Pegaptanib Sodium for the Treatment of Central Retinal Vein Occlusion

In a multi-center, dose-ranging, double-masked, phase-II clinical trial, Wroblewski et al (2009) examined the safety and efficacy of intra-vitreous pegaptanib sodium for the treatment of macular edema (ME) following central retinal vein occlusion (CRVO).  This trial included subjects with CRVO for 6 months' or less duration randomly assigned (1:1:1) to receive pegaptanib sodium or sham injections every 6 weeks for 24 weeks (0.3 mg and 1 mg, n = 33; sham, n = 32).   Main outcome measure was visual acuity (VA) at week 30.  In the primary analysis at week 30, 12 of 33 (36 %) subjects treated with 0.3-mg of pegaptanib sodium and 13 of 33 (39 %) treated with 1-mg gained 15 or more letters from baseline versus 9 of 32 (28 %) sham-treated subjects (p = 0.48 for 0.3-mg and p = 0.35 for 1-mg of pegaptanib sodium versus sham).  In secondary analyses, subjects treated with pegaptanib sodium were less likely to lose 15 or more letters (9 % and 6 %; 0.3-mg and 1-mg pegaptanib sodium groups, respectively) compared with sham-treated eyes (31 %; p= 0.03 for 0.3-mg and p = 0.01 for 1-mg of pegaptanib sodium versus sham) and showed greater improvement in mean VA (+7.1 and +9.9, respectively, versus -3.2 letters with sham; p = 0.09 for 0.3-mg and p= 0.02 for 1-mg of pegaptanib sodium versus sham).  By week 1, the mean central retinal thickness (CRT) decreased in the 0.3-mg and 1-mg pegaptanib sodium groups by 269 um and 210 um, respectively, versus 5 um with sham (p < 0.001).  The authors concluded that based on this 30-week study, intra-vitreous pegaptanib sodium appeared to provide visual and anatomical benefits in the treatment of ME following CRVO.  These researchers stated that benefits accrued with intra-vitreous pegaptanib sodium treatment of ME following CRVO suggested a role for vascular endothelial growth factor (VEGF) in the pathogenesis of this condition.

The authors stated that compared with previous pegaptanib studies, there were no new safety signals reported in this trial.  However, this trial was not designed to detect small differences in safety events with statistical significance between treated and control subjects.  The positive results of the study merit further examination in a larger trial in which these more subtle pegaptanib effects may be examined with the added rigor afforded by larger treatment groups.  They stated that a phase-III randomized clinical trial to confirm this hypothesis is needed.

Braithwaite et al (2010) noted that CRVO is a common retinal vascular disorder in which ME may develop, with a consequent reduction in VA.  The visual prognosis in CRVO-ME is poor in a substantial proportion of patients, especially those with the ischemic subtype, and until recently there has been no treatment of proven benefit.  Macular grid laser treatment is ineffective, and while a few recent randomized controlled trials (RCTs) suggested short-term gains in VA with intra-vitreal steroids for patients with non-ischemic CRVO-ME, there is no established treatment for ischemic CRVO-ME.  Anti-VEGF agents have been used to treat ME resulting from a variety of causes and may represent a therapeutic option for CRVO-ME.  These investigators examined the safety and effectiveness of intra-vitreal anti-VEGF agents in the treatment of CRVO-ME.  They searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (the Cochrane Library 2010, Issue 8), Medline (January 1950 to August 2010), Embase (January 1980 to August 2010), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to August 2010), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (January 1937 to August 2010), OpenSIGLE (January 1950 to August 2010), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com) and ClinicalTrials.gov (www.clinicaltrials.gov).  There were no language or date restrictions in the search for trials.  The electronic databases were last searched on  August 10, 2010.  These investigators considered RCTs that compared intra-vitreal anti-VEGF agents of any dose or duration to sham injection or no treatment.  They focused on studies that included individuals of any age or gender with unilateral or bilateral disease and a minimum of 6 months follow-up.  Secondarily, they considered non-randomized studies with the same criteria, but did not conduct a separate electronic search for these.  Two review authors independently assessed trial quality and extracted data.  They found 2 RCTs that met the inclusion criteria after independent and duplicate review of the search results.  These RCTs utilized different anti-VEGF agents that could not be assumed to be directly comparable.  Thus, these researchers performed no meta-analysis.  Evidence from these trials and from other non-randomized case series was summarized in this review.  The authors concluded that ranibizumab and pegaptanib sodium had shown promise in the short-term treatment of non-ischemic CRVO-ME.  However, safety and effectiveness data from larger RCTs with follow-up beyond 6 months are not yet available.  There were no RCT data on anti-VEGF agents in ischemic CRVO-ME.  The use of anti-VEGF agents to treat this condition therefore remains experimental.

Ford et al (2014) reviewed systematically the RCT evidence for treatment of ME due to CRVO.  Data sources included Medline, Embase, CDSR, DARE, HTA, NHSEED, CENTRAL and meeting abstracts (January 2005 to March 2013); RCTs with at least 12 months of follow-up assessing pharmacological treatments for CRVO were included with no language restrictions; 2 authors screened titles and abstracts and conducted data extracted and Cochrane risk of bias assessment.  Meta-analysis was not possible due to lack of comparable studies.  A total of 8 studies (35 articles, 1,714 eyes) were included, assessing aflibercept (n = 2), triamcinolone (n = 2), bevacizumab (n = 1), pegaptanib (n = 1), dexamethasone (n = 1) and ranibizumab (n = 1) . In general, bevacizumab, ranibizumab, aflibercept and triamcinolone resulted in clinically significant increases in the proportion of patients with an improvement in VA of greater than or equal to 15 letters, with 40 to 60 % gaining greater than or equal to 15 letters on active drugs, compared to 12 to 28 % with sham.  Results for pegaptanib and dexamethasone were mixed.  Steroids were associated with cataract formation and increased intra-ocular pressure (IOP).  No overall increase in adverse events (AEs) was found with bevacizumab, ranibizumab, aflibercept or pegaptanib compared with control.  Quality of life (QOL) was poorly reported.  All studies had a low or unclear risk of bias.  The authors concluded that bevacizumab, ranibizumab, aflibercept and triamcinolone appeared to be effective in treating ME secondary to CRVO.  They stated that long-term data on the safety and effectiveness are needed.  Head-to-head trials and research to identify “responders” is needed to help clinicians make the right choices for their patients.  Research aimed to improve sight in people with ischemic CRVO is needed.

The main drawback of this review was that all studies evaluated a relatively short primary follow-up (1 year or less).  Most had an unmasked extension phase.  Furthermore, there was no head-to-head evidence; and the majority of participants included had non-ischemic CRVO.

In a Cochrane review, Braithwaite et al (2014) examined the safety and effectiveness of anti-VEGF therapies for the treatment of ME secondary to CRVO.  These investigators searched CENTRAL (which contains the CENTRAL and the Cochrane Eyes and Vision Group Trials Register) (the Cochrane Library 2013, Issue 10), Ovid Medline (January 1950 to October 2013), Embase (January 1980 to October 2013), LILACS (January 1982 to October 2013), CINAHL (January 1937 to October 2013), OpenGrey, OpenSIGLE (January 1950 to October 2013), the mRCT (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov), the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en) and Web of Science Conference Proceedings Citation Index-Science (CPCI-S).  There were no language or date restrictions in the electronic search for trials.  The electronic databases and clinical trials registers were last searched on October 29, 2013.  These researchers considered RCTs that compared intravitreal anti-VEGF agents of any dose or duration to sham injection or no treatment.  They focused on studies that included individuals of any age or gender and a minimum of 6 months follow-up.  Two review authors independently assessed trial quality and extracted data.  The primary outcome was the proportion of participants with a gain in best-corrected visual acuity (BCVA) from baseline of greater than or equal to 15 letters (3 lines) on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart.  Secondary outcomes included the proportion of participants with a loss of 15 letters or more of BCVA, the mean change from baseline BCVA, the mean change in CRT, the number and type of complications or adverse outcomes, and the number of additional interventions administered.  Where available, these investigators also presented QOL and economic data.  They found 6 RCTs that met the inclusion criteria after independent and duplicate review of the search results.  These RCTs included 937 participants and compared outcomes at 6 months to sham injection for 4 anti-VEGF agents: aflibercept (VEGF Trap-Eye, Eylea), bevacizumab (Avastin), pegaptanib sodium (Macugen) and ranibizumab (Lucentis); 3 trials were conducted in Norway, Sweden and the USA, and 3 trials were multi-center, 1 including centers in the USA, Canada, India, Israel, Argentina and Columbia, a 2nd including centers in the USA, Australia, France, Germany, Israel, and Spain, and a 3rd including centers in Austria, France, Germany, Hungary, Italy, Latvia, Australia, Japan, Singapore and South Korea.  These researchers performed meta-analysis on 3 key visual outcomes, using data from up to 6 trials.  High-quality evidence from 6 trials revealed that participants receiving intra-vitreal anti-VEGF treatment were 2.71 times more likely to gain at least 15 letters of VA at 6 months compared to participants treated with sham injections (risk ratio (RR) 2.71; 95 % confidence intervals (CI): 2.10 to 3.49).  High-quality evidence from 5 trials suggested anti-VEGF treatment was associated with an 80 % lower risk of losing at least 15 letters of VA at 6 months compared to sham injection (RR 0.20; 95 % CI: 0.12 to 0.34).  Moderate-quality evidence from 3 trials (481 participants) revealed that the mean reduction from baseline to 6 months in CRT was 267.4 µm (95 % CI: 211.4 µm to 323.4 µm) greater in participants treated with anti-VEGF than in participants treated with sham.  The meta-analyses demonstrated that treatment with anti-VEGF is associated with a clinically meaningful gain in vision at 6 months.  One trial demonstrated sustained benefit at 12 months compared to sham.  No significant ocular or systemic safety concerns were identified in this time-period.  The authors concluded that compared to no treatment, repeated intra-vitreal injection of anti-VEGF agents in eyes with CRVO-ME improved visual outcomes at 6 months.  All agents were relatively well-tolerated with a low incidence of adverse effects in the short-term.  These researchers stated that future trials should address the relative safety and efficacy  of the anti-VEGF agents and other treatments, including intra-vitreal corticosteroids, for longer-term outcomes.

Furthermore, an UpToDate review on “Retinal vein occlusion: Treatment” (Covert and Han, 2019) states that “VEGF inhibitors in patients with RVO are hypothesized to limit macular edema and improve vision by decreasing vascular permeability.  Four anti-VEGF intravitreal agents are available for clinical use: pegaptanib, bevacizumab, ranibizumab, and aflibercept.  Only ranibizumab and aflibercept are approved for treatment of RVO by the US Food and Drug Administration (FDA).  There are no evidence-based criteria for determining which of these drugs to use, and clinical decisions are based mostly on medication cost”.

Ranibizumab / Bevacizumab for the Treatment of Hypertensive Retinopathy

Georgiadis et al (2014) presented the case of a patient with bilateral hypertensive retinopathy complicated with retinal neovascularization who received anti-vascular endothelial growth factor (VEGF) intra-vitreal injection (IVI) in 1 eye and pan-retinal photocoagulation (PRP) in the fellow eye.  Subject was a 33-year old man presented with gradual visual loss in both eyes for the last 5 months.  At that time, he was examined by an ophthalmologist and occlusive retinopathy due to malignant systematic hypertension was diagnosed.  He was put on anti-hypertensive treatment but no ophthalmic treatment was undertaken.  At presentation, 5 months later, best-corrected visual acuity (BCVA) was 0.1 in the right eye (RE) and 0.9 in the left eye (LE).  Fundus examination was compatible with hypertensive retinopathy complicated with retinal neovascularization.  Fluorescein angiography (FFA) revealed macular ischemia mainly in the RE and large areas of peripheral retinal ischemia and neovascularization with vascular leakage in both eyes.  The patient was treated with 2 anti-VEGF (ranibizumab) injections with 2 months interval in the RE and PRP laser in the LE.  Follow-up examination after 12 months showed mild improvement in BCVA, and FFA documented regression of retinal neovascularization in both eyes.  The authors concluded that hypertensive retinopathy can be rarely complicated with retinal neovascularization; treatment with PRP can be undertaken.  In this case, the use of an IVI of anti-VEGF agent appeared to halt its progression satisfactorily.  These researchers stated that their approach of using ranibizumab could trigger further research towards the evaluation of anti-VEGF agents in the management of retinal ischemia and neovascularization.

In a randomized trial, Pece et al (2016) examined the effect of timolol 0.1 % eye gel on short-term intra-ocular pressure (IOP) after an IVI of ranibizumab.  A total of 150 eyes of 150 IVI-naïve patients with macular edema caused by various pathological conditions (age-related macular degeneration, central or branch retinal vein occlusion, and diabetic retinopathy) were scheduled to undergo an IVI of ranibizumab (0.5 mg/0.05 cc).  Patients were randomly divided into 3 groups: 50 were not treated with timolol before the IVI (group 1); 50 received an instillation of timolol 0.1 % eye gel the evening before the IVI (group 2); and 50 received an instillation of timolol 0.1 % eye gel 2 hours before the IVI (group 3).  The incidence of clinically significant intra-ocular hypertensive spikes (greater than 25 mmHg and greater than 40 mmHg) was then assessed.  The results showed that mean IOP at baseline was significantly higher than at both 5 and 60 mins after IVI (p < 0.01).  Spikes of greater than 25 mmHg were recorded at either time in 27 patients (54 %) in group 1, 23 patients (44 %) in group 2, and 24 patients (48 %) in group 3.  None of the between-group differences was significant.  Spikes of greater than 40 mmHg (which were only detected 5 mins after IVI) were recorded in 9 (18 %), 8 (16 %), and 1 patient (2 %) in groups 1, 2, and 3, respectively.  The only significant difference was between the control and group 3 (p = 0.012).  The authors concluded that an increase in IOP after anti-VEGF IVI was a frequent complication.  The prophylactic use of timolol 0.1 % gel effectively reduced the mean IOP when administered 2 hours before IVI and was also effective in preventing dangerous IOP spikes of greater  40 mmHg; thus, it was recommended.

Furthermore, an UpToDate review on “Moderate to severe hypertensive retinopathy and hypertensive encephalopathy in adults” (Elliott and Varon, 2019) does not mention bevacizumab and ranibizumab as therapeutic options.

Ranibizumab (Lucentis), Ranibizumab-eqrn (Cimerli), and Ranibizumab-nuna (Byooviz)

U.S. Food and Drug Administration (FDA)-Approved Indications for Lucentis and Cimerli

• Diabetic macular edema
• Neovascular (wet) age-related macular degeneration
• Macular edema following retinal vein occlusion
• Diabetic retinopathy
• Myopic choroidal neovascularization

U.S. Food and Drug Administration (FDA)-Approved Indications for Byooviz

• Neovascular (wet) age-related macular degeneration
• Macular edema following retinal vein occlusion
• Myopic choroidal neovascularization

Ranibizumab is available as Lucentis (Genentech, Inc.). Ranibizumab is a recombinant monoclonal antibody, ophthalmic Vascular Endothelial Growth Factor (VEGF) Inhibitor. Ranibizumab binds to and inhibits vascular endothelial growth factor (VEGF‐A) from promoting growth of new blood vessels beneath the retina, by intravitreal injection.

Lucentis is contraindicated in ocular or periocular infections and hypersensitivity. Lucentis carries warnings and precautions for endophthalmitis and retinal detachments, which may occur following intravitreal injections, and increases in intraocular pressure (IOP) pre- and post-intravitreal injection. There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors. Fatal events occurred more frequently in patients with diabetic macular edema and diabetic retinopathy at baseline, who were treated monthly with Lucentis compared with control (Genentech, 2018).

On June 30, 2006, the United States Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection, Genentech Inc., South San Francisco, CA) for the treatment of patients with neovascular AMD.  Lucentis is designed to block new blood vessel growth and leakiness, and is the first treatment which, when given monthly, can maintain the vision of more than 90 % of patients with this type of AMD.  In contrast to pegaptanib (Macugen), ranibizumab is a recombinant humanized monoclonal antibody fragment with specificity for all isoforms of human VEGF.  Ranibizumab exhibits high affinity for human VEGF and exerts its neutralizing effects by inhibiting the VEGF-receptor interaction.  Unlike the larger whole antibody, ranibizumab can penetrate the internal limiting membrane and reach the sub-retinal space following intravitreal injection (van Wijngaarden et al, 2005).

The FDA approval of Lucentis is based on data from 2 phase III clinical studies (MARINA and ANCHOR).  In these studies, nearly all patients (about 95 %) treated with Lucentis (0.5 mg) maintained (defined as the loss of less than 15 letters in VA) and up to 40 % improved (defined as the gain of 15 letters or more in VA) vision at 1-year, as measured on the Early Treatment of Diabetic Retinopathy eye chart.  On average, patients treated with Lucentis in the MARINA study experienced an improvement from baseline of 6.6 letters at 2-year compared to a loss of 14.9 letters in the sham group.  In the ANCHOR study, patients treated with Lucentis, on average, experienced an 11.3 letter gain from baseline at 1-year compared to a loss of 9.5 letters in the Visudyne photodynamic therapy control group.  Up to 40 % of patients treated with Lucentis achieved vision of 20/40 or better.

In addition to data from the 2 phase III clinical trials, data from phase I/II studies were also included in the FDA review.  In an open-label, 2-center, uncontrolled, randomized, phase I clinical trial, Rosenfeld and colleagues (2006) examined if multiple intravitreal doses of up to 2 mg of ranibizumab can be tolerated and are biologically active when injected using a dose-escalating strategy in eyes of patients with neovascular AMD.  A total of 32 patients with primary or recurrent sub-foveal choroidal neovascularization secondary to AMD were enrolled.  Baseline best-corrected VA in the study eye was from 20/40 to 20/640 (Snellen equivalent).  Treatment regimens consisted of 5, 7, or 9 intravitreal injections of ranibizumab at 2- or 4-week intervals for 16 weeks, with escalating doses ranging from 0.3 to 2.0 mg.  Patients were evaluated through day 140, 4 weeks after their last injection.  Safety was assessed based on ocular and non-ocular adverse events, changes in VA, changes in intraocular pressure (IOP), slit-lamp ocular examination, changes in lesion characteristics based on fluorescein angiography and color fundus photography, and the presence of anti-ranibizumab antibodies.  A total of 29 patients received an injection at baseline, and 27 patients completed the study through day 140.  Results were similar across the 3 treatment groups.  All patients experienced ocular adverse events, most of which were mild.  The most common ocular adverse events were iridocyclitis (83 %), and injection-site reactions (72 %).  Inflammation did not increase with repeated injections, despite the increasing ranibizumab doses.  Transient mild IOP elevations were common after ranibizumab injection.  No serum anti-ranibizumab antibodies were detected.  In general, median and mean VAs in the study eyes improved by day 140 in all 3 groups.  Only 3 of the 27 patients lost significant vision.  There was no significant lesion growth, and a decrease in area of leakage from choroidal neovascularization was detected through day 140.  The authors concluded that multiple intravitreal injections of ranibizumab at escalating doses ranging from 0.3 to 2.0 mg were well-tolerated and biologically active in eyes with neovascular AMD through 20 weeks.  Mild transient ocular inflammation was the most common post-injection adverse event.

In a multi-center, controlled, open-label, phase I/II clinical study, Heier and associates (2006) evaluated the safety of repeated intravitreal injections of ranibizumab in treating neovascular AMD, and assessed changes in VA and AMD lesion characteristics.  A total of 64 patients with sub-foveal predominantly or minimally classic AMD-related choroidal neovascularization were enrolled.  In part 1, patients were randomized to monthly intravitreal ranibizumab for 3 months (4 injections of 0.3 mg or 1 injection of 0.3 mg followed by 3 injections of 0.5 mg; n = 53) or usual care (UC; n = 11).  In part 2, patients could continue their regimen for 3 additional months or cross over to the alternative treatment.  Main outcome measures were adverse events, IOP, VA, and lesion characteristics assessed by fluorescein angiography and fundus photography.  Of the 64 randomized subjects, 62 completed the 6-month study.  Twenty of 25 subjects (80 %) randomized to 0.3 mg, and 22 of 28 subjects (79 %) randomized to 0.5-mg ranibizumab in part 1 continued on that treatment in part 2; 9 of 11 (82 %) subjects randomized to UC in part 1 crossed over to ranibizumab treatment in part 2.  The most common side effects with ranibizumab were reversible inflammation and minor injection-site hemorrhages.  Serious side effects were iridocyclitis, endophthalmitis, and central retinal vein occlusion (1 subject each).  Post-injection, IOP increased transiently in 22.6 % of ranibizumab-treated eyes in parts 1 and 2.  After 4 ranibizumab injections (day 98), mean (+/- standard deviation) VA increased 9.4 +/- 13.3 and 9.1 +/- 17.2 letters in the 0.3- and 0.5-mg groups, respectively, but decreased 5.1 +/- 9.6 letters with UC.  In part 2 (day 210), VA increased from baseline 12.8 +/- 14.7 and 15.0 +/- 14.2 letters in subjects continuing on 0.3 and 0.5 mg, respectively.  Visual acuity improved from baseline greater than or equal to 15 letters in 26 % (day 98) and 45 % (day 210) of subjects initially randomized to and continuing on ranibizumab, respectively, and areas of leakage and sub-retinal fluid decreased.  No UC subject had a greater than or equal to 15-letter improvement at day 98.  These investigators concluded that repeated intravitreal injections of ranibizumab had a good safety profile and were associated with improved VA and decreased leakage from choroidal neovascularization in subjects with neovascular AMD.

In clinical trials, the most common side effects among patients treated with Lucentis (reported in at least 6 % more patients than in the control groups in at least one study) included conjunctival hemorrhage, eye pain, vitreous floaters, increased IOP and intraocular inflammation.  Although there was a low rate (less than 4 %) of arterial thromboembolic events observed in the Lucentis clinical studies that was not statistically different between the Lucentis and control groups, there is a theoretical risk of arterial thromboembolic events following intravitreal use of inhibitors of VEGF.  Serious side effects related to the injection procedure occurred in less than 0.1 % of intravitreal injections, including endophthalmitis (severe inflammation of the interior of the eye), retinal tear, retinal detachment, and traumatic cataract.  Lucentis is contraindicated in patients with hypersensitivity and ocular or periocular infections.

In June 2010, the FDA approved Lucentis (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO).  The FDA approval was based upon 2 randomized controlled clinical studies -- the BRAVO study, which assessed the safety and efficacy profile of ranibizumab in a total of 397 patients with macular edema following branch-RVO, and the CRUISE study, which assessed the safety and efficacy profile of ranibizumab in a total of 392 patients with macular edema following central-RVO.  During the first 6-month period, participants in both trials received monthly injections of either 0.3 mg or 0.5 mg of ranibizumab (n = 527) or monthly sham injections (n = 262).  The primary endpoint of both studies was mean change from baseline in best-corrected visual acuity (BCVA) at 6 months compared with patients receiving sham injections.  In the BRAVO study, the percentage of patients in the ranibizumab 0.5 mg study arm who gained 15 or more letters in BCVA from baseline at month 6 was 61 % (compared with 29 % in the sham injection arm).  In the CRUISE study, the percentage of patients in the ranibizumab 0.5 mg study arm who gained 15 or more letters in BCVA from baseline at month 6 was 48 % (compared with 17 % in the sham injection arm).  At month 6, patients in BRAVO who received 0.5 mg of ranibizumab had a mean gain of 18.3 letters (compared to 7.3 letters in patients receiving sham injections).  In the CRUISE study, at month 6, patients who received 0.5 mg of ranibizumab had a mean gain of 14.9 letters (compared to 0.8 letters for patients receiving sham injections).

In a phase IIIb, multi-center, 12-month, randomized core study and 24-month open-label extension study, Schmidt-Erfurth et al (2014) evaluated long-term efficacy and safety profiles during 3 years of individualized ranibizumab treatment in patients with visual impairment due to DME.  Of the 303 patients who completed the randomized RESTORE 12-month core study, 240 entered the extension study.  In the extension study, patients were eligible to receive individualized ranibizumab treatment as of month 12 guided by BCVA and disease progression criteria at the investigators' discretion.  Concomitant laser treatment was allowed according to the ETDRS guidelines.  Based on the treatments received in the core study, the extension study groups were referred to as prior ranibizumab, prior ranibizumab + laser, and laser.  Main outcome measures were change in BCVA and incidence of ocular and non-ocular adverse events (AEs) over 3 years.  Overall, 208 patients (86.7 %) completed the extension study.  In patients treated with ranibizumab during the core study, consecutive individualized ranibizumab treatment during the extension study led to an overall maintenance of BCVA and central retinal subfield thickness (CRST) observed at month 12 over the 2-year extension study (+8.0 letters, -142.1 μm [prior ranibizumab] and +6.7 letters, -145.9 μm [prior ranibizumab + laser] from baseline at month 36) with a median of 6.0 injections (mean, 6.8 injections; prior ranibizumab) and 4.0 (mean, 6.0 injections; prior ranibizumab + laser).  In the prior laser group, a progressive BCVA improvement (+6.0 letters) and CRST reduction (-142.7 μm) at month 36 were observed after allowing ranibizumab during the extension study, with a median of 4.0 injections (mean, 6.5 injections) from months 12 to 35.  Patients in all 3 treatment groups received a mean of less than 3 injections in the final year.  No cases of endophthalmitis, retinal tear, or retinal detachment were reported.  The most frequently reported ocular and non-ocular AEs over 3 years were cataract (16.3 %) and nasopharyngitis (23.3 %); 8 deaths were reported during the extension study, but none was suspected to be related to the study drug/procedure.  The authors concluded that ranibizumab was effective in improving and maintaining BCVA and CRST outcomes with a progressively declining number of injections over 3 years of individualized dosing.  Ranibizumab was generally well-tolerated with no new safety concerns over 3 years.

The FDA approved ranibizumab injection (Lucentis) for the treatment of diabetic retinopathy (DR) in people with diabetic macular edema (DME) (Genentech, 2015).  The FDA granted Lucentis Breakthrough Therapy Designation and Priority Review for this indication based on results from the RISE and RIDE Phase III clinical trials. 

RISE and RIDE were two identically-designed, parallel, double-masked, sham treatment-controlled trials in 759 patients with DR and DME at baseline who were randomized into three groups to receive monthly treatment with 0.3 mg Lucentis, 0.5 mg Lucentis or sham injection (Genentech, 2015). The primary outcome in RISE and RIDE was visual acuity gain at 24 months for DME patients. 

The safety and efficacy of Lucentis for the treatment of DR with DME was assessed over three years in patients with baseline DR severity scores ranging from 10 to 75 in the study eye (on the ETDRS diabetic retinopathy severity scale) (Genentech, 2015). Secondary and exploratory outcomes were evaluated at 24 months. At Month 24, a higher proportion of patients had observed a three-step or better improvement of their disease compared to sham, as determined by color fundus photography. The safety in the RISE and RIDE Phase III trials was consistent with previous studies. 

In the third year of the studies, patients from the control group had the option to cross over to receive monthly treatment with 0.5 mg Lucentis; patients originally randomized to 0.3 mg or 0.5 mg Lucentis continued to receive the same dose and all patients were followed for 12 additional months (Genentech, 2015). The 0.3 mg dose of Lucentis is approved for both DME and for DR in people with DME.

The FDA approved ranibizumab 0.3 mg for the monthly treatment of all forms of diabetic retinopathy, including diabetic retinopathy in people who have been diagnosed either with or without diabetic macular edema (DME) (Genentech, 2017).

The FDA granted Lucentis Priority Review for the treatment of diabetic retinopathy without DME based on an analysis of the Diabetic Retinopathy Clinical Research Network’s (DRCR.net) Protocol S study (Genentech, 2017). The Diabetic Retinopathy Clinical Research Network’s (DRCR.net) Protocol S study was a randomized, active-controlled study comparing ranibizumab to panretinal photocoagulation (PRP) in 305 patients with proliferative diabetic retinopathy, including those with and without diabetic macular edema (DME).

In the Protocol S study, Gross et al (2015) evaluated the noninferiority of intravitreous ranibizumab compared with PRP for visual acuity outcomes in patients with proliferative diabetic retinopathy. The randomized clinical trial was conducted at 55 US sites among 305 adults with proliferative diabetic retinopathy enrolled between February and December 2012 (mean age, 52 years; 44% female; 52% white). Both eyes were enrolled for 89 participants (1 eye to each study group), with a total of 394 study eyes. The final 2-year visit was completed in January 2015. Individual eyes were randomly assigned to receive PRP treatment, completed in 1 to 3 visits (n = 203 eyes), or ranibizumab, 0.5 mg, by intravitreous injection at baseline and as frequently as every 4 weeks based on a structured re-treatment protocol (n = 191 eyes). Eyes in both treatment groups could receive ranibizumab for DME. The primary outcome was mean visual acuity change at 2 years (5-letter noninferiority margin; intention-to-treat analysis). Secondary outcomes included visual acuity area under the curve, peripheral visual field loss, vitrectomy, DME development, and retinal neovascularization.  Mean visual acuity letter improvement at 2 years was +2.8 in the ranibizumab group vs +0.2 in the PRP group (difference, +2.2; 95 % confidence interval [CI]: -0.5 to +5.0; p < 0.001 for noninferiority). The mean treatment group difference in visual acuity area under the curve over 2 years was +4.2 (95 % CI: +3.0 to +5.4; p < 0.001). Mean peripheral visual field sensitivity loss was worse (-23 dB versus -422 dB; difference, 372 dB; 95 % CI: 213 to 531 dB; p < 0.001), vitrectomy was more frequent (15 % versus 4 %; difference, 9 %; 95 % CI: 4 % to 15 %; p < 0.001), and DME development was more frequent (28 % versus 9 %; difference, 19 %; 95 % CI: 10 % to 28 %; p < 0.001) in the PRP group versus the ranibizumab group, respectively. Eyes without active or regressed neovascularization at 2 years were not significantly different (35 % in the ranibizumab group versus 30 % in the PRP group; difference, 3 %; 95 % CI: -7 % to 12 %; p = 0.58).  One eye in the ranibizumab group developed endophthalmitis.  No significant differences between groups in rates of major cardiovascular events were identified.  The investigators concluded that, among eyes with proliferative diabetic retinopathy, treatment with ranibizumab resulted in visual acuity that was noninferior to (not worse than) PRP treatment at 2 years.  The authors stated that. although longer-term follow-up is needed, ranibizumab may be a reasonable treatment alternative, at least through 2 years, for patients with proliferative diabetic retinopathy.

Beaulieu et al (2016) compared patient-centered outcomes in patients with proliferative diabetic retinopathy (PDR) treated with ranibizumab vs panretinal photocoagulation (PRP) from the Protocol S study. The multicenter trial was conducted at 55 U.S. sites and involved  216 adults with 1 study eye out of 305 adults (excluding participants with 2 study eyes, because each eye received a different treatment) with PDR, visual acuity 20/320 or better, no history of PRP. Subjects were assigned to ranibizumab (0.5 mg/0.05 mL) versus PRP. The primary outcome was change from baseline to 2 years in composite and prespecified subscale scores from the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25), University of Alabama Low Luminance Questionnaire (UAB-LLQ), and Work Productivity and Activity Impairment Questionnaire (WPAIQ). For the NEI VFQ-25 and UAB-LLQ composite scores, ranibizumab–PRP treatment group differences (95% CI) were +4.0 (-0.2, +8.3, P = .06) and +1.8 (-3.5, +7.1, P = 0.51) at 1 year, and +2.9 (-1.5, +7.2, P = .20) and +2.3 (-2.9, +7.5, P = .37) at 2 years, respectively. Work productivity loss measured with the WPAIQ was 15.6% less with ranibizumab (-26.3%, −4.8%, P = .005) at 1 year and 2.9% (-12.2%, +6.4%, P = .54) at 2 years. Eighty-three ranibizumab participants (97%) were 20/40 or better in at least 1 eye (visual acuity requirement to qualify for an unrestricted driver's license in many states) at 2 years compared with 82 PRP participants (87%, adjusted risk ratio = 1.1, 95% CI: 1.0, 1.2, P = .005). The authors concluded that, though differences in some work productivity and driving-related outcomes favored ranibizumab over PRP, no differences between treatment regimens for PDR were identified for most of the other patient-centered outcomes considered.

An American Academy of Ophthalmology Preferred Practice Pattern on Diabetic Retinopathy (AAO, 2016) states: "Currently, the role of anti-VEGF therapy in the management of severe NPDR and non-high-risk PDR is under investigation." Regarding the Protocol S study, the AAO states "Very recently, the DRCR.net study protocol S has demonstrated that alternative use of anti-VEGF agents (ranibizumab was used in this protocol), may be an alternative to panretinal laser photocoagulation. However, many feel that panretinal photocoagulation remains the first choice for management of PDR. The anti-VEGF alternative could be considered for patients who can follow-up regularly. Further studies are required to determine the long-term implications of using anti-VEGF agents alone." 

An editorial accompanying the protocol S study (Olsen, 2015) also raised concerns about the need for compliance with ranibizumab treatments for DRE, and the lack of long-term data. "Several other important and unanswered questions arise as a result of this study. What is the long-term role of the anti-VEGF alternative treatment for high-risk PDR? What happens to the PDR beyond 2 years? Does the PDR involute and eliminate the need for continued injections or PRP? Will high-risk features gradually recur once the anti-VEGF injections stop? If so, in what percentage of patients will high-risk features recur? Will the anti-VEGF treatment alternative lead to a lifetime of frequent visits and intravitreal injections? How often should stable patients be followed up in the absence of PRP? In younger patients with diabetes and PDR, should earlier PRP be selected to avoid the rare yet known potential complication of endophthalmitis that may result during a lifetime of anti-VEGF injections? Laser treatments are highly cost-effective in the management of PDR. How will the use of anti-VEGF injections affect the cost of care to society, especially given the high and increasing prevalence of diabetes in the United States?"

Li and colleagues (2017) examined the effect of vitreous injection with ranibizumab, laser coagulation and cryotherapy in treating stage 3 Coats' disease with exudative retinal detachment.  A total of 17 patients with stage 3 Coats' disease were enrolled in the study.  All eyes were treated with vitreous injection of ranibizumab as initial treatment, and subsequent treatment depended on the absorption of subretinal fluid, Including cryotherapy and laser photocoagulation.  Repeat treatment for the 2 treatment intervals occurred in greater than or equal to 1 month.  The mean follow-up time was 24.12 ± 5.99 months.  The main data evaluation and outcome measurements included the patient's vision, IOP, optical coherence tomography (OCT), slit lamp examination, indirect ophthalmoscopy, color Doppler imaging (CDI) and color fundus image analysis.  The following variables were compared between groups: abnormal vascular changes, subretinal fluid and exudate absorption, retinal re-attachment and complications.  The final follow-up results were used to determine the effectiveness of treatment.  Of the 17 patients included, 88.24 % were men and 11.76 % were women; VA was less than 0.02 in 12 eyes before surgery and 8 eyes after surgery; VA improved in 7 eyes, accounting for 41.18 % of cases, and remained unchanged in 7 eyes, accounting for 41.18 % of cases; 3 patients were too young to undergo the operation, accounting for 17.65 % of cases.  The best vision was 0.1.  Patients were treated 1 to 5 times for an average of 2.82 ± 0.95 times each.  There was no statistically significant difference (t = 1.580, p = 0.135) between the pre-operative and post-operative IOP.  However, there was a statistically significant difference between the pre-operative and post-operative retinal detachment height (2- related samples Wilcoxon signed rank test with z = 3.517, p = 0.000).  The results further showed that all patients had different degrees of subretinal fluid absorption, and some of the new blood vessels subsided.  All patients were successfully treated with laser and cryosurgery.  No ocular or systemic complications were observed during follow-up.  The authors concluded that intravitreal ranibizumab, laser coagulation and cryotherapy were effective in the treatment of Coats' disease with exudative retinal detachment.  Moreover, they stated that a larger sample size with longer follow-up period should be included in a multi-center study to standardize the therapeutic approach.

In a retrospective study, Zhao and colleagues (2018) reported a cohort of patients with polypoidal choroidal vasculopathy (PCV) treated with PDT followed by intravitreal ranibizumab injection 24 to 48 hours later, and compared the findings between eyes with PCV treated by PDT followed by intravitreal anti- VEGF injection and intravitreal anti-VEGF injection followed by PDT by meta-analysis.  Medical records of patients with PCV who were initially treated using PDT followed by intravitreal ranibizumab injection 24 to 48 hours after PDT and had completed at least 2y follow-up were reviewed and analyzed.  Clinical data, including age, sex, BCVA, fundus photograph, fluorescein angiography (FA), indocyanine green angiography (ICGA) and OCT were examined.  They also performed a systematic literature review, and a visual outcome of studies over 1 year was compared using meta-analysis.  A total of 52 patients were included in the study.  Mean BCVA at baseline and follow-up at 1 year or 2 years were 0.71 ± 0.61, 0.51 ± 0.36 and 0.68 ± 0.51 logMAR, respectively.  The cumulative hazard rate for recurrence at 1- and 2-year follow-up were 15.4 % and 30.3 %, respectively.  The percentage of eyes with polyps regression at 3-, 12- and 24-month follow-up was 88.5 %, 84.6 % and 67.3 %, respectively.  A meta-analysis based on 22 independent studies showed the overall vision improvements at 1-, 2- and 3-yearfollow-up were 0.13 ± 0.04 (p < 0.001), 0.12 ± 0.03 (p < 0.001), 0.16 ± 0.06 (p < 0.001), respectively.  The proportion of polyps regression at 1-year follow-up was 64.6 % (95 % CI: 51.5 % to 77.7 %, p < 0.001) in 434 eyes treated by intravitreal anti-VEGF agents before PDT and 76.0 % (95 % CI: 64.8 % to  87.3 %, p = 0.001) in 199 eyes treated by intravitreal anti-VEGF agents after PDT.  The authors concluded that intravitreal ranibizumab injection 24 to 48 hours following PDT effectively stabilized VA in the eye with PCV; PDT followed by intravitreal anti-VEGF agents may contribute to a relatively higher proportion of polyps' regression as compared to that of intravitreal anti-VEGF before PDT.

These researchers noted that this study had several drawbacks: They only reported a cohort of patients with PCV treated by PDT followed by intravitreal ranibizumab injection 24 to 48 hours later, without a control group of patients with PCV treated by intravitreal ranibizumab before PDT, they could not show the optimal time for intravitreal ranibizumab injection in combined therapy in the current retrospective study.  The retrospective study design was prone to bias.  For example, in the long follow-up period at a tertiary center, a significant number of patients failed to continue their treatment and follow-up.  The patients with recurrence and aggressive disease tended to be more compliant during follow-up.  There was no strict and specified interval for ICGA or FA, and the judgment of recurrence and decision of repeated combined treatments might be delayed for 1 or 2 months.  There might have been an inter-device difference in the OCT results, as some were time-domain OCT and others spectral-domain OCT.  Taking into account that central foveal thickness (CFT) measured by time-domain OCT is thinner and a great proportion of patients in this study had CFT measured by time-domain OCT, these investigators omitted the result of CFT changes during follow-up.  Because most of the patients underwent time-domain OCT at baseline, the authors considered the CFT at baseline as a potential risk factor for visual outcome in the statistical analysis.  Further prospective study with a fixed spectral-domain OCT device may help to demonstrate the nature of changes to CFT after combined treatment.  Because these researchers had only 9 eyes with VA loss, other risk factors failed to relate to poor visual outcome in this study, including larger lesion size, proximity to fovea, type of PED, and scar or atrophy of the macula.  Further studies should look into the potential risk factors in detail.  It is well-known repeat PDT treatments may damage the retinal pigment epithelial (RPE), the 2 patients with visual loss who had experienced subretinal hemorrhage due to recurrent polyps within the original PDT lesion in this cohort did not show significant RPE damages on their follow-up OCTs.  The protocol of PDT treatment using small and multi-spots to cover the recurrent polyps and the macular sparing treatment may help to reduce the damages of PDT to RPE at fovea.  Further studies with longer follow-up and more recurrent cases may help to address the relationship between RPE damages and VA loss.  For the pooled analysis, the authors failed to include studies without logMAR scores of mean BCVA at baseline or most recent follow-up.  Pooling data from such heterogeneous studies may limit the application of the results of this meta-analysis.  The variations in study design, follow-up period, anti-VEGF agents and population should be taken into account when interpreting the results.

In January 2017, the FDA approved Lucentis (ranibizumab injection) for the treatment of patients with myopic choroidal neovascularization (mCNV), a condition that can lead to blindness. Myopic CNV is a complication of severe near-sightedness and most commonly affects people between the ages of 45 and 64. The approval was based on the results from the randomized, double-masked, active-controlled, Phase III RADIANCE study, which demonstrated that treatment with Lucentis provided superior visual acuity gains in people with mCNV compared to verteporfin photodynamic therapy (vPDT). The study compared the efficacy and safety in 276 patients with visual impairment due to mCNV. At three months, average visual acuity gains for patients treated with Lucentis were more than 12 letters, compared to 1.4 letters for those treated with vPDT. Adverse events were similar to those seen in other Lucentis trials (Genentech, 2017).

Ranibizumab-nuna is available as Byooviz (Biogen Inc.) and is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab-nuna mediates its effects through binding to and inhibiting the biologic activity of human endothelial growth factor A (VEGF-A). This binding to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation (Biogen, 2021).

Per the prescribing information, ranibizumab-nuna (Byooviz) is contraindicated in patients with ocular or periocular infections and also when the patient has a hypersensitivity.

Ranibizumab-nuna (Byooviz) carries the following warnings and precautions as noted in the prescribing information:

• Endophthalmitis and retinal detachments may occur following intravitreal injections.
• Increases in intraocular pressure (IOP) have been noted both pre- and post-intravitreal injection.
• There is a potential risk of arterial thrombembolic events following intravitreal use of VEGF inhibitors.

The most common adverse reactions include conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP (Biogen, 2021).

On September 17, 2021, the United States Food and Drug Administration (FDA) approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several ocular diseases and conditions, including neovasular (wet) age-related macular degneration (nAMD). Additonally, Byooviz is approved for the treatment of macular edema following retinal vein occlusion and myopic choroidal neovascularization. This FDA approval was established on a review of evidence that consisted of extensive structural and functional characterization, comparative clinical efficacy and safety evaluations, inclusive of potential immunogenicity (type of immune response) that demonstrated Byooviz is biosimilar to Lucentis (FDA, 2021).

On August 2, 2022, the United States Food and Drug Administration (FDA) approved Cimerli (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis (ranibizumab) for all five Lucentis FDA-approved indications, satisfying the FDA's high standards to the reference product, including safety, efficacy, and quality. Cimerli is an anti-vascular endothelial growth factor (VEGF) therapy possessing the same product characteristics as Lucentis with regard to dosage strengths, formulation and excipients, and amino acid sequence. The FDA approval was based on supporting data from the COLUMBUS-AMD study, a head-to-head study, in which Cimerli achieved its primary endpoint of change from baseline in best corrected visual acuity (BCVA) at week 8 as compared to the reference product, ranibizumab. Cimerli demonstrated that clinical outcomes are anticipated to be the same for any given patient across all indications. Although Cimerlii is the second biosimilar to Lucentis after Byooviz (ranibizumab-nuna), it is the first to be granted as interchangeable biosimilar across all 5 indications (Coherus BioSciences, 2022b).

Ranibizumab Injection (Susvimo)

U.S. Food and Drug Administration (FDA)-Approved Indications for Susvimo

Susvimo is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) who have previously responded to at least two intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor.

Ranibizumab injection is available as Susvimo (Genentech, Inc.) and is a recombinat humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab mediates its effects through binding to and inhibiting the biologic activity of human endothelial growth factor A (VEGF-A). This binding to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation (Genentech, 2021).

Per the prescribing information, ranibizumab injection (Susvimo) is contraindicated in the following:

• Ocular or periocular infections
• Active intraocular inflammation
• Hypersensitivity.

Ranibizumab (Susvimo) carries the following warnings and precautions as noted in the prescribing information:

• The Susvimo implant and/or implant-related procedures have been associated with endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, vitreous hemorrhage, conjunctival retraction, conjunctival erosion, and conjunctival bleb.
• Postoperative decrease in visual acuity: A decrease in visual acuity usually occurs over the first two postoperative months.

The most common adverse reactions included conjunctival hemorrhage (72%), conjunctival hyperthermia (26%), iritis (23%) and eye pain (10%) (Genentech, 2021).

On October 22, 2021, the United States Food and Drug Administration (FDA) approved Susvimo (ranibizumab injection) for intravitreal use via ocular implant for the treatment of individuals with neovascular (wet) age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Susvimo was previously called the Port Delivery System with ranibizumab. This FDA approval was based on supporting data from the Archway study (Genentech, 2021a).

The Archway study was a phase 3, randomized, visual assessor-masked, active treatment-controlled trial in which study investigators assessed the clinical efficacy and safety of Susvimo (ranibizumab injection) in 415 enrolled participants with AMD. Participants were diagnosed with neovascular age-related macular degeneration (nAMD) within 9 months prior to screening and received ≥ 3 doses of anti-VEGF intravitreal agents in the study eye within the last 6 months prior to screening. Participants were required to have a demonstrated response to an anti-VEGF intravitreal agent prior to randomization. Participants were randomized in a 3:2 ratio to receive continuous delivery of Susvimo (ranibizumab injection) 2 mg (0.02 mL of 100 mg/mL solution) via the Susvimo implant every 24 weeks or 0.5 mg intravitreal ranibizumab injections every 4 weeks. Additionally, supplemental treatment with 0.5 mg intravitreal ranibizumab injections was availalbe at weeks 16, 20, 40, 44, 64, 68, 88, and 92, if necessary, in the Susvimo arm. A primary analysis of the primary efficacy outcome of change from baseline in distance best corrected visual acuity (BCVA) score averaged over week 36 and week 40 revealed that Susvimo was equivalent to intravitreal ranibizumab injections administered every 4 weeks (Genentech, 2021a; 2021b).

Ranibizumab for Type 1 Retinopathy of Prematurity

Kimyon et al (2018) investigated the effects of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity (ROP) affecting zone 1. Files of the patients who received intravitreal bevacizumab (IVB) or ranibizumab (IVR) treatment for ROP affecting zone 1 were evaluated retrospectively. Spherical equivalent (SE) and axial length (AXL) measurements were performed at 1 year of adjusted age. Sixty-eight eyes of 37 patients were included in the study. All patients had initial disease regression but 6 patients (4 in the IVB, 2 in the IVR group) showed reactivation (p = 0.679). The number of eyes with incomplete vascularization were 15 and 12 in the IVB and IVR groups, respectively (p = 0.725). Mean AXL was 20.50 ± 0.99 mm in the IVB group and 19.30 ± 0.48 mm in the IVR group (p < 0.001). Mean SE was -1.49 ± 2.38 dpt in the IVB group and 0.98 ± 2.18 dpt in the IVR group (p < 0.001). The authors concluded that bevacizumab and ranibizumab showed similar effectiveness in the treatment of type 1 ROP affecting zone 1. The AXL was longer and SE was more myopic in eyes treated with IVB. This difference might be caused by the longer intravitreal half-life of bevacizumab than ranibizumab. 

Lin et al (2016) conducted a comparative, consecutive, original study to report on the axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for threshold retinopathy of prematurity. Twenty-five eyes of 13 patients with threshold retinopathy of prematurity received one intravitreal ranibizumab treatment, and 15 eyes of eight patients received one intravitreal bevacizumab treatment. In the ranibizumab group, the mean gestational age was 26.15±2.08 weeks, with a mean birth weight of 811.15±287.3 g. In the bevacizumab group, the mean gestational age was 26.50±2.14 weeks, with a mean birth weight of 938.38±200.4 g. The mean axial length was 20.34±0.97 mm and the mean spherical equivalent was 0.46±1.36 D in the ranibizumab group, with complete vascularization in 15 of 25 (60%) eyes. The mean axial length was 20.91±1.54 mm and the mean spherical equivalent was -0.60±3.86 D in the bevacizumab group, with complete vascularization in seven of 15 (46.7%) eyes. The authors concluded that there were no significant differences in the axial length and refraction between children with threshold retinopathy of prematurity who received intravitreal bevacizumab compared to those who received ranibizumab after 1 year of follow-up. It appeared that the ranibizumab treatment could achieve more complete retinal vascularization than the bevacizumab treatment; however, there was no statistical significance and long-term follow-up is needed.

Alyamaç Sukgen et al (2016) compared the effects on the process of retinal vascularization of intravitreal ranibizumab (IVR) and intravitreal bevacizumab (IVB) in the treatment of severe retinopathy of prematurity. This was a bi-centered retrospective study. While 44 eyes of 22 patients in group 1 were applied 0.625 mg bevacizumab, 46 eyes of 23 patients in group 2 were applied 0.25 mg ranibizumab. Retinal vascularization was evaluated clinically. The mean time for completion of vascularization was found to be postmenstrual 55.93 ± 4.13 weeks in group 1 and 56.30 ± 4.30 weeks in group 2. There were significant differences in the recurrence prevalence between the two groups. The prevalence of recurrence was found to be significantly higher in the ranibizumab group than in the bevacizumab group (p = 0.023). The authors concluded that after IVR or IVB treatment, vascularization could be completed with delay; there were no differences in this delay time between the ranibizumab and bevacizumab groups. Besides, avascular areas may remain in the peripheral retina, and additional treatment may be necessary after IVB or IVR treatment. When the treatment was applied as monotherapy, more recurrence was observed in the ranibizumab group. 

Other Indications

Ciulla and Rosenfeld (2009) stated that anti-VEGF treatments that arrest choroidal angiogenesis and reduce vascular permeability have revolutionized clinical practices for neovascular eye diseases.  These researchers reviewed anti-VEGF therapies that are being evaluated in ocular diseases, other than neovascular AMD, in which neovascularization plays a critical role in pathogenesis.  Early studies of the anti-VEGF agents, pegaptanib sodium, ranibizumab, bevacizumab, VEGF trap, and bevasiranib in the treatment of various neovascular diseases (e.g., diabetic macular edema, retinal vein occlusion, choroidal neovascularization) have shown promising results.  The efficacy and safety of these agents, either alone or combined with standard treatments (e.g., laser photocoagulation), anti-inflammatory agents, or other non-VEGF-based anti-angiogenic therapies, was actively investigated.  Non-VEGF-driven pathways and growth factors other than VEGF may play important roles in pathogenesis and are included in certain combination therapies with VEGF inhibitors.  The authors concluded that the discovery of VEGF-A's role in the pathogenesis of neovascular ocular disease provided a strong rationale for the development of anti-VEGF-based therapies.  There is now ample evidence that anti-VEGF therapies are viable treatment options for these diseases.  Nevertheless, large, randomized controlled trials are still needed to confirm early safety and efficacy findings from small, open-label prospective studies.

Rodriguez-Fontal et al (2009) stated that ranibizumab is a Fab-Antibody with high affinity for VEGF, and is being designed to bind to all VEGF isoforms.  This quality makes it a powerful drug for VEGF inhibition.  Diseases of retinal and choroidal blood vessels are the most prevalent causes of moderate and severe vision loss in developed countries.  Vascular endothelial growth factor plays a critical role in the pathogenesis of many of these diseases.  Results of the pilot studies showed that intra-ocular injections of ranibizumab decrease the mean retinal thickness and improve the best corrected visual acuity in all the subjects.  Proliferative diabetic retinopathy, currently treated with destructive laser photocoagulation, represents another potential target for anti-VEGF therapy.  The early experience in animal models with proliferative retinopathy and neovascular glaucoma shows that posterior and anterior neovascularizations are very sensitive to anti-VEGF therapy. The outcome of 2 phase III clinical trials will increase the knowledge of the role of ranibizumab in the treatment of diabetic macular edema.

Neovascular glaucoma is a severe, blinding consequence of ocular ischemia.  Rubeosis (neovascularization of the iris) develops followed by the onset of neovascular glaucoma once the angle structures are involved.  The natural history of the disease is progressive, and may ultimately result in blindness.  All cases of rubeosis and neovascular glaucoma require treatment of the underlying condition which caused the retinal ischemia, most often with panretinal photocoagulation (Sivak-Callcott et al, 2001).  The onset of the beneficial effect of panretinal photocoagulation takes approximately 3 weeks after treatment to be evident.  In patients with fulminant neovascular glaucoma where sight-threatening elevated intraocular pressure is present, treatment involves providing panretinal photocoagulation, or panretinal cryotherapy when the retina is not visible, followed by glaucoma filtration surgery, preferably waiting several weeks for the neovascularization to regress before the filter surgery (Allen et al, 1982).  Florid neovascularization that is visible at presentation will slowly regress after panretinal photocoagulation, eventually positively influencing the outcome and reducing the complication rate of filtration surgery.  However, during the several weeks waiting for an effect, the patient is at great risk for losing further vision due to glaucoma.  For those eyes that have rubeosis with only minimal involvement of the anterior chamber angle withe neovascularization, intravitreal bevacizumab may be able to prevent further progression by hastening the regression of neovascularization.  Case series have demonstrated that intravitreal bevacizumab will cause the intraocular pressure to drop rapidly.  In order to preserve the effect, panretinal photocoagulation must still be performed, but the rapidity with which intravitreal bevacizumab acts in days may save substantial visual function.  There is currently substantial published literature documenting the positive effect of bevacizumab-induced regression of anterior segment neovascularization and positive influences on the outcome of glaucoma surgery when it is necessary.  This adjuvant use of intravitreal bevacizumab is not a repeated, long-term therapy to treat neovascular glaucoma; rather, it is used as a bridge to create a more favorable intraocular environment for further treatment of the neovascular glaucoma with other modalities like panretinal photocoagulation and filtration surgery.  Concerns about intraocular pressure spikes and resulting secondary ischemia from intravitreal bevacizumab are outweighed by the need for prompt treatment of progressive ischemia from neovascular glaucoma.

Mennel et al (2010) reported a case of retinal juxtapapillary capillary hemangioma causing consecutive leakage with macular involvement.  The tumor was treated with a combination of anti-VEGF and PDT and was followed for 1 year.  A 44-year-old woman with retinal juxtapapillary capillary hemangioma in the right eye experienced a decrease of visual acuity from 20/20 to 20/60 because of a severe leakage from the tumor involving the macula with lipid depositions.  Two sessions of PDT (sparing the part of the hemangioma located within the optic disc) and 5 injections of bevacizumab were applied in a period of 5 months.  Visual acuity, visual field testing, retinal thickness measurements, fundus photography and fluorescein angiography were performed to evaluate the treatment effect.  One year after the last injection, visual acuity increased to 20/40.  All lipid exudates at the posterior pole resolved.  Retinal thickness decreased from 490 to 150 microm with the restoration of normal central macular architecture.  Leakage in fluorescence angiography reduced significantly, but hyper-fluorescence of the tumor was still evident.  Visual field testing and angiography did not show any treatment-related vaso-occlusive side-effects.  The authors concluded that in this single case, the combination of anti-VEGF and PDT appeared to be an effective strategy for the treatment of retinal juxtapapillary capillary hemangioma without side-effects.  The authors stated that further studies with a greater number of eyes and adequate follow-up are necessary to support these first clinical results.

Nicholson and Schachat (2010) stated that diabetic retinopathy (DR) is a leading cause of vision loss in the working-age population worldwide.  Many observational and pre-clinical studies have implicated VEGF in the pathogenesis of DR, and recent successes with anti-VEGF therapy for AMD have prompted research into the application of anti-VEGF drugs to DR.  These researchers reviewed the early studies that suggested a potential role for anti-VEGF agents in the management of DR.  The authors concluded that for DME, phase II trials of intra-vitreal pegaptanib and intra-vitreal ranibizumab have shown short-term benefit in visual acuity.  Intra-vitreal bevacizumab also has been shown to have beneficial short-term effects on both VA and retinal thickness.  For proliferative diabetic retinopathy (PDR), early studies suggest that intra-vitreal bevacizumab temporarily decreases leakage from diabetic neovascular lesions, but this treatment may be associated with tractional retinal detachment (TRD).  Furthermore, several studies indicated that bevacizumab is likely to prove a helpful adjunct to diabetic pars plana vitrectomy (PPV) for TRD.  Finally, 3 small series suggested a potential beneficial effect of a single dose of bevacizumab to prevent worsening of DME after cataract surgery.  Use of anti-VEGF medications for any of these indications is off-label.  These investigators stated that despite promising early reports on the safety of these medications, they eagerly await the results of large, controlled trials to substantiate the safety and efficacy of anti-VEGF drugs for DR.

Boscia (2010) noted that DR is a major cause of blindness in Europe and North America, and the incidence is expected to increase in parallel with the rising incidence of diabetes mellitus.  Boscia reviewed the current state of knowledge of the epidemiology, clinical presentation and pathophysiology of DR and its principal associated complications, DME and neovascularization, and then proceeded to the primary focus of clinical management.  A series of major randomized controlled trials conducted over the past few decades has confirmed that tight glycemic regulation is the most effective measure to reduce the risk of developing DR and to minimize the likelihood of its progression, and that control of blood pressure is also an important feature of preventive management.  Laser-based therapies remain the cornerstone of treatment, with pan-retinal photocoagulation indicated for PDR and severe non-PDR and focal photocoagulation indicated for treatment of DME.  For patients who do not benefit from these approaches, vitrectomy may provide therapeutic benefits.  Medical therapies include 2 broad classes of agents: anti-inflammatory drugs and agents with molecular targets.  The utility of oral anti-inflammatory drugs remains to be established, as dose-finding studies have yet to provide definitive conclusions.  Intra-vitreal corticosteroids may be of value in specific circumstances, although adverse effects include cataract progression and elevated IOP.  However, these complications appear to have been limited with new extended-release technologies.  With respect to molecular targets, evidence has been adduced for the roles of VEGF, tumor necrosis factor (TNF)-alpha and protein kinase C (PKC)-beta2 in the pathogenesis of DR, and agents targeting these factors are under intense investigation.  Preliminary efficacy of pegaptanib and ranibizumab in the treatment of DME is being confirmed in additional clinical trials with these agents and with the off-label use of bevacizumab, another monoclonal antibody related to ranibizumab.  Moreover, other agents targeting VEGF, as well as drugs directed against TNF-alpha and PKC-beta2, are under study.  Evaluation of the ultimate utility of these approaches will await the safety and effectiveness results of properly designed phase III trials.

In a review on diabetic retinopathy, Cheung and colleagues (2010) stated that although anti-VEGF therapy has promising clinical applications for management of DR, its long-term safety in patients with diabetes has not yet been established.  Moreover, Elman and associates (2011) stated that further investigation is needed to ascertain the role of anti-VEGF drugs in the prevention or treatment of PDR.

Waisbourd et al (2011) summarized the latest developments in the treatment of DR with anti-VEGF drugs.  These researchers reviewed recent studies that evaluated the role of the anti-VEGF agents bevacizumab, ranibizumab and pegaptanib in the treatment of DR.  There was only 1 large randomized controlled trial that evaluated the role of ranibizumab in DME.  Other prospective and retrospective studies provided important insight into the role of anti-VEGF drugs in DR, but most of them were not conducted in large scales.  The growing evidence indicates that anti-VEGF drugs are beneficial in DR, especially in DME.  The authors concluded that further studies are needed to fully evaluate the role of these agents, especially in PDR and in DR candidates for vitrectomy surgery.

Mintz-Hittner et al (2011) stated that ROP is a leading cause of childhood blindness worldwide.  Peripheral retinal ablation with conventional (confluent) laser therapy is destructive, causes complications, and does not prevent all vision loss, especially in cases of retinopathy of prematurity affecting zone I of the eye.  Case series in which patients were treated with VEGF inhibitors suggested that these agents may be useful in treating ROP.  These researchers conducted a prospective, controlled, randomized, stratified, multi-center trial to assess IVB monotherapy for zone I or zone II posterior stage 3+ (i.e., stage 3 with plus disease) ROP.  Infants were randomly assigned to receive IVB (0.625 mg in 0.025 ml of solution) or conventional laser therapy, bilaterally.  The primary ocular outcome was recurrence of ROP in 1 or both eyes requiring re-treatment before 54 weeks' post-menstrual age.  These investigators enrolled 150 infants (total sample of 300 eyes); 143 infants survived to 54 weeks' post-menstrual age, and the 7 infants who died were not included in the primary-outcome analyses.  Retinopathy of prematurity recurred in 4 infants in the IVB group (6 of 140 eyes [4 %]) and 19 infants in the laser-therapy group (32 of 146 eyes [22 %], p = 0.002).  A significant treatment effect was found for zone I ROP (p = 0.003) but not for zone II disease (p = 0.27).  The authors concluded that IVB monotherapy, as compared with conventional laser therapy, in infants with stage 3+ ROP showed a significant benefit for zone I but not zone II disease.  Development of peripheral retinal vessels continued after treatment with IVB, but conventional laser therapy led to permanent destruction of the peripheral retina.

Dani et al (2012) reported the preliminary findings in 7 premature infants with complicated ROP or aggressive posterior ROP (APROP) who were treated with IVB as first line monotherapy or rescue therapy combined with laser treatment.  These researchers studied retrospectively 7 preterm infants, who were affected by APROP (n = 4) or pre-threshold ROP (n = 3).  Infants were treated with IVB (0.625 mg; Avastin) monotherapy (n = 2) when they were too sick to undergo lengthy laser treatment.  Monotherapy IVB (n = 3 eyes) and IVB combined with laser therapy (n = 3 eyes) of APROP cases were followed by regression of the ROP and complete peripheral vascularization.  The combined therapy with IVB and laser therapy of pre-threshold ROP (5 eyes) produced a regression of neovascularization and good retinal anatomical outcome.  The authors concluded that in this series, IVB was successful in treating ROP in a small cohort of extremely preterm infants with APROP or pre-threshold ROP, both as monotherapy or rescue treatment after laser therapy, without the development of ocular and systemic short- and long-term adverse effects.

Choovuthayakorn and Ubonrat (2012) reported the effectiveness of IVB injection for advanced ROP patients.  A retrospective chart review was performed for 19 advanced ROP patients (34 eyes), who had IVB injection between January 1, 2007 and July 31, 2009.  The baseline characteristics including gestational age, post-menstrual age of first injection, anterior and posterior segment changes, and complications between treatments to 1-year followed-up were analyzed.  The patients were divided into 2 groups according to the indications for treatment.  Group 1 -- 2 patients (4 eyes), received initial IVB injection followed by laser photocoagulation due to APROP.  Group 2 -- 17 patients (30 eyes), received IVB injection due to persistence of the vascular activity after laser treatment.  There were statistical significant difference between the 2 groups in terms of a mean gestation age, a mean birth weight, and a mean time for first intra-vitreal injection (p = 0.002, 0.008, and 0.007 respectively).  However, there was no statistical significant difference between the 2 groups in terms of timing for resolution of vascular activity and retinal vasculogenesis across the laser scar (p = 0.172).  One patient with APROP progressed to stage 4A ROP with successful anatomical attachment by pars plana vitrectomy.  At 1-year follow-up, no other ocular or systemic side effects were observed.  There was no statistical significant difference of a mean spherical equivalent between the 2 groups (p = 0.280).  The authors concluded that IVB injection is an effective procedure either as an adjuvant or initial treatment in advanced ROP cases.

Autrata et al (2012) evaluated the safety and effectiveness of intravitreal injection of pegaptanib or bevacizumab and laser photocoagulation for treatment of threshold stage 3+ ROP affecting zone I and posterior zone II, and compared the results in terms of regression, development of peripheral retinal vessels with conventional laser photocoagulation or combined with cryotherapy.  In this prospective comparative study, a total of 174 eyes of 87 premature babies, from January 2008 to December 2011, were included.  All infants were diagnosed with stage 3+ ROP for zone I or posterior II.  Patients were randomly assigned to receive intravitreal pegaptanib (0.3 mg) or bevacizumab (0.625 mg/0.025 ml of solution) with conventional diode laser photocoagulation (Group A, 92 eyes of 46 infants) or laser therapy combined with cryotherapy (Group 8, 82 eyes of 41 infants), bilaterally.  The main evaluated outcomes include time of regression and decrease of plus signs and development of peripheral retinal vessels after treatment, final structural-anatomic outcomes compared in the both groups of patients.  Risk factors and other characteristics of infants include birth weight, gestational age, Apgar score, duration of intubation and hospitalizations, post-menstrual age at treatment, sepsis, surgery for necrotizing enterocolitis, intra-ventricular hemorrhage.  Primary outcome of treatment success was defined as absence of recurrence of stage 3+ ROP in 1 or both eyes (recurrence rate = 0) by 55 weeks' post-menstrual age.  Treatment failure was defined as the recurrence of neovascularization (recurrence rate = 1 or 2) in 1 or both eyes requiring re-treatment.  The mean follow-up after treatment was 23.5 months (range of 4 to 45 months) in the Group A, and 25.2 months in the Group B (range of 3 to 48 months).  Final favorable anatomic outcome and stable regression of ROP at last control examination have 90.2 % of eyes after adjuvant intravitreal pegaptanib or bevacizumab in the Group A, and 62 % of eyes after only conventional treatment in the Group B (p = 0.0214).  Regression of plus disease and peripheral retinal vessels development appeared significantly more rapidly in Group A patients who received intravitreal VEGF inhibitors and laser.  An absence of recurrence of neovascularization (stage 3+ ROP) was identified at 87 % of patients in the Group A, and 53 % of patients in the Group B.  This difference between the both groups was statistically significant (p = 0.0183).  Retinopathy of prematurity recurred in 7 from 92 eyes (7.6 %) in the Group A, and 23 from 82 eyes (28 %) in the group B (p = 0.0276).  Significantly better treatment effect was found for adjuvant intravitreal pegaptanib or bevacizumab with laser compared with conventional therapy of ROP 3+ in zone I and posterior zone II.  Peri-operative retinal hemorrhages after laser photocoagulation occurred in 8 % of eyes in the Group A, and 11 % of eyes in the group B (p = 0.358), in all eyes with spontaneous resorption.  No systemic or significant ocular complications of intravitreal anti-VEGF injections, such as endophthalmitis or retinal detachment were found during follow-up period after operation.  The authors concluded that a combination of intravitreal pegaptanib or bevacizumab injection and laser photocoagulation showed to be a safe, well-tolerated and effective therapy in patients with stage 3+ ROP in zone I and posterior zone II.  Adjuvant intravitreal anti-VEGF injection, as compared with conventional laser or cryotherapy, showed significant benefit in terms of better final anatomic outcome, induction of prompt regression, rapid development of peripheral retinal vascularization and decrease of recurrence rate of neovascularization.  The authors concluded that results of this study supported the administration of pegaptanib and bevacizumab as an alternative useful therapy in the management of stage 3+ ROP.

Jalali et al (2013) reported serious adverse events and long-term outcomes of initial experience with intra-ocular bevacizumab in ROP.  Consecutive vascularly active ROP cases treated with bevacizumab, in addition to laser and surgery, were analyzed retrospectively from a prospective computerized ROP database.  Primary efficacy outcome was regression of new vessels.  Secondary outcomes included the anatomic and visual status.  Serious systemic and ocular adverse events were documented.  A total of 24 ROP eyes in 13 babies, received single intra-ocular bevacizumab for severe stage 3 plus after failed laser (7 eyes), stage 4A plus (8 eyes), and stage 4B/5 plus (9 eyes).  Drug was injected intravitreally in 23 eyes and intracamerally in 1 eye.  New vessels regressed in all eyes.  Vision salvage in 14 of 24 eyes and no serious neurodevelopmental abnormalities were noted up to 60 months (mean of 30.7 months) follow-up.  Complications included macular hole and retinal breaks causing rhegmatogenous retinal detachment (1 eye); bilateral, progressive vascular attenuation, perivascular exudation and optic atrophy in 1 baby, and progression of detachment bilaterally to stage 5 in 1 baby with missed follow-up.  One baby who received intra-cameral injection developed hepatic dysfunction.  One eye of this baby also showed a large choroidal rupture.  The authors concluded that although intra-ocular bevacizumab, along with laser and surgery salvaged vision in many otherwise progressive cases of ROP, vigilance and reporting of serious adverse events is essential for future rationalized use of the drug.  These researchers reported 1 systemic and 4 ocular adverse events that require consideration in future use of the drug.

In a prospective, interventional, non-comparative case-study, Martinez-Castellanos et al (2013) evaluated ocular function and systemic development in premature infants treated with IVB injections for ROP over a period of 5 years.  The primary outcome measure was VA.  The secondary outcomes were structural assessment, other ocular functional measurements, and developmental state.  A total of 18 eyes of 13 consecutive patients were divided into 3 groups: Group 1, stage 4 unresponsive to previous conventional treatment (n = 4); Group 2, in which conventional treatment was difficult or impossible because of inadequate visualization of the retina (n = 5); and Group 3, newly diagnosed high-risk pre-threshold or threshold ROP (n = 9).  All patients showed initial regression of neovascularization.  One patient was diagnosed with recurrence of neovascularization and was treated with IVB.  Visual acuity was preserved, and median vision was 20/25 (excluding 2 operated eyes).  Twelve eyes developed mainly low myopia over the years, with an overall mean value of 3.2 diopters.  Electroretinography was normal in 4 eyes that had no previous detachment.  One patient showed delay in growth and neurodevelopment, whereas all the others were within the normal range.  The authors concluded that 5 years of follow-up in a small series suggested that IVB for ROP results in apparently preserved ocular function and systemic development.

In a multi-center, retrospective case series, Wu and colleagues (2013) examined the effectiveness and complications associated with the use of bevacizumab, an anti-vascular endothelial growth factor agent, in the treatment of pre-threshold ROP.  Data from patients who had received IVB injections for the treatment of ROP were collected from 4 medical centers in Taiwan.  The main outcome measures were the regression of ROP and the complications that were associated with the IVB injections.  A total of 162 eyes from 85 patients were included in the study.  After receiving IVB injections, 143 eyes (88 %) exhibited ROP regression.  Fourteen eyes (9 %) required additional laser treatment for ROP regression after the absence of a positive response to the IVB injections.  Three eyes (2 %) progressed to stage 4 ROP and required vitrectomies to re-attach the retinas.  Two eyes (1 %) received 1 additional IVB injection to decrease persistent plus disease.  All of the eyes (100 %) had attached retinas after the various treatments that they received.  The major ocular complications that were associated with IVB injections included vitreous or pre-retinal hemorrhage in 2 eyes (1 %); cataract in 1 eye (1 %); and exotropia in 1 eye (1 %).  No notable systemic complications related to the IVB injections were observed.  The authors concluded that IVB injection seems to be an effective and well-tolerated method of treating pre-threshold ROP. Laser therapy may still be required as a backup treatment for patients who do not respond to an IVB injection or for those in whom ROP worsens after an IVB injection.

In a retrospective, non-randomized, interventional comparative study, Harder et al (2013) evaluated refractive error in infants who underwent IVB injection for treatment of threshold ROP.  The study group included all infants who consecutively received a single IVB (0.375 mg or 0.625 mg) injection for therapy of threshold ROP in fundus zone I or zone II.  The control group included infants who had previously undergone retinal argon laser therapy of ROP.  The follow-up examination included refractometry under cycloplegic conditions.  The study group included 12 children (23 eyes; mean birth weight of 622 ± 153 g; gestational age of 25.2 ± 1.6 weeks) and the control group included 13 children (26 eyes; birth weight of 717 ± 197 g; gestational age of 25.3 ± 1.8 weeks).  Both groups did not differ significantly in birth age and weight and follow-up.  At the end of follow-up at 11.4 ± 2.3 months after birth, refractive error was less myopic in the study group than in the control group (-1.04 ± 4.24 diopters [median of 0 diopters] versus -4.41 ± 5.50 diopters [median of -5.50 diopters]; p = 0.02).  Prevalence of moderate myopia (17 % ± 8 % versus 54 % ± 10 %; p = 0.02; OR: 0.18 [95 % CI: 0.05, 0.68]) and high myopia (9 % ± 6 % versus 42 % ± 10 %; p = 0.01; OR: 0.13 [95 % CI: 0.03, 0.67]) was significantly lower in the bevacizumab group.  Refractive astigmatism was significantly lower in the study group (-1.0 ± 1.04 diopters versus 1.82 ± 1.41 diopters; p = 0.03).  In multi-variate analysis, myopic refractive error and astigmatism were significantly associated with laser therapy versus bevacizumab therapy (p = 0.04 and p = 0.02, respectively).  The authors concluded that in a 1-year follow-up, a single IVB injection as compared to conventional retinal laser coagulation was helpful for therapy of ROP and led to less myopization and less astigmatism.

Sahin et al (2013) evaluated the treatment outcomes of IVB injections, used as a monotherapy in type 1 ROP.  A retrospective chart review was performed for 17 type 1 ROP patients (34 eyes), who had IVB injection between July 2011 and June 2012.  Birth weight, gestational age at birth, the stage and the location of ROP, IVB injection time, the time of complete retinal vascularization, and additional treatments if needed, were noted.  Bevacizumab (0.625 mg in 0.025 ml) was injected intravitreally.  A total of 30 eyes of 17 patients with type 1 ROP were treated with IVB injection enrolled in the study.  Of them 7 had APROP, 6 had stage 2 ROP, and 4 had stage 3 ROP.  The mean gestational age was 28.44 weeks (range of 26 to 31 weeks); and the mean birth weight was 1,151.88 g (range of 600 to 1,600 g).  The mean age for IVB injection was 35.47 weeks.  The mean full retinal vascularization time was 136.6 ± 26.6 days.  The mean follow-up time was 285.3 ± 70 days.  Retinopathy of prematurity was regressed and retinal vascularization was completed in all cases except 1 eye which had threshold disease.  The authors concluded that IVB injection, used as a monotherapy, is an effective treatment approach in patients with type 1 ROP.  These investigators suggested that timely treatment of stage 2 and early stage 3 ROP cases in which disease progression was observed prevents vitreo-retinal membrane formation in posterior disease.

Kim et al (2014) examined the anatomical outcome of combined IVB injection and zone I sparing laser ablation in patients with type 1 ROP in zone I.  The medical records of consecutive 18 eyes of 10 infants, who underwent combined IVB (0.25 mg) injection and zone I sparing laser ablation for the treatment of type 1 ROP in zone I, were retrospectively reviewed.  Laser photocoagulation was performed on the avascular retina anterior to the margin of zone I extending to the ora serrata.  Anatomical outcomes including progression to stage 4/5, macular changes, and vitreous organization were reviewed.  The mean gestational age at birth and the birth weight of included patients were 24.0 weeks and 628 g, respectively.  The timing of IVB injection ranged from post-menstrual age 33 to 35 weeks (mean of 34.3 weeks).  Post-menstrual age at last follow-up ranged from 74 to 107 weeks (mean of 83.6 weeks).  All 18 eyes demonstrated prompt regression of neovascular pathology and plus disease without recurrence.  Previously avascular zone I retina was vascularized in all eyes after the treatment.  All eyes showed excellent anatomical outcome with intact macula, but 1 eye showed mild vitreous organization above the vascular/avascular junction.  The authors concluded that combined IVB injection and zone I sparing laser ablation for type 1 ROP in zone I seem to be effective treatment options.  Possible advantages include lower dose of anti-VEGF, less recurrence than monotherapy, and preservation of central visual field.

Also, an UpToDate review on “Retinopathy of prematurity” (Paysse, 2013) states that “Treatment consists of ablation of the peripheral avascular retina, usually by laser photocoagulation.  Bevacizumab is effective in treating some forms of severe ROP, but long-term systemic and ocular outcomes are unknown”.

Ranibizumab has been used to treat retinopathy of prematurity, with similar results (see, e.g., Castellanos, et al., 2013).

Orozco-Gomez et al (2011) evaluated the effectiveness of combined laser-ranibizumab therapy for ROP with threshold-prethreshold and "plus disease" and studied development of the newborn.  This was a prospective, experimental, longitudinal and open study including newborns of either less than 32 weeks of gestation or with a birth weight less than 1,500 g, with threshold-prethreshold retinopathy or "plus disease".  The effect of treatment was analyzed and development of the newborn was determined.  These investigators studied 34 eyes of 17 patients.  Age at birth was 29.9 ± 2.6 weeks.  Birth weight was 1,120 ± 253 g.  The statistics demonstrated an important relationship between severity of retinopathy and early birth age, along with a high probability of threshold-prethreshold disease at 29.4 weeks of age or 1,204 g birth weight.  The Bayley scale reported normal development in 23.5 % of cases, global retardation in 23.5 %, psychomotor retardation but normal mental behavior in 29.4 %, and mental retardation but normal psychomotor development in 23.5 %.  These researchers demonstrated regression of retinopathy in all cases.  Persistence of vascular tortuosity was present in 17.6 % of cases without vascular dilatation, and vitreous membrane development was demonstrated in 11.7 % of patients.  The authors concluded that laser-ranibizumab treatment has allowed a better control of retinopathy for threshold-prethreshold and "plus disease" in this group of patients.

Lin et al (2012) reported the effects of intravitreal ranibizumab as salvage therapy in an extremely low-birth-weight (ELBW) infant with rush type ROP. This case was a girl of 23 weeks gestational age weighing 480 g at birth.  At a post-conceptual age of 33 weeks, she presented with zone 1, stage 3 ROP with plus disease.  Despite intravitreal bevacizumab and laser photocoagulation, extra-retinal fibro-vascular proliferation persisted.  Intravitreal 0.25 mg (0.025 ml) ranibizumab was injected OU.  After treatment, extra-retinal fibro-vascular proliferation disappeared.  Fundus examination showed flat retinas and normal vasculature in both eyes.  She has been followed-up for 2 years.  Intravitreal ranibizumab injection seems effective and well-tolerated as salvage therapy in an ELBW infant with rush type ROP.  No short-term ocular or systemic side effects were identified.  The authors concluded that more cases and longer follow-up are mandatory.

Mota et al (2012) reported on 2 cases of APROP) treated with intravitreal ranibizumab and laser photocoagulation.  Two premature females, born at 25 and 26 weeks' gestation with a birth weight of 530 and 550 g, respectively, with AP ROP received combined treatment with laser photocoagulation and intravitreal ranibizumab (0.3 mg [30 µl]) to each eye.  Structural outcomes were evaluated by indirect ophthalmoscopy and documented by retinography.  An intravitreal injection was made at 34 weeks of post-menstrual age in the first case, followed by laser photocoagulation 1 week later.  There was a partial regression of ROP with treatment.  Five weeks later, neovascularization regrowth with bleeding in both eyes (intraretinal and subhyaloid) occurred and re-treatment with combined therapy was performed.  In the second case, single therapy with laser photocoagulation was made at 34 weeks of post-menstrual age.  In spite of the confluent photocoagulation in the avascular area, progression to 4A ROP stage occurred 1 week later.  Both eyes were re-treated 1 week later with intravitreal ranibizumab and laser photocoagulation.  Treatment resulted in ROP regression in both cases.  There were no signs of systemic or ocular adverse side effects.  The authors concluded that these 2 cases showed that combination therapy of indirect laser photocoagulation and intravitreal ranibizumab can be effective in the management of AP ROP.  They stated that further investigation on anti-VEGF safety in premature infants is necessary.

In an interventional case-series study, Castellanos et al (2013) evaluated ocular outcome in premature infants treated with intravitreal ranibizumab injections for ROP over a period of 3 years.  Premature infants with high-risk prethreshold or threshold ROP with plus disease received an off-label monotherapy with intravitreal injections of ranibizumab.  The primary outcome was treatment success defined as regression of neovascularization (NV) and absence of recurrence.  The secondary outcomes were ocular and systemic adverse events and VA.  A total of 6 eyes were included in the study and treated with intravitreal injections of ranibizumab.  All showed complete resolution of NV after a single injection.  The anti-angiogenic intravitreal injections allowed for continued normal vessel growth into the peripheral retina, without any signs of disease recurrence or progression during the follow-up period.  No ocular or systemic adverse effects were observed.  The authors concluded that 3 years of follow-up in a small series suggested that intravitreal ranibizumab injections for ROP result in apparently preserved ocular outcome.  Moreover, they stated that further large scale studies are needed to address the long-term safety and effectiveness.

Aflibercept, also known as VEGF Trap-Eye, is a highly potent blocker of VEGF and placental growth factor.  It is a fully human fusion protein consisting of portions of VEGF receptors 1 and 2, which binds all forms of VEGF-A, along with the related placental growth factor, which the drug blocks.

Bandello et al (2012) stated that DME is the most important cause of vision loss in patients with diabetes mellitus.  Diabetic retinopathy has a remarkable impact on public health and on the quality of life of diabetic patients and thus requires special consideration.  The first line of treatment remains the management of systemic risk factors but is often insufficient in controlling DME and currently, laser retinal photocoagulation is considered the standard of care.  However, laser treatment reduces the risk of moderate visual loss by approximately 50 % without guaranteeing remarkable effects on visual improvement.  For these reasons, new strategies in the treatment of DME have been studied, in particular the use of anti-VEGF drugs.  VEGF is a pluripotent growth factor that acts as a vaso-permeability factor and an endothelial cell mitogen.  For this reason, it represents an interesting candidate as a therapeutic target for the treatment of DME. 

Lang (2012) noted that diabetic retinopathy is one of the major complications of diabetes mellitus and a leading cause of visual loss.  Diabetic macular edema is an ocular manifestation of the disease causing visual deterioration.  The prevalence of visual impairment due to DME is estimated to be 5.4 % in Europe.  Vascular endothelial growth factor is over-expressed in diabetic eyes and plays a key role in the development of DME.  VEGF levels were proven to be elevated in the vitreous and retina in patients with diabetic retinopathy.  VEGF causes a breakdown of the blood-retinal barrier by influencing the tight junctions of retinal endothelial cells and leading to accumulation of fluid in the macula.  Therefore, intravitreal VEGF inhibitors are ideal candidates to treat DME by counteracting VEGF overexpression.  The author summarized the results of the most recent prospective, controlled studies on DME with promising novel VEGF inhibitors.  It focuses on the efficacy and safety aspects of anti-VEGF treatment of DME.

Zechmeister-Koss et al (2012) addressed the question of whether anti-VEGF lead to better clinical outcomes than current treatments in patients with clinically manifest DME, which is the leading cause of vision loss in the working age population in developed countries.  The authors performed a systematic literature search in common databases and compiled the evidence according to the GRADE methodology.  The authors analyzed clinically relevant improvement of visual acuity, vision-related quality of life and local or systemic adverse events.  In a proportion of patients (on average 25 %), VEGF inhibitors result in better VA (≥ 15 ETDRS letters or equivalent) than in patients treated with laser photocoagulation or sham injection.  The number of injections required for long-term improvement as well as the general long-term efficacy is unknown.  The evidence is not sufficient to confirm safety of the products in patients with DME and does not suggest superiority of a single product.  The authors concluded that for some patients with DME, VEGF inhibitors seem to be more effective as a short-term treatment option than alternative therapies.  The evidence is not of sufficient quality to confirm safety. 

In a review on “Anti-vascular endothelial growth factor drug treatment of diabetic macular edema”, Stewart (2012) noted that diabetic mellitus is the leading cause of blindness in working aged patients in developing nations.  Due to the buildup of abnormal metabolites from several overactive biochemical pathways, chronic hyperglycemia causes oxidative stress in the retina, which up-regulates VEGF.  Together with other growth factors and metabolites, VEGF causes endothelial cell proliferation, vasodilation, recruitment of inflammatory cells, and increased vascular permeability, leading to breakdown of the blood-retinal barrier.  This allows trans-cellular exudation into the interstitial space resulting in DME.  For over 3 decades the standard treatment for DME has been laser photocoagulation.  Though laser reduces the incidence of vision loss by 50 %, few eyes with diffuse edema experience improved vision.  This has led physicians to use the VEGF-binding drugs pegaptanib, ranibizumab, and aflibercept, each of which has been approved for the treatment of exudative macular degeneration, and bevacizumab that is commonly used off-label for a variety of chorio-retinal disorders.  Intravitreal administration of each drug frequently causes rapid improvement of DME with sustained improvement in vision through 2 years.  Though these drugs significantly out-perform laser photocoagulation over treatment periods of 1 year of less, the advantages appear to lessen when trials approach 2 years.  The author concluded that further studies to better determine relative efficacies of anti-VEGF drugs and laser photocoagulation are continuing.

In a Cochrane review, Virgili et al (2012) evaluated the safety, effectiveness, and cost-effectiveness of anti-VEGF therapy for preserving or improving vision in people with DME.  These investigators searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 6), MEDLINE (January 1946 to June 2012), EMBASE (January 1980 to June 2012), the metaRegister of Controlled Trials (mRCT), ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP).  They did not use any date or language restrictions in the electronic searches for trials.  They last searched the electronic databases on June 13, 2012.  These researchers included randomized controlled trials (RCTs) comparing any anti-angiogenic drugs with an anti-VEGF mechanism of action versus another treatment, sham treatment, or no treatment in patients with DME.  They also included economic evaluations to assess cost-effectiveness.  Two review authors independently extracted the data.  The RR of visual loss and visual gain of 3 or more lines was estimated at least 6 months after treatment.  Each economic analysis was described narratively using a structured format.  A total of 11 studies provided data on 3 comparisons of interest in this review.  These investigators based their conclusions on the RR of gain or loss of 3 or more lines of vision at about 1 year, which was more consistently reported as follow-up.  Compared with sham treatment, there was evidence of moderate quality in 3 studies (497 participants, follow-up 8 to 12 months) that anti-angiogenic therapy (pegaptanib: 2 studies, 246 participants; ranibizumab: 1 study, 151 participants) doubled and, respectively, halved, the chance of gaining or losing 3 or more lines of vision (RR: 2.19, 95 % confidence interval (CI): 1.36 to 3.53; RR: 0.28, 95 % CI: 0.13 to 0.59).  In meta-analyses, the benefit was larger for ranibizumab compared to pegaptanib, but no significant subgroup difference could be demonstrated regarding our primary outcome.  Compared with grid laser photocoagulation, there was evidence of moderate quality that anti-angiogenic therapy (bevacizumab: 2 studies, 167 participants; ranibizumab: 2 studies, 300 participants; aflibercept: 1 study, 221 participants, 89 used for data extraction) more than doubled and, respectively, reduced by at least 2/3, the chance of gaining or losing 3 or more lines of vision (RR: 3.20, 95 % CI: 2.07 to 4.95 and RR: 0.13, 95 % CI: 0.05 to 0.34, respectively).  In meta-analyses, no significant subgroup difference could be demonstrated between bevacizumab, ranibizumab and aflibercept regarding our primary outcome, but, again, there was little power to detect a difference.  Compared with grid laser photocoagulation alone, there was high quality evidence that ranibizumab plus photocoagulation (3 studies, 783 participants) doubled and, respectively, at least halved, the chance of gaining or losing 3 or more lines of vision (RR: 2.11, 95 % CI 1.67 to 2.67; RR: 0.29, 95 % CI: 0.15 to 0.55).  Systemic and ocular adverse events were rare in the included studies.  Meta-analyses conducted for all anti-angiogenic drugs compared with either sham or photocoagulation (9 studies, 104 events in 2,159 participants) did not show a significant difference regarding arterial thromboembolic events (RR: 0.85 (0.56 to 1.28).  Similarly, no difference was suggested regarding overall mortality (53 events, RR: 0.95 (0.52 to 1.74), but clinically significant differences could not be ruled out.  The authors concluded that there is moderate quality evidence that anti-angiogenic drugs provide a definite, but small, benefit compared to current therapeutic options for DME, i.e., grid laser photocoagulation, or no treatment when laser is not an option.  The quality and quantity of the evidence was larger for ranibizumab, but there was little power to investigate drug differences.  Most data were obtained at 1 year, and a long-term confirmation is needed, since DME is a chronic condition.  Safety of both drug and the intravitreal injection procedure were good in the trials, but further long-term data are needed to exclude small, but clinically important differences regarding systemic adverse events.

In a meta-analysis, Hu and colleagues (2014) evaluated the safety and effectiveness of bevacizumab in the treatment of pterygium and explored its effects on recurrence rate and complications.  These investigators searched MEDLINE, EMBASE, Web of Science, and Cochrane Central Register from the inception to July 2013 for relevant RCTs that examined bevacizumab therapy for pterygium.  Data concerning study design, patient characteristics, treatment, and outcomes were extracted.  The methodological quality of the studies included was assessed using the Jadad score.  Relative risk (RR) was calculated for recurrence rate and complications.  A total of 474 patients with 482 eyes in 9 RCTs were analyzed.  The pooled estimate showed that bevacizumab had no statistically significant effect on preventing pterygium recurrence [RR 0.90, 95 % CI: 0.77 to 1.07, p = 0.23].  None of the subgroup analyses yielded significant results in favor of bevacizumab (surgery group: RR 0.77, 95 % CI: 0.50 to 1.18, p = 0.23; non-surgery group: RR 0.98, 95 % CI: 0.86 to 1.11, p = 0.76; primary pterygium group: RR 0.82, 95 % CI: 0.53 to 1.26, p = 0.36; recurrent pterygium group: RR 0.95, 95 % CI: 0.82 to 1.09, p = 0.44).  There were no statistically significant differences in the complications between the 2 groups (RR 1.00, 95 % CI: 0.73 to 1.37, p = 1.00).  However, the bevacizumab group was associated with a higher risk of developing subconjunctival hemorrhage (RR 3.34, 95 % CI: 1.07 to 10.43, p = 0.04).  The authors concluded that topical or subconjunctival bevacizumab was relatively safe and well-tolerated, but it had no statistically significant effect on preventing pterygium recurrence.  They stated that a large-scale trial with a suitable dosage and a longer follow-up would be needed to rule out the possibility of any treatment benefit.

Moradi et al (2013) stated that diabetic retinopathy (DR) is the most common cause of visual loss among working age individuals.  Diabetic macular edema (DME) is an important complication of DR that affects around 1/3 of the patients with DR.  Several treatments have been approved for DME ranging from blood pressure and glycemic control to photocoagulation and more recently the use of vascular endothelial growth factor (VEGF) antagonists.  These investigators discussed aflibercept (EYLEA^®-Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, and Bayer Healthcare Pharmaceuticals, Berlin, Germany) in the context of other VEGF antagonists currently available for the treatment of DME.  They performed a systematic search of literature on PubMed, Scopus, and Google Scholar with no limitation on language or year of publication.  Pre-clinical studies of aflibercept have shown a higher affinity of this molecule for VEGF-A along with a longer duration of action as compared to other VEGF antagonists.  Recent clinical trials have shown visual outcome results for aflibercept to be similarly favorable as compared to other available agents with the added benefit of fewer required injections and less frequent monitoring.   The authors concluded that aflibercept presents a potential exciting new addition to the armamentarium of current VEGF antagonists available for the treatment of DME and other retinal vascular diseases.  However, they stated that further studies are needed to confirm the role, safety, and efficacy of aflibercept for DME.

In a cost-effectiveness analysis of treatment of DME, Pershing et al (2014) reported that VEGF inhibitor monotherapy was sometimes preferred over laser treatment plus a VEGF inhibitor, depending on the reduction in quality of life with loss of visual acuity.  When the VEGF inhibitor bevacizumab was as effective as ranibizumab, it was preferable because of its lower cost.  This study did not include aflibercept in the analysis.

On behalf of the Diabetic Macular Edema Treatment Guideline Working Group, Mitchell and Wong (2014) provided evidence-based recommendations for DME management based on updated information from publications on DME treatment modalities.  A literature search for "diabetic macular edema" or "diabetic maculopathy" was performed using the PubMed, Cochrane Library, and ClinicalTrials.gov databases to identify studies from January 1, 1985 to July 31, 2013.  Meta-analyses, systematic reviews, and randomized controlled trials with at least 1 year of follow-up published in the past 5 years were preferred sources.  Although laser photocoagulation has been the standard treatment for DME for nearly 3 decades, there is increasing evidence that superior outcomes can be achieved with anti-VEGF therapy.  Data providing the most robust evidence from large phase II and phase III clinical trials for ranibizumab demonstrated visual improvement and favorable safety profile for up to 3 years.  Average best-corrected visual acuity (BCVA) change from baseline ranged from 6.1 to 10.6 ETDRS letters for ranibizumab, compared to 1.4-5.9 ETDRS letters with laser.  The proportion of patients gaining greater than or equal to 10 or greater than or equal to 15 letters with ranibizumab was at least 2 times higher than that of patients treated with laser.  Patients were also more likely to experience visual loss with laser than with ranibizumab treatment.  Ranibizumab was generally well-tolerated in all studies.  Studies for bevacizumab, aflibercept, and pegaptanib in DME were limited but also in favor of anti-VEGF therapy over laser.  The authors concluded that anti-VEGF therapy is superior to laser photocoagulation for treatment of moderate to severe visual impairment caused by DME.

Also, an UpToDate review on “Diabetic retinopathy: Prevention and treatment” (Fraser and D’Amico, 2014) notes that “VEGF inhibitors for ME -- VEGF inhibitors (pegaptanib, bevacizumab, ranibizumab) have been widely studied as a treatment for diabetic ME, and this therapy represents a major treatment advance.  In 2012, the US Food and Drug Administration (FDA) approved a 0.3 mg intravitreal dose of ranibizumab for treatment of diabetic ME.  Consequently, for many patients and clinicians, intravitreal pharmacotherapy with ranibizumab will be the initial treatment of choice, but the precise interrelation between this treatment and other modalities is not yet conclusively defined”.  This review does not include aflibercept as a therapeutic option of DME.

The National Institute for Health and Care Excellence clinical practice guideline on “Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy” (NICE, 2014) states that “Aflibercept in combination with irinotecan and fluorouracil-based therapy is not recommended within its marketing authorization for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.  People currently receiving aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen should be able to continue treatment until they and their clinician consider it appropriate to stop”.

Aravantinos et al (2014) conducted a systematic literature review to identify available safety and effectiveness data for bevacizumab in ovarian cancer as well as for newer anti-angiogenic agents in development.  These researchers analyzed published data from randomized, controlled phase II/III clinical trials enrolling women with ovarian cancer to receive treatment with bevacizumab.  They also reviewed available data for emerging anti-angiogenic agents currently in phase II/III development, including trebananib, aflibercept, nintedanib, cediranib, imatinib, pazopanib, sorafenib and sunitinib.  Significant efficacy gains were achieved with the addition of bevacizumab to standard chemotherapy in 4 randomized, double-blind, phase III trials, both as front-line treatment (GOG-0218 and ICON7) and in patients with recurrent disease (OCEANS and AURELIA).  The type and frequency of bevacizumab-related adverse events was as expected in these studies based on published data.  Promising efficacy data have been published for a number of emerging anti-angiogenic agents in phase III development for advanced ovarian cancer.  The authors concluded that further research is needed to identify predictive or prognostic markers of response to bevacizumab in order to optimize patient selection and treatment benefit; data from phase III trials of newer anti-angiogenic agents in ovarian cancer are awaited.

Agarwal and colleagues (2014) stated that the therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has been revolutionized by the arrival of multiple novel agents in the past 2 years.  Immunotherapy in the form of sipuleucel-T, androgen axis inhibitors, including abiraterone acetate and enzalutamide, a chemotherapeutic agent, cabazitaxel, and a radiopharmaceutical, radium-223, have all yielded incremental extensions of survival and have been recently approved.  A number of other agents appear promising in early studies, suggesting that the armamentarium against castrate-resistant prostate cancer is likely to continue to expand.  Emerging androgen pathway inhibitors include androgen synthesis inhibitors (TAK700), androgen receptor inhibitors (ARN-509, ODM-201), AR DNA binding domain inhibitors (EPI-001), selective AR down-regulators or SARDs (AZD-3514), and agents that inhibit both androgen synthesis and receptor binding (TOK-001/galeterone).  Promising immunotherapeutic agents include poxvirus vaccines and CTLA-4 inhibitor (ipilimumab).  Biologic agents targeting the molecular drivers of disease are also being investigated as single agents, including cabozantinib (Met and VEGFR2 inhibitor) and tasquinimod (angiogenesis and immune modulatory agent).  Despite the disappointing results seen from studies evaluating docetaxel in combination with other agents, including GVAX, anti-angiogenic agents (bevacizumab, aflibercept, lenalinomide), a SRC kinase inhibitor (dasatinib), endothelin receptor antagonists (atrasentan, zibotentan), and high-dose calcitriol (DN-101), the results from the trial evaluating docetaxel in combination with the clusterin antagonist, custirsen, are eagerly awaited.  New therapeutic hurdles consist of discovering new targets, understanding resistance mechanisms, the optimal sequencing and combinations of available agents, as well as biomarkers predictive for benefit.  Novel agents targeting bone metastases are being developed following the success of zoledronic acid and denosumab.  The authors concluded that all of these modalities do not appear curative, suggesting that clinical trial enrollment and a better understanding of biology remain of paramount importance.

Kim and colleagues (2013) compared the short-term effects of bevacizumab and ranibizumab injections on the regression of corneal neovascularization (NV).  A total of 16 eyes of 16 patients with corneal NV were randomly assigned for an injection with 2.5 mg of bevacizumab (group 1, n = 8) or 1 mg of ranibizumab (group 2, n = 8) through subconjunctival and intrastromal routes.  The patients were prospectively followed-up for 1 month after the injections.  Corneal NV areas, as shown on corneal slit-lamp photographs stored in JPEG format, were calculated using Image J software before the injection, 1 week after the injection, and 1 month after the injection.  The corneal NV areas were compared before and after the injections.  A total of 7 women and 9 men, with an average age of 51 years, presented with corneal NV secondary to herpetic keratitis (7 cases), graft rejection (6), chemical burn (1), pemphigoid (1), and recurrent ulcer (1).  In group I, the pre-operative corneal NV area (8.75 ± 4.33 %) was significantly decreased to 5.62 ± 3.86 % 1 week after the injection and to 6.35 ± 3.02 % 1 month after the injection (p = 0.012, 0.012, respectively).  The corneal NV area in group 2 also exhibited a significant change, from 7.37 ± 4.33 % to 6.72 ± 4.16 % 1 week after the injection (p = 0.012).  However, no significant change was observed 1 month after the injection.  The mean decrease in corneal NV area 1 month after injection in group 1 (28.4 ± 9.01 %) was significantly higher than in group 2 (4.51 ± 11.64 %, p = 0.001).  The authors concluded that bevacizumab injection resulted in a more effective and stable regression of corneal NV compared to the ranibizumab injection.  Moreover, they stated that the potency and dose of these 2 drugs for the regression of corneal NV require further investigation.

Ahn et al (2014) reported on the case of a 32-year old female diagnosed with herpetic kerato-conjunctivitis with refractory corneal NV despite 2 previous subconjunctival and intrastromal bevacizumab injections, received 2 subconjunctival and intrastromal ranibizumab injections.  Six months post-operatively, there was significant regression of the neovascular area and vessel caliber.  The authors reported a case of improvement in corneal NV with subconjunctival and intrastromal ranibizumab injections, which was previously refractory to bevacizumab injection.  They stated that these findings may suggest a new prospect in treating corneal NV.

Turkcu et al (2014) compared the effectiveness of the topical and subconjunctival (SC) ranibizumab treatment in experimental corneal NV model in rats.  A model of NV was generated by cauterizing right corneas of 30 Sprague-Dawley rats with silver nitrate.  The animals were separated into 5 groups randomly: first group (control group) received topical artificial tear drops 2 times daily while second and third groups received topical ranibizumab 4 times daily at concentrations of 5 mg/ml and 10 mg/ml, respectively; fourth and fifth groups were given 0.5 mg/0.05 ml and 1 mg/0.1 ml of SC ranibizumab in the 1st, 3rd and 7th days.  The measurements (percentage of NV area and number of vessels) from digital photographs of the corneas were determined and analyzed using analysis software (ImageJ, v1.38).  The animals were sacrificed on the 10th day and their corneas were subjected to hemotoxylin-eosin histopathological staining and antisera against CD34 and von-Willebrand factor to evaluate microvascular structures immunohistochemically.  The percentage of the corneal NV area and number of vessels in all treatment groups was found to be significantly lower than the control group.  There was no significant difference in relation to the percentage of NV area and number of vessels in the treatment groups.  Score of the corneal edema was determined to be significantly less in the groups that undertook treatment.  Number of vessels and inflammatory cells were significantly lower in the histological and immunohistochemical sections in the treated groups than in the control group.  In all treatment groups, fibroblast intensity was significantly lower than the control group (p = 0.005).  The authors concluded that topical or SC administration of ranibizumab seems to be a promising and effective medication in the treatment of corneal NV.  Moreover, they stated that further research is recommended to assess the potential side effects and effective dose.

In a meta-analysis, Papathanassiou et al (2013) evaluated the therapeutic effect of bevacizumab on corneal NV.  A systematic review and meta-analysis of the literature was performed.  A total of 7 eligible clinical human studies and 18 eligible experimental animal studies examining the effectiveness of bevacizumab treatment on corneal NV were included in the meta-analysis.  Pertinent publications were identified through a systematic search of PubMed.  All references of relevant reviews and eligible articles were also screened, and data were extracted from each eligible study.  The random-effects model (of DerSimonian and Laird) was used to combine the results from the selected studies.  Heterogeneity was explored using available data.  Publication bias was also assessed.  A significant reduction of corneal neovascularized area was seen in clinical human studies, with a pooled reduction of 36 % [95 % CI: 18 % to 54 %] overall, of 32 % (95 % CI: 10 % to 54 %) for subconjunctival anti-VEGF injections, and 48 % (95 % CI: 32 % to 65 %) for topical treatment.  Pooled mean change in BCVA showed an improvement in BCVA by 0.04.  The summary standardized mean difference in animal studies indicated a statistically significant reduction in the area of corneal NV when treated with bevacizumab compared with the control group by -1.71 (95 % CI: -2.12 to -1.30).  The subtotal pooled standardized mean differences were -1.83 (95 % CI: -2.38 to -1.28) for subconjunctival anti-VEGF injections and -1.50 (95 % CI: -1.88 to -1.12) for topical treatment.  The authors concluded that these findings suggested that both topical and subconjunctival bevacizumab achieve significant reduction in the area of corneal NV.  This meta-analysis provided an evidential basis for the new therapeutic concept of treating corneal NV with anti-angiogenic therapy.  Moreover, the clinical significance of an improvement in BCVA by 0.04 is unclear.

In a pilot study, Petsoglou et al (2013) evaluated the off-label use of subconjunctival bevacizumab for corneal NV (CoNV).  A total of 30 patients with recent-onset CoNV from various causes were randomly assigned into a double-masked, placebo-controlled trial.  Each received three 0.1-ml injections containing either 2.5 mg bevacizumab or 0.9 % saline at monthly intervals.  Dexamethasone 0.1 % drops were used 4 times a day for the 1st month, when the dose was modified if clinically indicated.  The primary outcome was change in area of corneal involvement by CoNV from baseline to 3 months measured using specialized imaging technology.  The mean area of CoNV reduced by -36 % (range of -92 % to +40 %) in the 15 eyes that received bevacizumab compared with an increase of 90 % (range of -58 % to +1,394 %) in eyes that received saline placebo (analysis of covariance (ANCOVA); p = 0.007).  One outlier in the placebo arm developed corneal graft rejection with aggressive neovascularization (+1,384 %), but even when this patient was excluded the mean reduction in CoNV in the placebo group (-3 %, range of -58 % to +40 %) was still significantly different from the treatment arm (ANCOVA; p = 0.016).  Changes in BCVA, central corneal thickness, IOP and endothelial cell counts were similar between groups.  The intervention was well-tolerated with no major safety concerns.  The authors concluded that 3 subconjunctival injections of 2.5-mg bevacizumab are more effective than placebo at inducing the regression of recent onset CoNV.  Moreover, they stated that further studies are needed to confirm this effect and these findings suggested that a sample size of 40 patients per treatment group is needed.

Krizova and colleagues (2014) evaluated anti-angiogenic effect of local use of bevacizumab in patients with corneal NV.   Patients were divided into 2 groups.  All patients suffered from some form of corneal NV.  Patients in group A received 0.2 to 0.5 ml of bevacizumab solution subconjunctivally (concentration 25 mg/ml) in a single dose.  Group A included 28 eyes from 27 patients.  Patients in group B applied bevacizumab eye drops twice-daily (concentration 2.5 mg/ml) for 2 weeks.  Group B included 38 eyes from 35 patients.  These investigators evaluated the number of corneal segments affected by NV, CDVA, and the incidence of complications and subjective complaints related to the treatment.  The minimum follow-up period was 6 months.  By the 6-month follow-up, in group A the percentage reduction of the affected peripheral segments was 21.6 % and of the central segments was 9.6 %; in group B the percentage reduction of the central segments was 22.7 % and of the central segments was 38.04 %.  In both groups these researchers noticed a statistically significant reduction in the extent of NV.  The authors concluded that the use of bevacizumab seems to be an effective and safe method in the treatment of corneal NV, either in the subconjunctival or topical application form.  It is unclear whether the statistically significant reduction in the extent of NV is of clinical significance; the findings of this study need to be validated in well-designed studies.

Furthermore, an UpToDate review on “Overview of angiogenesis inhibitors” (Kuo, 2014) does not mention corneal neovascularization as an indication of bevacizumab or ranibizumab.

Coats’ disease (Coates' disease, also known as exudative retinitis or retinal telangiectasis) is a very rare congenital, non-hereditary eye disorder, causing full or partial blindness, characterized by abnormal development of blood vessels behind the retina.  Coats' disease can also fall under glaucoma.

In a prospective, interventional case series, Goel et al (2011) evaluated the role of IVB in the treatment of Coats' disease diagnosed in adulthood.  A total of 3 patients with Coats' disease diagnosed in adulthood were managed with a single intravitreal injection of bevacizumab (1.25 mg) with peripheral laser photocoagulation 3 weeks later.  All 3 patients had exudation at the macula (Stage 2B) along with peripheral retinal telangiectasia and aneurysms.  They were followed-up for 9 months.  An appreciable reduction in the exudation at the macula and macular edema was observed in all cases following IVB therapy.  In all patients, the visual acuity improved, and no signs of recurrence were observed at the final follow-up at 9 months.  The authors concluded that IVB may be effective as an adjunctive treatment for adult-onset Coats' disease with foveal exudation along with laser photocoagulation to the peripheral retinal vascular abnormalities. 

Sisk et al (2010) determined the effectiveness of off-label IVB for the treatment of pediatric retinal and choroidal vascular diseases.  Retrospective, non-comparative, open-label, interventional, consecutive case series of all patients younger than 18 years treated with off-label IVB at a single center from January 1, 2005, to January 1, 2008 were selected for analysis.  Primary outcome measures with BCVA by age-appropriate testing and central macular thickness by time-domain OCT.  A total of 35 eyes of 33 patients were treated with IVB alone or in combination with other treatments for CNV, Coats' disease, familial exudative vitreoretinopathy, and various other indications.  Intravitreal bevacizumab was used in 24 eyes to reduce excess retinal fluid and exudation.  Mean Snellen VA improved from 20/170 at baseline to 20/100 at 1 month (p = 0.006), 20/80 at 3 months (p = 0.006), and 20/50 at 6 months (p = 0.023).  Central macular thickness improved from 356 μm at baseline to 287 μm at 6 months (p = 0.028).  Intravitreal bevacizumab was used in 11 eyes to control peripheral retinal neovascularization and iris rubeosis.  Although IVB reduced vascular engorgement, it did not prevent the progression of pre-retinal tractional forces.  Mean VA was maintained at each time-point.  No systemic or ocular adverse events were directly attributable to IVB in any patient.  The authors concluded that IVB reduced vascular leakage and temporarily regressed pathologic neovascularization of the choroid, retina, and iris in this series of pediatric patients.  They stated that further prospective studies are needed.

Ramasubramanian and Shields (2012) evaluated the effect of supplemental IVB for management of Coats' disease.  This study was a retrospective analysis of 8 patients with Coats' disease manifesting total or partial exudative retinal detachment where the retinal telangiectasia was treated with standard laser photocoagulation and/or cryotherapy plus additional IVB (1.25 mg/0.05 ml).  The mean patient age was 88 (range of 7 to 240) months and 63 % were male.  Coats' disease was classified as stage 2 (n = 1, 12 %), 3a (n = 3, 38 %) and 3b (n = 4, 50 %).  Features included retinal detachment (n = 8, 100 % with mean detachment extent involving 8 clock hours), telangiectasia (n = 8, 100 % with mean extent of 8 clock hours), peripheral retinal ischemia on fluorescein angiography (n = 7, 88 %) and no evidence of neovascularization.  Treatment consisted of cryotherapy (n = 8, 100 %), laser photocoagulation (n = 4, 50 %) and IVB (n = 8) with median number of 1 injection per eye (mean of 1.75, and range of 1 to 4 injections).  After a mean follow-up of 8.5 months, resolution of retinopathy (n = 8, 100 %), Coats'-related subretinal fluid (n = 8, 100 %) and retinal exudation (n = 6, 75 %) was noted.  However, vitreous fibrosis developed (n = 4, 50 %) at a mean of 5 months following a mean of 1.75 IVB injections with 3 (38 %) evolving into traction retinal detachment.  The authors concluded that Coats' disease treated with IVB in addition to standard therapy can develop to vitreo-retinal fibrosis and potentially traction retinal detachment.  These tractional features are not often found in Coats' disease treated with standard measures without bevacizumab.  They stated that caution is advised in the use of IVB for patients with Coats' disease.

Ray and colleagues (2013) compared the effectiveness of IVB plus ablative therapy with ablative therapy alone for Coats' disease.  These researchers performed a retrospective review of all pediatric patients who received treatment for Coats' disease from a single surgeon (GBH) from January 1, 2001 to March 31, 2010.  A total of 10 consecutive patients who received IVB as part of their treatment were matched to 10 patients treated with ablative therapy alone by macular appearance, quadrants of subretinal fluid, and quadrants of telangiectasias.  Outcomes evaluated were number of treatment sessions, time to full treatment, and resolution of disease.  There was no statistical difference between baseline characteristics when comparing the IVB and control groups.  Eyes treated with IVB required more treatments over a longer time period compared to the control group.  All patients in the IVB group were successfully treated while 2 of the patients in the control group failed ablative techniques.  The authors concluded that IVB may play a role as adjuvant therapy in select cases of Coats' disease, but its use does not reduce the time to full treatment.  Resolution of disease was seen in the most severe cases treated with IVB plus thermal ablation whereas their matched controls failed therapy with laser and cryotherapy alone.

Raoof and Quhill (2013) noted that traditional methods of managing exudative retinal detachment secondary to Coats' disease have been associated with varying degrees of success.  These researchers described a case of a 34-year old male who presented with a sub-total exudative retinal detachment of the right eye that encroached upon the macula, associated with a vaso-proliferative tumor secondary to Coats' disease.  The patient underwent successful treatment with 2 IVB injections combined with targeted laser photocoagulation with a 532 nm Pascal laser.  The VA improved 5 days after the second IVB injection from 6/18 to 6/5, with no residual macular edema and complete regression of the vaso-proliferative tumor.  The improvement in VA was maintained at 12 months post-treatment.  These researchers believed this was the first case report describing the successful use of Pascal laser photocoagulation with IVB in the treatment of Coats' disease.  Their aim was to defer laser treatment until 'near total' retinal re-attachment and regression of the vaso-proliferative tumor was achieved.  The authors concluded that there were, however, reports of vitreous fibrosis in patients with Coats' disease treated with IVB suggesting that further long-term follow-up studies are needed in patients treated with this approach.

In a single-center, open-label, phase II clinical trial, Toy and associates (2012) evaluated the safety and preliminary efficacy of intravitreal ranibizumab for non-neovascular idiopathic macular telangiectasia Type 2.  This study enrolled 5 participants with bilateral non-neovascular idiopathic macular telangiectasia Type 2.  Intravitreal ranibizumab (0.5 mg) was administered every 4 weeks in the study eye for 12 months with the contralateral eye observed.  Outcome measures included changes in BCVA, area of late-phase leakage on FA, and retinal thickness on OCT.  The study treatment was well-tolerated and associated with few adverse events.  Change in BCVA at 12 months was not significantly different between treated study eyes (0.0 ± 7.5 letters) and control fellow eyes (+2.2 ± 1.9 letters).  However, decreases in the area of late-phase FA leakage (-33 ± 20 % for study eyes, +1 ± 8 % for fellow eyes) and in OCT central subfield retinal thickness (-11.7 ± 7.0 % for study eyes and -2.9 ± 3.5 % for fellow eyes) were greater in study eyes compared with fellow eyes.  The authors concluded that despite significant anatomical responses to treatment, functional improvement in visual acuity was not detected.  They stated that intravitreal ranibizumab administered monthly over a time course of 12 months is unlikely to provide a general and significant benefit to patients with non-neovascular idiopathic macular telangiectasia Type 2.

Chaudhary et al (2013) stated that VEGF is an important factor in the pathogenesis of multiple retinal neovascular disorders.  This report focused on the quality and depth of new evidence for the use of VEGF inhibitors in selected pediatric ocular diseases, including Coats' disease, Best disease, and childhood uveitis.  Because much of the literature comprised case reports and retrospective case series, the level of evidence supporting its use as a primary treatment option, or even as adjuvant therapy, is low.  The standard of care is treatment of the underlying disorder to prevent neovascularization (retinal or subretinal), vitreous hemorrhage, or subsequent retinal detachment.  However, these complications may not present until late in the disease course.  It may then be useful to treat with these agents.  The authors concluded that prospective studies are needed to further elucidate the role of anti-VEGF therapy in these diseases.

Do and colleagues (2014) evaluated the effects of 0.3 mg or 0.5 mg of ranibizumab in eyes with macular telangiectasia type 2 without subretinal neovascularization.  A total of 10 eyes were randomized to either 0.3 mg or 0.5 mg ranibizumab group in 1 eye only.  Study eye received ranibizumab at baseline and at months 1 and 2.  Injections at months 3, 4, and 5 were at investigator's discretion.  Participants were followed monthly through 6 months with BCVA, fluorescein angiography, and OCT.  For study eyes at baseline, median BCVA letter score was 60 (20/64 Snellen equivalent) and central subfield retinal thickness was 181.5 μm.  Median number of injections was 6.  Median change in BCVA at month 3 was 4 letters (range of -5 to 9 letters) at both doses in the study eye and 3 letters (range of -10 to 5 letters) in the untreated fellow eye.  At month 3, retinal leakage decreased 0.87 disk area and 0.76 disk area for 0.3 mg and 0.5 mg ranibizumab, respectively.  Median change in central subfield retinal thickness was 1 μm and -11 µm for 0.3 mg and 0.5 mg ranibizumab, respectively.  The authors concluded that anibizumab (0.3 mg or 0.5 mg) decreases leakage secondary to macular telangiectasia type 2, but accompanying improvements in BCVA  appeared similar to improvements in the untreated fellow eye where retinal thickness is relatively unchanged.

Zhang et al (2015) noted that CNV secondary to pathologic myopia has a very high incidence in global, especially in Asian, populations.  It is a common cause of irreversible central vision loss, and severely affects the quality of life in the patients with pathologic myopia.  The traditional therapeutic modalities for CNV secondary to pathologic myopia include thermal laser photocoagulation, surgical management, transpupillary thermotherapy, and PDT with verteporfin.  However, the long-term outcomes of these modalities are disappointing.  Recently, intra-vitreal administration of anti-VEGF biological agents, including bevacizumab, ranibizumab, pegaptanib, aflibercept, and conbercept, has demonstrated promising outcomes for this ocular disease.  The anti-VEGF regimens are more effective on improving VA, reducing central fundus thickness and central retina thickness than the traditional modalities.  The authors stated that these anti-VEGF agents thus hold the potential to become the first-line medicine for treatment of CNV secondary to pathologic myopia.

Gadducci and Guerrieri (2015) stated that pharmacological treatment plays a major role in the management of advanced, persistent or recurrent uterine leiomyosarcoma (LMS), whereas its usefulness in the adjuvant setting is still debated.  These investigators performed a thorough literature search using the PubMed databases.  Systematic reviews and controlled trials on medical treatment of uterine LMS were collected and critically analyzed.  Other study types were secondarily considered when pertinent.  Doxorubicin (DOX), ifosfamide and dacarbazine have been long used in the treatment of this malignancy.  Novel active agents are represented by gemcitabine, docetaxel, trabectedin, pazopanib and aromatase inhibitors, whereas the role of eribulin, bevacizumab, aflibercept and mammalian target of rapamycin inhibitors is still investigational.

SooHoo and colleagues (2015) stated that neovascular glaucoma (NVG) is a potentially blinding disease associated with ocular ischemia.  Use of an anti-VEGF agent has been reported as a treatment option for NVG.  In a prospective, interventional case-series study, these researchers investigated initial results regarding the treatment of NVG with intravitreal aflibercept.  Patients with newly diagnosed stage 1 or 2 NVG were eligible to participate in this study.  A total of 4 patients with newly diagnosed stage 1 or 2 NVG were treated with intravitreal aflibercept at the time of diagnosis, with planned repeat injection at 4 weeks, 8 weeks and then every 8 weeks thereafter up until 52 weeks after study initiation.  Primary outcomes were regression of neovascularization of the iris and angle (NVI, NVA).  Secondary outcome measurements included VA and IOP.  Intravitreal aflibercept resulted in rapid regression of NVI and NVA; IOP was stable or reduced in all patients at the 52-week study visit.  The authors concluded that these results suggested that intravitreal aflibercept may be an effective treatment for stage 1 and 2 NVG, resulting in rapid and sustained regression of NVI and NVA as well as control of IOP.  Moreover, they stated that further research is needed to determine the full duration of effect and the optimal dose and timing of administration.

Anti-Vascular Endothelial Growth Factor for Control of Wound Healing in Glaucoma Surgery

Cheng and colleagues (2016) stated that trabeculectomy is performed as a treatment for glaucoma to lower IOP. The surgical procedure involves creating a channel through the wall of the eye.  However scarring during wound healing can block this channel that will lead to the operation failing.  Anti-vascular endothelial growth factor (VEGF) agents have been proposed to slow down healing response and scar formation.  In a Cochrane review,  these investigators evaluated the effectiveness of anti-VEGF therapies administered by sub-conjunctival injection for the outcome of trabeculectomy at 12 months follow-up and examined the balance of benefit and harms when compared to any other anti-scarring agents or no additional anti-scarring agents.  These investigators searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2015, Issue 10), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to November 2015), EMBASE (January 1980 to November 2015), the ISRCTN registry, ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP).  They did not use any date or language restrictions in the electronic searches for trials.  They last searched the electronic databases on November 12, 2015.  These researchers included RCTs of anti-VEGF therapies administered by sub-conjunctival injection compared to any other anti-scarring agents or no additional anti-scarring agents (no treatment or placebo) in trabeculectomy surgery.  They used standard methodological procedures expected by Cochrane.  The primary outcome was successful trabeculectomy at 12 months after surgery that was defined as achieving a target IOP (usually no more than 21 mm Hg) without any additional intervention.  Other outcomes included: qualified success (achieving target IOP with or without additional intervention), mean IOP and adverse events.  These researchers included 5 RCTs (175 participants, 177 eyes) that met the inclusion criteria in this review; 1 trial conducted in Iran (37 participants, 37 eyes) compared anti-VEGF (bevacizumab 0.2 mg) versus control (sham injection) in people with refractory glaucoma.  They judged this study to be at low risk of bias.  The primary outcome of this review was not reported; mean IOP at 3 months was 15.1 mm Hg (standard deviation 1.0) in both anti-VEGF and control groups.  Four trials compared anti-VEGF to mitomycin C (MMC) (138 participants, 140 eyes).  These studies were conducted in India, Iran, Turkey and the USA.  The anti-VEGF agent used in these 4 trials was bevacizumab 2.5 mg (2 trials), bevacizumab 1.25 mg 3 times and ranibizumab 0.5 mg.  Two trials were at high risk of bias in 2 domains and 1 trial was at high risk of bias in 4 domains.  Only 1 of these trials reported the primary outcome of this review (42 participants, 42 eyes).  Low quality evidence from this trial showed that people receiving bevacizumab 2.5 mg during primary trabeculectomy were less likely to achieve complete success at 12 months compared to people receiving MMC; but the CI was wide and compatible with increased chance of complete success for anti-VEGF (RR 0.71, 95 % CI: 0.46 to 1.08).  Assuming that about 81 % of people receiving MMC achieved complete success, the anticipated success using anti-VEGF agents would be between 37.2 % and 87.4 %.  The same trial suggested no evidence for any difference in qualified success between bevacizumab and MMC (RR 1.00, 95 % CI: 0.87 to 1.14, moderate quality evidence).  Two trials of primary trabeculectomy provided data on mean IOP at 12 months; 1 trial of bevacizumab 2.5 mg and 1 trial of ranibizumab 0.5 mg.  Mean IOP was 1.86 mm Hg higher (95 % CI: 0.15 to 3.57) in the anti-VEGF groups compared to the MMC groups (66 people, low quality evidence).  ata were reported on wound leak, hypotony, shallow anterior chamber and endophthalmitis, but these events occurred rarely and currently there are not enough data available to detect any differences, if any, between the 2 treatments.  The authors concluded that the evidence is currently of low quality that is insufficient to refute or support anti-VEGF sub-conjunctival injection for control of wound healing in glaucoma surgery. They stated that the effect on IOP control of anti-VEGF agents in glaucoma patients undergoing trabeculectomy is still uncertain, compared to MMC; further RCTs of anti-VEGF sub-conjunctival injection in glaucoma surgery are needed, particularly compared to sham treatment with at least 12 months follow-up.

---

Appendix

Table: Comparison of VEGF Inhibitors for Ophthalmologic Use

VEGF Inhibitors	Indications	Ophthalmologic UseFootnote1*
Lucentis (ranibizumab)	Age-related macular degeneration (wet/exudative)	FDA
	Macular retinal edema post retinal vein occlusion	FDA
	Diabetic macular edema	FDA
	Diabetic retinopathy	FDA
	Choroidal retinal neovascularization	FDA
Cimerli (ranibizumab-eqrn)	Age-related macular degeneration (wet/exudative)	FDA
	Macular retinal edema post retinal vein occlusion	FDA
	Diabetic macular edema	FDA
	Diabetic retinopathy	FDA
	Choroidal retinal neovascularization	FDA
Byooviz (ranibizumab-nuna)	Age-related macular degeneration (wet/exudative)	FDA
	Macular retinal edema post retinal vein occlusion	FDA
	Choroidal retinal neovascularization	FDA
Susvimo (ranibizumab injection)	Age-related macular degeneration (wet/exudative)	FDA
Eylea (aflibercept)	Age-related macular degeneration (wet/exudative)	FDA
	Macular retinal edema post retinal vein occlusion	FDA
	Diabetic macular edema	FDA
	Retinopathy of prematurity	FDA
	Diabetic retinopathy	FDA
Eylea HD (aflibercept)	Age-related macular degeneration (wet/exudative)	FDA
	Diabetic macular edema	FDA
	Diabetic retinopathy	FDA
Macugen (pegaptanib)	Age-related macular degeneration (wet/exudative)	FDA
Avastin (bevacizumab) Alymsys (bevacizumab-maly) Mvasi (bevacizumab-awwb) Vegzelma (bevacizumab-adcd) Zirabev (bevacizumab-bvzr)	Age-related macular degeneration (wet/exudative)	Compendial
	Macular retinal edema post retinal vein occlusion	Compendial
	Diabetic macular edema	Compendial
	Retinopathy of prematurity	Compendial
	Diabetic retinopathy	Compendial
	Choroidal retinal neovascularization	Compendial
	Neovascular glaucoma	Compendial
	Polypoidal choroidal vasculopathy	Compendial
Beovu (brolucizumab-dbll)	Age-related macular degeneration (wet/exudative)	FDA
	Diabetic macular edema	FDA
Vabysmo (faricimab-svoa)	Age-related macular degeneration (wet/exudative)	FDA
	Diabetic macular edema	FDA

Footnote1* FDA = Food and Drug Administration labeled indication
Compendial = Off-label use indication

---

References